

CITATION REPORT

List of articles citing

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

DOI: 10.1200/jco.2006.07.9525

Journal of Clinical Oncology, 2007, 25, 1960-6.

Source: <https://exaly.com/paper-pdf/42327240/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2253	Risk factors for coronary calcification in older subjects. The Rotterdam Coronary Calcification Study. 2004 , 25, 48-55		63
2252	Pancreatic cancer. 2004 , 363, 1049-57		1569
2251	Randomized phase II--study evaluating EGFR targeting therapy with cetuximab in combination with radiotherapy and chemotherapy for patients with locally advanced pancreatic cancer--PARC: study protocol [ISRCTN56652283]. 2005 , 5, 131		54
2250	Current treatment strategies for pancreatic cancer in the elderly. 2006 , 23, 403-10		11
2249	Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. 2006 , 12, 4283-7		142
2248	Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials. 2006 , 94, 1107-15		63
2247	A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. 2006 , 95, 587-92		164
2246	Neoadjuvant chemoradiation in patients with pancreatic adenocarcinoma. 2006 , 8, 22-8		13
2245	[Targeted therapy in the treatment of solid tumors and in hematology-oncology. Advances and disappointments]. 2006 , 47, 633-41		1
2244	Adjuvant and neoadjuvant approaches to treat surgically resectable pancreatic cancer. 2006 , 7, 381-8		5
2243	Advances in molecular diagnostics and therapeutics in head and neck cancer. 2006 , 7, 3-11		26
2242	Rationale and appropriate use of chemotherapy and radiotherapy for pancreatic ductal adenocarcinoma. 2006 , 8, 111-20		4
2241	Chemotherapy and other systemic therapies for hepatocellular carcinoma and liver metastases. 2006 , 23, 99-108		13
2240	Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study. 2006 , 94, 481-5		108
2239	In Reply. <i>Journal of Clinical Oncology</i> , 2007 , 25, 4508-4508	2.2	4
2238	Erlotinib in pancreatic cancer patients: do we need more information from the NCIC CTG trial?. <i>Journal of Clinical Oncology</i> , 2007 , 25, 4320-1; author reply 4321-2	2.2	3
2237	Role of platinum agents in the management of advanced pancreatic cancer. 2007 , 8, 2719-27		14

2236 Optimizing Anti-EGFR Strategies in Cancer Treatment. **2007**, 3, 267-275

2235 Does a statistically significant survival benefit of erlotinib plus gemcitabine for advanced pancreatic cancer translate into clinical significance and value?. *Journal of Clinical Oncology*, **2007**, 25, 4506-7; author reply 4508 2.2 62

2234 Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer. **2007**, 73, 221-7 40

2233 The area between the curves gets no respect: is it because of the median madness?. *Journal of Clinical Oncology*, **2007**, 25, 5531 2.2 9

2232 The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006. **2007**, 18 Suppl 7, vii1-vii10 50

2231 Tackling EGFR signaling with TACE antagonists: a rational target for metalloprotease inhibitors in cancer. **2007**, 11, 1287-98 23

2230 Treatment of squamous cell carcinoma of the head and neck in the metastatic and refractory settings: advances in chemotherapy and the emergence of small molecule epidermal growth factor receptor kinase inhibitors. **2007**, 7, 666-73 18

2229 Targeted therapies: cui prodest?. *Journal of Clinical Oncology*, **2007**, 25, 4691-2; author reply 4692 2.2 2

2228 Leukocytoclastic vasculitis during treatment with the oral EGFR tyrosine kinase inhibitor erlotinib. **2007**, 18, 1582-3 21

2227 Phase I study of oxaliplatin, full-dose gemcitabine, and concurrent radiation therapy in pancreatic cancer. *Journal of Clinical Oncology*, **2007**, 25, 4587-92 2.2 47

2226 Mechanisms of disease: chronic inflammation and cancer in the pancreas--a potential role for pancreatic stellate cells?. **2007**, 4, 454-62 77

2225 Erlotinib in pancreatic cancer: are tumor cells the (only) target?. *Journal of Clinical Oncology*, **2007**, 25, 5836-7 2.2 4

2224 Methodological Issues of Clinical Research with EGFR Inhibitors. **2007**, 3, 292-302 3

2223 Lessons learned in the management of advanced pancreatic cancer. *Journal of Clinical Oncology*, **2007**, 25, 1949-52 2.2 29

2222 Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. *Journal of Clinical Oncology*, **2007**, 25, 4787-92 2.2 147

2221 Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. **2007**, 13, 3913-21 324

2220 Erlotinib: recent clinical results and ongoing studies in non small cell lung cancer. **2007**, 13, s4589-92 11

2219 Targets, trials, and travails in pancreas cancer. **2007**, 5, 1042-53 10

2218	An open-label, noncomparative phase II trial to evaluate the efficacy and safety of docetaxel in combination with gefitinib in patients with hormone-refractory metastatic prostate cancer. 2007 , 30, 355-60	19
2217	EGFR targeting of solid tumors. 2007 , 14, 295-304	220
2216	Phase II trial of weekly docetaxel/irinotecan combination in advanced pancreatic cancer. 2007 , 13, 257-62	19
2215	Update in colorectal, hepatobiliary and pancreatic cancers. 2007 , 2, 141-156	
2214	Cellular responses to EGFR inhibitors and their relevance to cancer therapy. 2007 , 254, 165-77	121
2213	EGFR genomic gain and aberrant pathway signaling in pancreatic cancer patients. 2007 , 143, 20-6	30
2212	Oncogenic K-Ras signals through epidermal growth factor receptor and wild-type H-Ras to promote radiation survival in pancreatic and colorectal carcinoma cells. 2007 , 9, 341-8	70
2211	Gemcitabine-induced reversible posterior leukoencephalopathy syndrome: a case report and review of the literature. 2007 , 12, 1332-5	53
2210	Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. 2007 , 67, 11012-20	252
2209	EGFR, HER2 and VEGF pathways: validated targets for cancer treatment. 2007 , 67, 2045-75	97
2208	Erlotinib in pancreatic cancer. 2007 , 5, 7-8	
2207	Capecitabine: an evidence-based review of its effectiveness in the treatment of carcinoma of the pancreas. 2007 ,	
2206	Targeting cell signaling pathways for drug discovery: an old lock needs a new key. 2007 , 102, 580-92	107
2205	Gemcitabine-based combinations for inoperable pancreatic cancer: have we made real progress? A meta-analysis of 20 phase 3 trials. 2007 , 110, 525-33	83
2204	The multidisciplinary management of gastrointestinal cancer. Pancreatic cancer: from pathogenesis to cure. 2007 , 21, 997-1014	11
2203	A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer. 2007 , 7, 142	60
2202	Future strategies for targeted therapies and tailored patient management in pancreatic cancer. 2007 , 34, 354-64	8
2201	[Systemic treatment of peritoneal metastases]. 2007 , 78, 1117-22	3

2200	A Phase II study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) and gemcitabine in advanced pancreatic carcinoma. A trial of the Princess Margaret hospital Phase II consortium. 2007 , 25, 553-8	71
2199	Progress in the development of prognostic and predictive markers for gastrointestinal malignancies. 2007 , 8, 339-51	15
2198	Pancreatic cancer: an update. 2007 , 9, 170-6	28
2197	Pankreaskarzinom. 2007 , 2, 4-17	
2196	Targeted therapy for oesophageal cancer: an overview. 2008 , 27, 273-88	18
2195	Pancreatic cancer: from molecular pathogenesis to targeted therapy. 2008 , 27, 495-522	66
2194	Clinical biomarkers of kinase activity: examples from EGFR inhibition trials. 2008 , 27, 387-402	26
2193	Clinical biomarkers of angiogenesis inhibition. 2008 , 27, 415-34	39
2192	HER2 gene amplification and chromosome 17 copy number do not predict survival of patients with resected pancreatic adenocarcinoma. 2008 , 53, 3026-32	13
2191	A phase I trial of CEP-701 + gemcitabine in patients with advanced adenocarcinoma of the pancreas. 2008 , 26, 241-7	31
2190	A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas. 2008 , 26, 369-79	63
2189	The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP) predicts in vivo metabolic inhibition. 2008 , 64, 31-41	96
2188	Inhibition by erlotinib of primary lung adenocarcinoma at an early stage in male mice. 2008 , 62, 605-20	29
2187	A phase II study of capecitabine plus gemcitabine in patients with locally advanced or metastatic pancreatic cancer. 2008 , 62, 763-8	12
2186	[Molecular tumour therapy: antibodies and small molecules]. 2008 , 49, 581-92	1
2185	[Pancreatic carcinoma]. 2008 , 49, 1079-86; quiz 1087	3
2184	Can we predict the response to epidermal growth factor receptor targeted therapy?. 2008 , 3, 87-99	1
2183	Innovative Therapieansätze für das Pankreasadenokarzinom. 2008 , 1, 8-10	

2182	Molekulare Aspekte des Pankreaskarzinoms [ein Update. 2008 , 1, 57-62	
2181	Systemtherapie des Pankreaskarzinoms. 2008 , 1, 74-77	1
2180	Rash from EGFR inhibitors: opportunities and challenges for palliation. 2008 , 10, 304-8	16
2179	Future perspectives in the treatment of pancreatic cancer. 2008 , 1, 27-30	
2178	Molecular biology of pancreatic cancer. 2008 , 10, 530-7	8
2177	Prognoseadaptierte Therapie beim fortgeschrittenen CUP-Syndrom. 2008 , 14, 920-930	0
2176	Unilateral face swelling as first manifestation of metastatic pancreatic cancer: case report and review of the literature. 2008 , 120, 693-6	3
2175	Molecular targeting therapy for pancreatic cancer: current knowledge and perspectives from bench to bedside. 2008 , 43, 905-11	38
2174	Targeting angiogenesis in pancreatic cancer: rationale and pitfalls. 2008 , 393, 901-10	27
2173	Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. 2008 , 113, 808-14	98
2172	Systemic cancer therapy: evolution over the last 60 years. 2008 , 113, 1857-87	42
2171	Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. 2008 , 113, 2046-52	109
2170	End-of-life planning and its relevance for patients' and oncologists' decisions in choosing cancer therapy. 2008 , 113, 3540-7	21
2169	EGFR Inhibition in the Treatment of Non-Small Cell Lung Cancer. 2008 , 69, 359-372	34
2168	Dysregulation of apoptotic signaling in cancer: molecular mechanisms and therapeutic opportunities. 2008 , 104, 1124-49	140
2167	Pancreatic cancer: progress in cancer therapy. 2008 , 67, 27-38	30
2166	Pancreatic cancer: from molecular signature to target therapy. 2008 , 68, 197-211	35
2165	Locally advanced non-metastatic pancreatic cancer--can we do more?. 2008 , 20, 532-4	2

2164	EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. 2008 , 19, 717-23	225
2163	Allo-SCT using reduced-intensity conditioning against advanced pancreatic cancer: a Japanese survey. 2008 , 42, 99-103	7
2162	Survival from cancer of the pancreas in England and Wales up to 2001. 2008 , 99 Suppl 1, S24-5	6
2161	Palliative treatment of pancreatic cancer. 2008 , 9, 1-7	20
2160	Enhanced distribution of NK012, a polymeric micelle-encapsulated SN-38, and sustained release of SN-38 within tumors can beat a hypovascular tumor. 2008 , 99, 1258-64	39
2159	Tumeurs digestives et bvacizumab. 2008 , 145, 16-20	
2158	Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy). 2008 , 8, 361	61
2157	Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. 2008 , 8, 82	315
2156	Molecular mechanisms for individualized cancer care. 2008 , 207, 250-8	20
2155	Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine. 2008 , 93, 2057-62	122
2154	Targeted therapies for patients with germ cell tumors. 2008 , 17, 511-22	17
2153	Epidermal growth factor receptor inhibitor-related skin toxicity: mechanisms, treatment, and its potential role as a predictive marker. 2008 , 7, 33-43	46
2152	Biological approaches to therapy of pancreatic cancer. 2008 , 8, 431-61	19
2151	Erlotinib: the first biologic in the management of pancreatic cancer. 2008 , 9, 1595-607	8
2150	Current challenges and future perspectives in the medical treatment of solid tumours. 2008 , 6, 91-93	
2149	EGFR Signaling Networks in Cancer Therapy. 2008 ,	7
2148	Radiotherapy combined with gemcitabine and oxaliplatin in pancreatic cancer cells. 2008 , 1, 36-43	22
2147	Drug insight: antiangiogenic therapies for gastrointestinal cancers--focus on monoclonal antibodies. 2008 , 5, 250-67	28

2146 Les thfapies ciblès. **2008**,

2145 Molecular targeted therapies for pancreatic cancer. **2008**, 196, 430-41

42

2144 EGFR antagonists in cancer treatment. **2008**, 358, 1160-74

1570

2143 Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents. **2008**, 11, 99-109

27

2142 Erlotinib in combination with capecitabine and docetaxel in patients with metastatic breast cancer: a dose-escalation study. **2008**, 44, 419-26

32

2141 Budget impact model of adding erlotinib to a regimen of gemcitabine for the treatment of locally advanced, nonresectable or metastatic pancreatic cancer. **2008**, 30, 775-84

20

2140 Phase II trial of curcumin in patients with advanced pancreatic cancer. **2008**, 14, 4491-9

997

2139 Gastro-Highlights 2007. **2008**, 3, 68-70

2138 Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. **2008**, 371, 2101-8

213

2137 Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial. **2008**, 9, 39-44

114

2136 Improving treatment of pancreatic cancer. **2008**, 9, 7-8

15

2135 Trials in palliative treatment--have the goal posts been moved?. **2008**, 9, 186-7

30

2134 Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. **2008**, 9, 962-72

623

2133 Targeted therapy for solid tumors: current status. **2008**, 17, 279-301, vii-viii

10

2132 Translation of recent advances and discoveries in molecular biology and immunology in the diagnosis and treatment of pancreatic cancer. **2008**, 17, 357-76, ix

1

2131 Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. *Journal of Clinical Oncology*, **2008**, 26, 1626-34

2.2 2666

2130 Implications of EGFR PharmDx kit for cetuximab eligibility. **2008**, 8, 141-8

15

2129 Activated epidermal growth factor receptor as a novel target in pancreatic cancer therapy. **2008**, 7, 4651-8

37

2128	Biology and management of pancreatic cancer. 2007 , 56, 1134-52		203
2127	Results from a monocentric phase II trial of erlotinib in patients with metastatic prostate cancer. 2008 , 19, 1624-8		42
2126	Targeted therapies for pancreatic cancer. 2008 , 87, 97-130		23
2125	Improving gemcitabine-mediated radiosensitization using molecularly targeted therapy: a review. 2008 , 14, 6744-50		49
2124	S-1 and gemcitabine as an outpatient-based regimen in patients with advanced or metastatic pancreatic cancer. 2009 , 39, 49-53		18
2123	Novel agents in the era of targeted therapy: what have we learned and how has our practice changed?. 2008 , 19 Suppl 7, vii281-8		3
2122	Influence of resection margins and treatment on survival in patients with pancreatic cancer: meta-analysis of randomized controlled trials. 2008 , 143, 75-83; discussion 83		231
2121	New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways. 2008 , 13, 289-98		73
2120	Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. <i>Journal of Clinical Oncology</i> , 2008 , 26, 183-9	2.2	153
2119	Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer. 2008 , 68, 2841-9		84
2118	A population-based, descriptive analysis of malignant intraductal papillary mucinous neoplasms of the pancreas. 2008 , 17, 2737-41		20
2117	HMGA1 is a molecular determinant of chemoresistance to gemcitabine in pancreatic adenocarcinoma. 2008 , 14, 1470-7		71
2116	A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer. 2008 , 14, 6277-83		59
2115	Inhibition of N-linked glycosylation disrupts receptor tyrosine kinase signaling in tumor cells. 2008 , 68, 3803-9		143
2114	How I treat pancreatic ductal adenocarcinoma. 2008 , 4, 46-7		
2113	Challenges in developing targeted therapy for pancreatic adenocarcinoma. 2008 , 12, 1389-401		14
2112	[Limitations and pitfalls of clinical studies in oncology]. 2008 , 31 Suppl 2, 67-71		1
2111	Venous thromboembolism and pancreatic cancer: incidence, pathogenesis and clinical implications. 2008 , 31, 129-35		3

2110	Biologic therapies for advanced pancreatic cancer. 2008 , 8, 1331-8		6
2109	RCAS-mediated retroviral gene delivery: a versatile tool for the study of gene function in a mouse model of pancreatic cancer. 2008 , 19, 896-906		8
2108	Toxicity of targeted therapies in elderly patients. 2008 , 8, 1965-76		4
2107	Novel advances in pancreatic cancer treatment. 2008 , 8, 993-1002		43
2106	Multidisciplinary management of resectable adenocarcinoma of the pancreatic head. 2008 , 8, 1611-21		1
2105	A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers. 2008 , 98, 1774-80		41
2104	Gemcitabine in the treatment of metastatic pancreatic cancer. 2008 , 8, 511-23		36
2103	Past and future of pancreas cancer: are we ready to move forward together?. <i>Journal of Clinical Oncology</i> , 2008 , 26, 3478-80	2.2	10
2102	Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. 2008 , 14, 1455-63		265
2101	Human Mena+11a isoform serves as a marker of epithelial phenotype and sensitivity to epidermal growth factor receptor inhibition in human pancreatic cancer cell lines. 2008 , 14, 4943-50		55
2100	Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study. <i>Journal of Clinical Oncology</i> , 2008 , 26, 4921-7	2.2	102
2099	Nuclear factor-kappaB p65/relA silencing induces apoptosis and increases gemcitabine effectiveness in a subset of pancreatic cancer cells. 2008 , 14, 8143-51		111
2098	Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial-SAKK 44/00-CECOG/PAN.1.3.001. <i>Journal of Clinical Oncology</i> , 2008 , 26, 3695-701	2.2	81
2097	Pilot study of combination chemotherapy using irinotecan plus S-1 for metastatic pancreatic cancer. 2008 , 75, 67-70		4
2096	Phase I study of biweekly oxaliplatin, gemcitabine and capecitabine in patients with advanced upper gastrointestinal malignancies. 2008 , 19, 1742-8		6
2095	Pancreatic cancer: a review and update. 2008 , 12, 735-41		21
2094	A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma. 2008 , 19, 86-91		60
2093	New treatment options for advanced pancreatic cancer. 2008 , 2, 673-96		25

2092	New aspects of regulatory signaling pathways and novel therapies in pancreatic cancer. 2008 , 8, 12-37		17
2091	Determinants of RASistance to anti-epidermal growth factor receptor agents. <i>Journal of Clinical Oncology</i> , 2008 , 26, 1582-4	2.2	69
2090	Neuropilin-2-mediated tumor growth and angiogenesis in pancreatic adenocarcinoma. 2008 , 14, 8052-60		66
2089	Bortezomib is ineffective in an orthotopic mouse model of pancreatic adenocarcinoma. 2008 , 7, 3624-31		29
2088	Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer. 2008 , 19, 340-7		60
2087	Phase I trial of a pathotropic retroviral vector expressing a cytotoxic cyclin G1 construct (Rexin-G) in patients with advanced pancreatic cancer. 2008 , 16, 979-84		37
2086	The treatment of advanced pancreatic cancer: current evidence and future challenges. 2008 , 19 Suppl 7, vii304-8		2
2085	Handling side-effects of targeted therapies: safety of targeted therapies in solid tumours. 2008 , 19 Suppl 7, vii146-52		8
2084	Metastatic pancreatic cancer 2008: is the glass less empty?. 2008 , 13, 562-76		94
2083	Pancreatic stellate cells and pancreatic cancer cells: an unholy alliance. 2008 , 68, 7707-10		174
2082	Coagulation, anticoagulation and pancreatic carcinoma. 2008 , 5, 445-55		18
2081	Apoptosis-inducing effect of erlotinib is potentiated by 3,3'-diindolylmethane in vitro and in vivo using an orthotopic model of pancreatic cancer. 2008 , 7, 1708-19		75
2080	Ethical, scientific, and regulatory perspectives regarding the use of placebos in cancer clinical trials. <i>Journal of Clinical Oncology</i> , 2008 , 26, 1371-8	2.2	45
2079	Small Molecules: Big Changes in the Cancer Treatment Paradigm. 2008 , 21, 17-35		1
2078	Pharmacodynamic monitoring of molecular-targeted agents in the peripheral blood of leukemia patients using flow cytometry. 2008 , 36, 133-9		15
2077	Second-line therapy in gemcitabine-pretreated patients with advanced pancreatic cancer. <i>Journal of Clinical Oncology</i> , 2008 , 26, 1178-9; author reply 1179	2.2	21
2076	The combination of epidermal growth factor receptor inhibitors with gemcitabine and radiation in pancreatic cancer. 2008 , 14, 5142-9		100
2075	Phase I pharmacokinetic/pharmacodynamic study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in first-line treatment of patients with metastatic colorectal cancer. 2008 , 14, 215-23		23

2074	A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients. 2008 , 19, 332-9	24
2073	Comparison of gemcitabine plus platinum analog with gemcitabine alone in advanced pancreatic cancer. 2008 , 5, 312-3	2
2072	Upper gastrointestinal tumors: current status and future perspectives. 2008 , 8, 975-91	6
2071	Current adjuvant and targeted therapies for pancreatic adenocarcinoma. 2008 , 15, 1674-83	14
2070	Pancreatic cancer--is the wall crumbling?. 2008 , 19, 1224-1230	30
2069	The role of second-line chemotherapy after gemcitabine failure in patients with advanced pancreatic cancer. 2008 , 4, 41-50	17
2068	Is there a role for advanced radiation therapy technologies in the treatment of pancreatic adenocarcinoma?. 2008 , 4, 241-55	
2067	Current status of antivasular therapy and targeted treatment in the clinic. 2008 , 24, 97-110	0
2066	Gemcitabine combined with gefitinib in patients with inoperable or metastatic pancreatic cancer: a phase II Study of the Hellenic Cooperative Oncology Group with biomarker evaluation. 2008 , 26, 784-93	58
2065	2) Chemical and Molecular-targeted Therapy of Digestive System Neoplasm. 2008 , 97, 2098-2104	
2064	Cytostatic and cytotoxic drugs. 2008 , 520-532	1
2063	Cancer of the pancreas: are we making progress? A review of studies in the US Oncology Research Network. 2008 , 15, 308-13	51
2062	Bibliography. Current world literature. Supportive care. 2008 , 20, 472-8	
2061	Gemcitabine/5-flourouracil/leucovorin for the treatment of advanced pancreatic carcinoma. 2008 , 1, 221-4	2
2060	Borderline resectable pancreatic cancer: on the edge of survival. 2008 , 15, 295-307	37
2059	Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer. 2008 , 3, 1003-11	54
2058	New directions in the management of advanced pancreatic cancer: a review. 2008 , 19, 435-46	32
2057	PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen as second-line therapy in patients with progressive or recurrent pancreatic cancer after gemcitabine-containing chemotherapy. 2008 , 31, 145-50	18

2056	Lapatinib/gemcitabine and lapatinib/gemcitabine/oxaliplatin: a phase I study for advanced pancreaticobiliary cancer. 2008 , 31, 140-4	36
2055	Hot topics and landmark studies from the 43rd annual meeting of the American Society of Clinical Oncology. 2008 , 19, 221-33	0
2054	Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma. 2008 , 37, 154-8	147
2053	From the podium to the patient: bringing the 2008 ASCO meeting to the clinic. 2008 , 19, 941-56	
2052	Lessons from Tarceva in pancreatic cancer: where are we now, and how should future trials be designed in pancreatic cancer?. 2008 , 20, 454-8	14
2051	Protein kinase C: a target for therapy in pancreatic cancer. 2008 , 36, 346-52	26
2050	Tolerance and efficacy of gemcitabine and gemcitabine-based regimens in elderly patients with advanced pancreatic cancer. 2008 , 36, e16-21	47
2049	Cell signaling modifiers in prostate cancer. 2008 , 14, 40-5	7
2048	Treatment of locally advanced and metastatic pancreatic cancer. 166-174	
2047	Are self-regulation and declaration of conflict of interest still the benchmark for relationships between physicians and industry?. 2008 , 189, 263-6	17
2046	Erlotinib in the treatment of advanced pancreatic cancer. 2008 , 2, 83-95	38
2045	Evolving therapies in the treatment of hepatocellular carcinoma. 2008 , 2, 453-62	13
2044	Small molecule tyrosine kinase inhibitors in pancreatic cancer. 2008 , 2, 707-15	13
2043	Therapy of adenocarcinoma of unknown primary: are we making progress?. 2008 , 6, 1061-7	13
2042	The Role of PPAR-gamma and Its Interaction with COX-2 in Pancreatic Cancer. 2008 , 2008, 326915	21
2041	Endoscopic ultrasound-guided intratumoural therapy for pancreatic cancer. 2008 , 22, 405-10	25
2040	What changes are needed to the current direction and interpretation of clinical cancer research to meet the needs of the 21st century?. 2009 , 190, 74-7	10
2039	Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy. 2009 , 419	

2038	Current use and potential role of bevacizumab in the treatment of gastrointestinal cancers. 2009 , 429		
2037	First-line simplified GEMOX (S-GemOx) versus classical GEMOX in metastatic pancreatic cancer (MPA): results of a GERCOR randomized phase II study. 2009 , 96, E18-22		9
2036	Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers. 2009 , 2009, 567486		85
2035	Epidermal growth factor receptor inhibition modulates the microenvironment by vascular normalization to improve chemotherapy and radiotherapy efficacy. 2009 , 4, e6539		103
2034	EGFR genomic alterations in cancer: prognostic and predictive values. 2009 , E3, 879		3
2033	Emerging drugs in the treatment of pancreatic cancer. 2009 , 14, 311-28		9
2032	Small-molecule inhibitors of the human epidermal receptor family. 2009 , 18, 1829-42		23
2031	Management of advanced pancreatic cancer. 2009 , 2, 527-41		2
2030	Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 2231-7	2.2	533
2029	Dual inhibition of the epidermal growth factor receptor pathway with cetuximab and erlotinib: a phase I study in patients with advanced solid malignancies. 2009 , 14, 119-24		18
2028	Monoclonal antibodies in the treatment of pancreatic cancer. 2009 , 1, 223-9		31
2027	Pancreatic cancer: advances in medical therapy. 2009 , 2, 173-80		
2026	Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3778-85	2.2	338
2025	Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5513-8	2.2	606
2024	Molecular changes in pancreatic cancer. 2009 , 9, 1487-97		17
2023	Erlotinib: applications in therapy and current status of research. 2009 , 2, 15-36		1
2022	Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer. 2009 , 15, 6639-48		95
2021	DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 1806-13	2.2	793

2020	A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer. 2009 , 101, 1658-63		128
2019	A phase I trial of Capecitabine+Gemcitabine with radical radiation for locally advanced pancreatic cancer. 2009 , 100, 37-43		5
2018	Cancer: the road to Amiens. <i>Journal of Clinical Oncology</i> , 2009 , 27, 328-33	2.2	89
2017	Lessons from gefitinib-induced interstitial lung disease: Pharmacovigilance for erlotinib in Japan. 2009 , 21, 161-167		
2016	Changing the paradigm in conducting randomized clinical studies in advanced pancreatic cancer: an opportunity for better clinical development. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5487-91	2.2	23
2015	Mechanisms of tumor resistance to EGFR-targeted therapies. 2009 , 13, 339-62		66
2014	Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 193-8	2.2	240
2013	Paclitaxel/carboplatin plus bevacizumab/erlotinib in the first-line treatment of patients with carcinoma of unknown primary site. 2009 , 14, 1189-97		46
2012	Pancreatic cancer and precursor pancreatic intraepithelial neoplasia lesions are devoid of primary cilia. 2009 , 69, 422-30		180
2011	Monitoring for lack of benefit: a critical component of a randomized clinical trial. <i>Journal of Clinical Oncology</i> , 2009 , 27, 629-33	2.2	27
2010	Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5506-12	2.2	74
2009	Current oncological treatment of patients with pancreatic cancer in germany: results from a national survey on behalf of the Arbeitsgemeinschaft Internistische Onkologie and the Chirurgische Arbeitsgemeinschaft Onkologie of the Germany Cancer Society. 2009 , 77, 40-8		17
2008	Do recurrent and metastatic pancreatic cancer patients have the same outcomes with gemcitabine treatment?. 2009 , 77, 217-23		23
2007	Fixed-dose-rate gemcitabine in combination with oxaliplatin in patients with metastatic pancreatic cancer refractory to standard-dose-rate gemcitabine: a single-institute study. 2009 , 76, 333-7		16
2006	Epigenetic modulation and attacking the hedgehog pathway: potentially synergistic therapeutic targets for pancreatic cancer. 2009 , 8, 1340-2		4
2005	Gemcitabine combined with uracil-tegafur in patients with advanced pancreatic cancer. 2009 , 101, 761-4		
2004	The role of downstream signaling pathways of the epidermal growth factor receptor for Artesunate's activity in cancer cells. 2009 , 9, 72-80		36
2003	Changing the clinical picture of challenging tumors: tales becoming reality?. 2009 , 5, 785-802		1

2002	Serine protease inhibitor Kazal type 1 promotes proliferation of pancreatic cancer cells through the epidermal growth factor receptor. 2009 , 7, 1572-81	79
2001	Second-line therapy in refractory pancreatic cancer. results of a phase II study. 2009 , 32, 99-102	18
2000	[Gastrointestinal oncology - therapy update 2008 / 2009]. 2009 , 47, 296-306	
1999	Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. 2009 , 16, 4066-218	86
1998	Prognostic signature for pancreatic cancer: are we close?. 2009 , 5, 313-21	12
1997	Adjuvante und palliative Therapie des Pankreaskarzinoms [Update. 2009 , 5, 261-279	
1996	Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects. 2009 , 10, 470-81	388
1995	Targeted therapies in solid tumours: pinpointing the tumour's Achilles heel. 2009 , 15, 207-42	9
1994	Risk in clinical research: size matters!. 2009 , 17, 1833-4	2
1993	Regular dose of gemcitabine induces an increase in CD14+ monocytes and CD11c+ dendritic cells in patients with advanced pancreatic cancer. 2009 , 39, 797-806	46
1992	A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. 2009 , 15, 5895-901	91
1991	Pancreatic cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. 2009 , 20 Suppl 4, 37-40	21
1990	Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5499-505 ^{2,2}	20
1989	Feasibility of radiotherapy with concomitant gemcitabine and oxaliplatin in locally advanced pancreatic cancer and distal cholangiocarcinoma: a prospective dose finding phase I-II study. 2009 , 20, 1369-74	13
1988	Regression of human pancreatic tumor xenografts in mice after a single systemic injection of recombinant vaccinia virus GLV-1h68. 2009 , 8, 141-51	86
1987	Incremental advance or seismic shift? The need to raise the bar of efficacy for drug approval. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5868-73	2.2 75
1986	Oral poly(ADP-ribose) polymerase-1 inhibitor BSI-401 has antitumor activity and synergizes with oxaliplatin against pancreatic cancer, preventing acute neurotoxicity. 2009 , 15, 6367-77	34
1985	Flavonoids, phenoxodiol, and a novel agent, triphendiol, for the treatment of pancreaticobiliary cancers. 2009 , 18, 469-79	26

1984	3,3'-Diindolylmethane enhances chemosensitivity of multiple chemotherapeutic agents in pancreatic cancer. 2009 , 69, 5592-600	89
1983	Translational advances and novel therapies for pancreatic ductal adenocarcinoma: hope or hype?. 2009 , 11, e34	6
1982	Erlotinib-induced hepatitis complicated by fatal lactic acidosis in an elderly man with lung cancer. 2009 , 43, 542-5	18
1981	How much is life worth: cetuximab, non-small cell lung cancer, and the \$440 billion question. 2009 , 101, 1044-8	274
1980	A case of bullous dermatitis induced by erlotinib. 2009 , 14, 1201-4	4
1979	Mucositis: The impact, biology and therapeutic opportunities of oral mucositis. 2009 , 45, 1015-20	295
1978	Patient-reported outcomes as a component of the primary endpoint in a double-blind, placebo-controlled trial in advanced pancreatic cancer. 2009 , 37, 135-43	19
1977	An antiendothelial combination therapy strategy to increase survival in experimental pancreatic cancer. 2009 , 146, 241-9	13
1976	Randomised Phase I/II trial assessing the safety and efficacy of radiolabelled anti-carcinoembryonic antigen I(131) KAb201 antibodies given intra-arterially or intravenously in patients with unresectable pancreatic adenocarcinoma. 2009 , 9, 66	28
1975	Management of venous thromboembolism and the potential to impact overall survival in patients with cancer. 2009 , 29, 1344-56	4
1974	Novel agents on the horizon for cancer therapy. 2009 , 59, 111-37	241
1973	Models for prevention and treatment of cancer: problems vs promises. 2009 , 78, 1083-94	117
1972	[Targeted biotherapies in digestive oncology: management of adverse effects]. 2009 , 33, 306-22	10
1971	Targeting EGFR resistance networks in head and neck cancer. 2009 , 21, 1255-68	61
1970	Treatment for patients with unknown primary carcinoma and unfavorable prognostic factors. 2009 , 36, 65-74	74
1969	Mutational profiling of cancer candidate genes in glioblastoma, melanoma and pancreatic carcinoma reveals a snapshot of their genomic landscapes. 2009 , 30, E451-9	37
1968	Carbohydrate antigen 19-9 change during chemotherapy for advanced pancreatic adenocarcinoma. 2009 , 115, 2630-9	89
1967	Pancreatic adenocarcinoma in a young patient population--12-year experience at Memorial Sloan Kettering Cancer Center. 2009 , 100, 8-12	23

1966	Antitumor activity of the HER2 dimerization inhibitor pertuzumab on human colon cancer cells in vitro and in vivo. 2009 , 135, 1377-86	21
1965	Combined therapies for cancer: a review of EGFR-targeted monotherapy and combination treatment with other drugs. 2009 , 135, 1137-48	34
1964	Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer. 2009 , 115, 115-21	101
1963	Inhibition of protein synthesis by imexon reduces HIF-1alpha expression in normoxic and hypoxic pancreatic cancer cells. 2009 , 27, 89-98	10
1962	Phase II study of calcitriol-enhanced docetaxel in patients with previously untreated metastatic or locally advanced pancreatic cancer. 2009 , 27, 374-8	37
1961	Interplay of tumor microenvironment cell types with parenchymal cells in pancreatic cancer development and therapeutic implications. 2009 , 40, 1-9	13
1960	Consensus on the treatment of pancreatic cancer in Spain. 2009 , 11, 290-301	4
1959	Skin toxicities associated with epidermal growth factor receptor inhibitors. 2009 , 4, 107-19	218
1958	Targeting mitogen-activated protein kinase kinase (MEK) in solid tumors. 2009 , 4, 267-73	19
1957	Axitinib--a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor. 2009 , 4, 297-305	69
1956	Implications of KRAS mutation status for the treatment of metastatic colorectal cancer. 2009 , 4, 311-22	3
1955	CC chemokine receptor 9 enhances proliferation in pancreatic intraepithelial neoplasia and pancreatic cancer cells. 2009 , 13, 1955-62; discussion 1962	27
1954	Pancreatic cancer [ASCO 2009]. 2009 , 2, 211-213	
1953	[The S3 guideline exocrine pancreatic cancer]. 2009 , 104, 869-74	9
1952	[Medical-oncological aspects in the treatment of pancreatic cancer]. 2009 , 49, 144-8	
1951	Basic principles and technologies for deciphering the genetic map of cancer. 2009 , 33, 615-29	12
1950	A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer. 2009 , 63, 313-9	79
1949	Adaptive group sequential design for phase II clinical trials: a Bayesian decision theoretic approach. 2009 , 28, 3347-62	12

1948	Tumor biology and cancer therapy - an evolving relationship. 2009 , 7, 19		10
1947	Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib. 2009 , 100, 1701-7		56
1946	Adenosquamous carcinoma of the pancreas harbors KRAS2, DPC4 and TP53 molecular alterations similar to pancreatic ductal adenocarcinoma. 2009 , 22, 651-9		61
1945	Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma. 2009 , 28, 2903-9		100
1944	Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts. 2009 , 100, 1267-76		100
1943	Does clinical method mask significant VTE-related mortality and morbidity in malignant disease?. 2009 , 100, 1837-41		12
1942	Chemoradiotherapy with concurrent gemcitabine and cisplatin with or without sequential chemotherapy with gemcitabine/cisplatin vs chemoradiotherapy with concurrent 5-fluorouracil in patients with locally advanced pancreatic cancer--a multi-centre randomised phase II study. 2009 , 101, 1853-9		47
1941	Epidermal growth factor receptor inhibitors: current status and future directions. 2009 , 33, 245-94		9
1940	Gemcitabine-based combination chemotherapy followed by radiation with capecitabine as adjuvant therapy for resected pancreas cancer. 2009 , 75, 1450-5		12
1939	Advances in the treatment of pancreatic cancer: limitations of surgery and evaluation of new therapeutic strategies. 2009 , 39, 466-75		38
1938	Editorial: Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus conference. 2009 , 16, 1757-9		5
1937	Ultimate fate of oncology drugs approved by the us food and drug administration without a randomized Trial. <i>Journal of Clinical Oncology</i> , 2009 , 27, 6243-50	2.2	69
1936	Phase II clinical trial of paclitaxel loaded polymeric micelle in patients with advanced pancreatic cancer. 2010 , 28, 186-94		63
1935	Rash associated with the use of pegylated filgrastim in a patient with advanced pancreatic cancer. 2009 , 28, 181-4		4
1934	Markers involved in resistance to cytotoxics and targeted therapeutics in pancreatic cancer. 2009 , 35, 167-74		46
1933	Molecular assignment of tissue of origin in cancer of unknown primary may not predict response to therapy or outcome: a systematic literature review. 2009 , 35, 221-7		69
1932	Treatment of advanced pancreatic cancer: from gemcitabine single agent to combinations and targeted therapy. 2009 , 35, 335-9		87
1931	Pancreatic cancer: current and future treatment strategies. 2009 , 35, 431-6		79

1930	Second-line therapy for advanced pancreatic cancer: a review of the literature and future directions. 2009 , 35, 676-84	27
1929	Cachexia in pancreatic cancer [Mechanisms and potential intervention. 2009 , 4, e337-e343	1
1928	A randomised Phase III trial of glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine. 2009 , 45, 1589-96	59
1927	Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma. 2009 , 45, 2316-23	70
1926	Staging for locally advanced pancreatic cancer. 2009 , 35, 963-8	27
1925	HER-family gene amplification and expression in resected pancreatic cancer. 2009 , 35, 1098-104	21
1924	Synergistic effects of acyclic retinoid and gemcitabine on growth inhibition in pancreatic cancer cells. 2009 , 273, 250-6	19
1923	Cancers of the pancreas and hepatobiliary system. 2009 , 25, 76-92	11
1922	Erlotinib has moderate single-agent activity in chemotherapy-naïve castration-resistant prostate cancer: final results of a phase II trial. 2009 , 74, 665-71	33
1921	[Targeted therapies and their indications in solid neoplasias]. 2009 , 30, 416-24	4
1920	Novel agents for the treatment of adenocarcinoma of the pancreas. 2009 , 9, 1473-85	22
1919	Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. 2009 , 53, 2231-47	885
1918	Upper gastrointestinal malignancies: a new era in clinical colorectal cancer. 2009 , 8, 185-9	1
1917	Intrinsic chemoresistance to gemcitabine is associated with constitutive and laminin-induced phosphorylation of FAK in pancreatic cancer cell lines. 2009 , 8, 125	95
1916	Updates in Gastrointestinal Oncology - insights from the 2008 44th annual meeting of the American Society of Clinical Oncology. 2009 , 2, 9	19
1915	The molecular basis of cancer and the development of targeted therapy. 2009 , 89, 1-15, vii	12
1914	Pancreatic cancer: molecular pathogenesis and new therapeutic targets. 2009 , 6, 412-22	165
1913	Surgical Treatment of Pancreatic Diseases. 2009 ,	3

1912	Targeting targeted agents: open issues for clinical trial design. 2009 , 28, 66		15
1911	In vitro models of pancreatic cancer for translational oncology research. 2009 , 4, 429-443		24
1910	Current status and future prospects for anti-angiogenic therapies in cancer. 2009 , 4, 961-79		24
1909	Proteomic and metabolic prediction of response to therapy in gastrointestinal cancers. 2009 , 6, 170-83		15
1908	Cucurbitacin B induces apoptosis by inhibition of the JAK/STAT pathway and potentiates antiproliferative effects of gemcitabine on pancreatic cancer cells. 2009 , 69, 5876-84		180
1907	Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. 2009 , 101, 1308-24		424
1906	Heterogeneity of tumour response to combined radiotherapy and EGFR inhibitors: differences between antibodies and TK inhibitors. 2009 , 85, 943-54		34
1905	Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5660-9	2.2	184
1904	A phase II study of flavopiridol (Alvocidib) in combination with docetaxel in refractory, metastatic pancreatic cancer. 2009 , 9, 404-9		32
1903	Cancer de pancreas. 2009 , 10, 1737-1743		
1902	EGFR signaling and drug discovery. 2009 , 77, 400-10		324
1901	Second- and third-line chemotherapy in patients with metastatic pancreatic adenocarcinoma: feasibility and potential benefits in a retrospective series of 117 patients. 2009 , 33, 1036-44		14
1900	Medical management of pancreatic adenocarcinoma. 2009 , 9, 223-32		12
1899	Prolonged survival in a patient with BRCA2 associated metastatic pancreatic cancer after exposure to camptothecin: a case report and review of literature. 2009 , 20, 634-8		37
1898	Oxaliplatin, 5-fluorouracil, and leucovorin as second-line treatment for advanced pancreatic cancer. 2009 , 32, 44-8		30
1897	Economic analysis of radiation therapy oncology group 97-14: multiple versus single fraction radiation treatment of patients with bone metastases. 2009 , 32, 423-8		71
1896	Targeted therapies to treat non-AIDS-defining cancers in patients with HIV on HAART therapy: treatment considerations and research outlook. 2009 , 21, 445-54		35
1895	Results of a phase I trial of 12 patients with locally advanced pancreatic carcinoma combining gefitinib, paclitaxel, and 3-dimensional conformal radiation: report of toxicity and evaluation of circulating K-ras as a potential biomarker of response to therapy. 2009 , 32, 115-21		17

1894	Chemoradioimmunotherapy in locally advanced pancreatic and biliary tree adenocarcinoma: a multicenter phase II study. 2009 , 38, e163-8	10
1893	Signalling pathways in prostate carcinogenesis: potentials for molecular-targeted therapy. 2009 , 117, 209-28	25
1892	NCCN Task Force Report: Management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer. 2009 , 7 Suppl 1, S5-21; quiz S22-4	87
1891	Intermittent erlotinib in combination with pemetrexed: phase I schedules designed to achieve pharmacodynamic separation. 2009 , 4, 862-8	38
1890	Antiangiogenic versus cytotoxic therapeutic approaches in a mouse model of pancreatic cancer: an experimental study with a multitarget tyrosine kinase inhibitor (sunitinib), gemcitabine and radiotherapy. 2009 , 22, 105-13	19
1889	Metastatic pancreatic adenocarcinoma: current standards, future directions. 2010 , 17, 79-85	
1888	Tyrosine kinases as molecular targets to inhibit cancer progression and metastasis. 2010 , 16, 1396-409	9
1887	Molecular targeted therapy of biliary tract cancer--results of the first clinical studies. 2010 , 11, 834-50	29
1886	Gemox: a widely useful therapy against solid tumors-review and personal experience. 2010 , 22, 298-303	5
1885	Erlotinib in combination with capecitabine (5'dFUR) in resistant pancreatic cancer cell lines. 2010 , 22, 129-33	9
1884	Update on pancreatic cancer treatment. 2010 , 35, 16-22; quiz 22-3	2
1883	Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. 2010 , 33, 828-33	728
1882	Preclinical studies of apogossypolone, a novel pan inhibitor of bcl-2 and mcl-1, synergistically potentiates cytotoxic effect of gemcitabine in pancreatic cancer cells. 2010 , 39, 323-31	21
1881	Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients. 2010 , 31, 1135-43	71
1880	Phase II trial of gemcitabine, irinotecan, and celecoxib in patients with advanced pancreatic cancer. 2010 , 44, 286-8	55
1879	Meta-analysis of randomized trials: evaluation of benefit of gemcitabine-based molecular targeted therapy for inoperable pancreatic cancer. 2010 , 39, 253-5	2
1878	Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the 'Arbeitsgemeinschaft Internistische Onkologie'. 2010 , 21, 94-100	21
1877	Contribution of thymidylate synthase to gemcitabine therapy for advanced pancreatic cancer. 2010 , 39, 1284-92	25

1876	Irinotecan plus bolus/infusional 5-Fluorouracil and leucovorin in patients with pretreated advanced pancreatic carcinoma: a multicenter experience of the Gruppo Oncologico Italia Meridionale. 2010 , 33, 461-4	39
1875	The road not taken and choices in radiation oncology. 2010 , 15, 332-7	1
1874	Impact of S-1 on the survival of patients with advanced pancreatic cancer. 2010 , 39, 989-93	27
1873	[Frontier of chemotherapy of pancreatic cancer]. 2010 , 99, 842-8	
1872	Pancreatic adenocarcinoma. 2010 , 8, 972-1017	137
1871	Metastatic pancreatic cancer: is gemcitabine still the best standard treatment? (Review). 2010 , 23, 1183-92	107
1870	Inhibition of MLK3 Decreases Proliferation and Increases Antiproliferative Activity of Epidermal Growth Factor Receptor (EGFR) Inhibitor in pancreatic cancer cell Lines. 2010 , 3, CGM.S2824	4
1869	Pankreaskarzinom: Algorithmus der palliativen Chemotherapie. 2010 , 26, 91-96	1
1868	Nutrition and diet in the aetiology and management of pancreatic cancer. 2010 , 8, 24-29	1
1867	Pancreatic cancer: pathobiology, treatment options, and drug delivery. 2010 , 12, 223-32	84
1866	EMAP II-based antiangiogenic-antiendothelial in vivo combination therapy of pancreatic cancer. 2010 , 17, 1442-52	20
1865	Society of surgical oncology presidential address: the war on cancer--shifting from disappointment to new hope. 2010 , 17, 1971-8	3
1864	Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer. 2010 , 62, 346-61	320
1863	Advanced or metastatic pancreatic cancer: molecular targeted therapies. 2010 , 77, 606-19	29
1862	Cardio-oncology/onco-cardiology. 2010 , 33, 733-7	59
1861	Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?. <i>Journal of Clinical Oncology</i> , 2010 , 28, 4769-77 ^{2.2}	214
1860	A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer. 2010 , 65, 527-36	32
1859	A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer. 2010 , 66, 287-94	19

1858	A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer. 2010 , 66, 1051-7	61
1857	Safety and activity of masitinib in combination with gemcitabine in patients with advanced pancreatic cancer. 2010 , 66, 395-403	50
1856	[Therapy with epidermal growth factor receptor inhibitors. Clinical spectrum of cutaneous adverse effects]. 2010 , 61, 654-61	9
1855	[The ABC's of medical statistics. Reading and understanding clinical trials]. 2010 , 51, 489-99; quiz 500	1
1854	Comparison of the long-term outcomes of uncinata process cancer and non-uncinata process pancreas head cancer: poor prognosis accompanied by early locoregional recurrence. 2010 , 395, 697-706	22
1853	Adjuvante und palliative Therapie des Pankreaskarzinoms. 2010 , 16, 595-603	
1852	Gemcitabine as first-line chemotherapy in elderly patients with unresectable pancreatic carcinoma. 2010 , 45, 1146-54	25
1851	Changing paradigms in clinical trials. 2010 , 3, 1-2	0
1850	Das ABC der medizinischen Statistik. 2010 , 3, 289-302	
1849	Gastrointestinal bleeding during anti-angiogenic peptide vaccination in combination with gemcitabine for advanced pancreatic cancer. 2010 , 3, 307-17	4
1848	Prognostic relevance of CA 19-9, CEA, CRP, and LDH kinetics in patients treated with palliative second-line therapy for advanced pancreatic cancer. 2010 , 31, 351-7	41
1847	Zielgerichtete Therapie gastrointestinaler Tumoren. 2010 , 5, 437-445	
1846	ABC transporters as molecular effectors of pancreatic oncogenic pathways: the Hedgehog-GLI model. 2010 , 41, 153-8	17
1845	TRAIL and triptolide: an effective combination that induces apoptosis in pancreatic cancer cells. 2010 , 14, 252-60	33
1844	Image-guided stereotactic radiosurgery for locally advanced pancreatic adenocarcinoma results of first 85 patients. 2010 , 14, 1547-59	85
1843	Targeted therapies in der Behandlung solider Tumoren. 2010 , 3, 48-51	
1842	EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance. 2010 , 122, 685-97	60
1841	Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. 2010 , 96, 219-30	172

1840	Venous thromboembolism and cancer: a systematic review. 2010 , 30, 67-78	33
1839	Pilot study of irinotecan/oxaliplatin (IROX) combination chemotherapy for patients with gemcitabine- and 5-fluorouracil- refractory pancreatic cancer. 2010 , 28, 343-9	15
1838	Drug interactions among the epidermal growth factor receptor inhibitors, other biologics and cytotoxic agents. 2010 , 128, 82-90	10
1837	Angiogenesis inhibitors: current strategies and future prospects. 2010 , 60, 222-43	350
1836	Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies. 2010 , 10, 368	120
1835	Complete response in gallbladder cancer to erlotinib plus gemcitabine does not require mutation of the epidermal growth factor receptor gene: a case report. 2010 , 10, 570	10
1834	Targeted drug delivery in pancreatic cancer. 2010 , 1805, 97-104	36
1833	Predicting gemcitabine transport and toxicity in human pancreatic cancer cell lines with the positron emission tomography tracer 3'-deoxy-3'-fluorothymidine. 2010 , 79, 587-95	36
1832	Kinases as targets in the treatment of solid tumors. 2010 , 22, 984-1002	71
1831	Oncogenic mutant forms of EGFR: lessons in signal transduction and targets for cancer therapy. 2010 , 584, 2699-706	110
1830	Targeting histone deacetylases in pancreatic ductal adenocarcinoma. 2010 , 14, 1255-63	19
1829	Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3. 2010 , 116, 5599-607	127
1828	Sorafenib: where do we go from here?. 2010 , 52, 360-9	80
1827	Concurrent inhibition of NF-kappaB, cyclooxygenase-2, and epidermal growth factor receptor leads to greater anti-tumor activity in pancreatic cancer. 2010 , 110, 171-81	21
1826	Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma. 2010 , 101, 587-92	126
1825	Induction chemotherapy followed by chemoradiation in locally advanced pancreatic cancer: an effective and well-tolerated treatment. 2010 , 22, 27-35	9
1824	Improving disease control in advanced colorectal cancer: Panitumumab and cetuximab. 2010 , 74, 193-202	21
1823	¹⁸ F-fluorodeoxyglucose PET is prognostic of progression-free and overall survival in locally advanced pancreas cancer treated with stereotactic radiotherapy. 2010 , 77, 1420-5	101

1822	Helical tomotherapy with concurrent capecitabine for the treatment of inoperable pancreatic cancer. 2010 , 5, 60	3
1821	TLN-4601 suppresses growth and induces apoptosis of pancreatic carcinoma cells through inhibition of Ras-ERK MAPK signaling. 2010 , 5, 18	17
1820	Cucurbitacin B, a novel in vivo potentiator of gemcitabine with low toxicity in the treatment of pancreatic cancer. 2010 , 160, 998-1007	54
1819	In vitro and in vivo evidence that a combination of lapatinib plus S-1 is a promising treatment for pancreatic cancer. 2010 , 101, 468-73	18
1818	Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer. 2010 , 101, 433-9	87
1817	Amphiregulin regulates the activation of ERK and Akt through epidermal growth factor receptor and HER3 signals involved in the progression of pancreatic cancer. 2010 , 101, 2351-60	38
1816	Expression of L1CAM, COX-2, EGFR, c-KIT and Her2/neu in anaplastic pancreatic cancer: putative therapeutic targets?. 2010 , 56, 440-8	22
1815	Osteopontin-mediated enhanced hyaluronan binding induces multidrug resistance in mesothelioma cells. 2010 , 29, 1941-51	36
1814	Activation of EGFR by proteasome inhibition requires HB-EGF in pancreatic cancer cells. 2010 , 29, 3146-52	12
1813	Increased circulating cell signalling phosphoproteins in sera are useful for the detection of pancreatic cancer. 2010 , 103, 223-31	15
1812	Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer. 2010 , 103, 649-55	61
1811	Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine. 2010 , 103, 1644-8	121
1810	Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. 2010 , 28, 585-93	191
1809	Targeting the cancer kinome through polypharmacology. 2010 , 10, 130-7	542
1808	Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. 2010 , 10, 241-53	410
1807	Metastatic Pancreatic Cancer: Systemic Therapy. 2010 , 137-146	
1806	Neoadjuvante und adjuvante Therapiekonzepte beim duktalem Pankreaskarzinom ¿was gibt es Neues?. 2010 , 26, 109-115	1
1805	Current and emerging therapies for the treatment of pancreatic cancer. 2010 , 3, 111-27	29

1804	Therapeutic antibodies for the treatment of pancreatic cancer. 2010 , 10, 1107-20		13
1803	Masitinib combined with standard gemcitabine chemotherapy: in vitro and in vivo studies in human pancreatic tumour cell lines and ectopic mouse model. 2010 , 5, e9430		55
1802	The Locally Advanced Nonmetastatic Cancer. 2010 , 123-136		
1801	Antitumor activity of erlotinib in combination with gemcitabine in in vitro and in vivo models of KRAS-mutated pancreatic cancers. 2010 , 1, 231-235		10
1800	Fixed-Dose-Rate Gemcitabine Infusion in Patients with Advanced Pancreatic or Biliary Tree Adenocarcinoma. 2010 , 96, 405-410		4
1799	Recent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer. 2010 , 16, 673-82		48
1798	Erlotinib treatment in pretreated patients with non-small cell lung cancer: A Phase II study. 2010 , 1, 335-338		3
1797	Further evidence of the prognostic role of pretreatment levels of CA 19-9 in advanced pancreatic cancer. 2010 , 56, 22-6		2
1796	Pankreaskarzinom: Ist die operative Therapie gerechtfertigt bei R2-Resektion, Lebermetastasen oder Rezidivtumor?. 2010 , 26, 103-108		1
1795	Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. <i>Journal of Clinical Oncology</i> , 2010 , 28, 1645-51	2.2	237
1794	Cytochrome P450-mediated bioactivation of the epidermal growth factor receptor inhibitor erlotinib to a reactive electrophile. 2010 , 38, 1238-45		58
1793	Phase II trial to evaluate gemcitabine and etoposide for locally advanced or metastatic pancreatic cancer. 2010 , 9, 2423-9		11
1792	Application of a time-varying covariate model to the analysis of CA 19-9 as serum biomarker in patients with advanced pancreatic cancer. 2010 , 16, 986-94		34
1791	Weekly Paclitaxel after failure of gemcitabine in pancreatic cancer patients with malignant ascites: a retrospective study. 2010 , 40, 1135-8		19
1790	Survival prediction for pancreatic cancer patients receiving gemcitabine treatment. 2010 , 9, 695-704		29
1789	Looking for efficiency rather than efficacy in randomized controlled trials in oncology. 2010 , 21, 1391-1393		2
1788	Pain and emotional well-being outcomes in Southwest Oncology Group-directed intergroup trial S0205: a phase III study comparing gemcitabine plus cetuximab versus gemcitabine as first-line therapy in patients with advanced pancreas cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 3611-6	2.2	18
1787	Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study. 2010 , 21, 2233-2239		31

1786	Effects of thymoquinone in the expression of mucin 4 in pancreatic cancer cells: implications for the development of novel cancer therapies. 2010 , 9, 1419-31	94
1785	Biologically targeted cancer therapy and marginal benefits: are we making too much of too little or are we achieving too little by giving too much?. 2010 , 16, 5972-80	98
1784	Translating clinical trials into meaningful outcomes. 2010 , 16, 5951-5	15
1783	A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603). 2010 , 15, 1310-9	56
1782	Regimen-related gastrointestinal toxicities in cancer patients. 2010 , 4, 26-30	40
1781	Evaluating patient-centered outcomes in the randomized controlled trial and beyond: informing the future with lessons from the past. 2010 , 16, 5963-71	20
1780	The way forward in treating pancreatic cancer. 2010 , 2, 157-60	
1779	Current status and problems in development of molecular target agents for gastrointestinal malignancy in Japan. 2010 , 40, 183-7	2
1778	Role of vitamin d in the prevention of pancreatic cancer. 2010 , 2010, 721365	11
1777	Combined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xenografts. 2010 , 21, 98-103	36
1776	S-1 monotherapy as second-line treatment for advanced pancreatic cancer after gemcitabine failure. 2010 , 40, 567-72	22
1775	Drug Discovery in Pancreatic Cancer. 2010 ,	
1774	Radiosensitization of epidermal growth factor receptor/HER2-positive pancreatic cancer is mediated by inhibition of Akt independent of ras mutational status. 2010 , 16, 912-23	47
1773	Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature. 2010 , 21, 7-12	111
1772	Phase I combination of sorafenib and erlotinib therapy in solid tumors: safety, pharmacokinetic, and pharmacodynamic evaluation from an expansion cohort. 2010 , 9, 751-60	16
1771	Palliative Management of Pancreatic Cancer. 2010 , 813-838	
1770	Understanding resistance to EGFR inhibitors-impact on future treatment strategies. 2010 , 7, 493-507	503
1769	Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. <i>Journal of Clinical Oncology</i> , 2010 , 28, 3605-10	2.2 499

1768	Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). <i>Journal of Clinical Oncology</i> , 2010 , 28, 3617-22	2.2	659
1767	Evolution of systemic therapy for advanced pancreatic cancer. 2010 , 10, 529-40		32
1766	Explaining marginal benefits to patients, when "marginal" means additional but not necessarily small. 2010 , 16, 5981-6		20
1765	On target? Off target? Why we really do not know. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2937-8	2.2	
1764	Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer. 2010 , 16, 5320-8		43
1763	Pancreatic cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2010 , 21 Suppl 5, v55-8		112
1762	New and potential clinical applications of KRAS as a cancer biomarker. 2010 , 4, 383-95		5
1761	Pancreatic proteolytic enzyme therapy compared with gemcitabine-based chemotherapy for the treatment of pancreatic cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2058-63	2.2	28
1760	Human Equilibrative Nucleoside Transporter 1 (hENT1) in Pancreatic Adenocarcinoma: Towards Individualized Treatment Decisions. 2010 , 2, 2044-54		24
1759	Response: Re: How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the \$440 Billion Question. 2010 , 102, 1207-1210		5
1758	Impact of S-1 in patients with gemcitabine-refractory pancreatic cancer in Japan. 2010 , 40, 774-80		33
1757	Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009. 2010 , 21 Suppl 6, vi1-10		35
1756	Systemic therapy for metastatic pancreatic adenocarcinoma. 2010 , 2, 85-106		4
1755	Current status of adjuvant therapy for pancreatic cancer. 2010 , 15, 1205-13		23
1754	Treatment of unresectable and metastatic cutaneous squamous cell carcinoma. 2010 , 15, 1320-8		92
1753	Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study. 2010 , 12, 1061-70		88
1752	ErbB3 expression promotes tumorigenesis in pancreatic adenocarcinoma. 2010 , 10, 555-63		48
1751	Acute Fatal Liver Toxicity under Erlotinib. 2010 , 3, 182-188		14

1750	Potential of gemcitabine by Turmeric Force in pancreatic cancer cell lines. 2010 , 23, 1529-35	21
1749	Recent advances in combined modality therapy. 2010 , 15, 372-81	28
1748	Clinical medicine and clinical trials. 2010 , 15, 382-7	
1747	Clinical pharmacogenetics in oncology: the paradigm of molecular targeted therapies. 2010 , 16, 2184-93	9
1746	Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301). 2010 , 59, 1527-34	60
1745	Silencing kinase-interacting stathmin gene enhances erlotinib sensitivity by inhibiting Ser ¹¹⁷ phosphorylation in epidermal growth factor receptor-expressing breast cancer. 2010 , 9, 3090-9	16
1744	Chemoprevention of pancreatic cancer: ready for the clinic?. 2010 , 3, 1375-8	6
1743	Challenges of drug resistance in the management of pancreatic cancer. 2010 , 10, 1647-61	38
1742	[Personalized therapy of gastrointestinal cancers--possibilities and limitations]. 2010 , 135, 1687-91	
1741	Novel therapies for pancreatic cancer: setbacks and progress. 2010 , 6, 1061-4	7
1740	Comparative effectiveness and health care spending--implications for reform. 2010 , 362, 460-5	203
1739	[Cutaneous side effects of EGFR inhibitors--appearance and management]. 2010 , 135, 149-54	24
1738	Kinase signaling pathways as targets for intervention in pancreatic cancer. 2010 , 9, 754-63	23
1737	Herbal interactions with anticancer drugs: mechanistic and clinical considerations. 2010 , 17, 1635-78	60
1736	Chemotherapy: Gemcitabine remains the standard of care for pancreatic cancer. 2010 , 7, 135-7	27
1735	Epidermal growth factor receptor in adrenocortical tumors: analysis of gene sequence, protein expression and correlation with clinical outcome. 2010 , 23, 1596-604	43
1734	In vitro and in vivo antitumor efficacy of docetaxel and sorafenib combination in human pancreatic cancer cells. 2010 , 10, 600-10	12
1733	Safety and efficacy of single-day GemOx regimen in patients with pancreatobiliary cancer: a single institution experience. 2010 , 9, 207-13	11

1732	The role of radiotherapy in locally advanced pancreatic carcinoma. 2010 , 7, 437-47	32
1731	Metronomic gemcitabine in combination with sunitinib inhibits multisite metastasis and increases survival in an orthotopic model of pancreatic cancer. 2010 , 9, 2068-78	42
1730	Novel targets for pancreatic cancer therapy. 2010 , 19, 419-29	10
1729	DNA mutational differences in cytological specimens from pancreatic cancer and cholangiocarcinoma. 2010 , 10, 429-33	7
1728	Randomized clinical trials in pancreatic adenocarcinoma. 2010 , 19, 115-50	5
1727	Aspects médico-économiques de la pneumologie. 2010 , 2, 205-222	
1726	Targeted therapies for solid tumors: current status and future perspectives. 2010 , 24, 303-16	15
1725	A tolerability and pharmacokinetic study of adjuvant erlotinib and capecitabine with concurrent radiation in resected pancreatic cancer. 2010 , 3, 373-9	16
1724	A review of erlotinib--an oral, selective epidermal growth factor receptor tyrosine kinase inhibitor. 2010 , 11, 311-20	28
1723	Targeted therapies for non-small cell lung cancer. 2010 , 67, 257-74	130
1722	Pancreatic cancer stem cells - update and future perspectives. 2010 , 4, 431-42	65
1721	Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer. 2010 , 9, 297-304	17
1720	HDAC2 attenuates TRAIL-induced apoptosis of pancreatic cancer cells. 2010 , 9, 80	59
1719	Implications of enhancer of zeste homologue 2 expression in pancreatic ductal adenocarcinoma. 2010 , 41, 1205-9	54
1718	Cardiac side-effects of cancer chemotherapy. 2010 , 144, 3-15	284
1717	Survival comparison between glioblastoma multiforme and other incurable cancers. 2010 , 17, 417-21	112
1716	[Recommendations for diagnosis, staging and treatment of pancreatic cancer (Part II)]. 2010 , 134, 692-702	13
1715	[Treatment of advanced hepatocellular carcinoma]. 2010 , 33, 461-8	2

1714	Dihydroartemisinin inactivates NF-kappaB and potentiates the anti-tumor effect of gemcitabine on pancreatic cancer both in vitro and in vivo. 2010 , 293, 99-108		137
1713	Targeted therapies of cancer: angiogenesis inhibition seems not enough. 2010 , 299, 1-10		48
1712	Esophagogastric cancer: targeted agents. 2010 , 36, 235-48		48
1711	A phase Ib/IIa trial to evaluate the CCK2 receptor antagonist Z-360 in combination with gemcitabine in patients with advanced pancreatic cancer. 2010 , 46, 526-33		25
1710	Antitumour activity of NK012, SN-38-incorporating polymeric micelles, in hypovascular orthotopic pancreatic tumour. 2010 , 46, 650-8		25
1709	Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib. 2010 , 46, 2010-9		58
1708	Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic pancreatic adenocarcinoma. 2010 , 46, 2753-62		72
1707	Advanced pancreatic carcinoma: current treatment and future challenges. 2010 , 7, 163-72		603
1706	Metabolism considerations for kinase inhibitors in cancer treatment. 2010 , 6, 1175-93		78
1705	Curcumin and gemcitabine in patients with advanced pancreatic cancer. 2010 , 62, 1137-41		194
1704	Pancreatic cancer. 2010 , 362, 1605-17		2151
1703	Gene Therapy for Pancreatic Cancer. 2010 , 1237-1268		
1702	Palliative chemotherapy for pancreatic malignancies. 2010 , 90, 365-75		4
1701	Randomized phase II trials: inevitable or inadvisable?. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2641-7	2.2	61
1700	Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine carcinogenesis. <i>Journal of Clinical Oncology</i> , 2010 , 28, 4425-33	2.2	86
1699	Therapeutic drug monitoring in cancer chemotherapy. 2010 , 2, 863-79		12
1698	Advanced phase I/II studies of targeted gene delivery in vivo: intravenous REXIN-G for gemcitabine-resistant metastatic pancreatic cancer. 2010 , 18, 435-41		54
1697	Tyrosine Kinase Inhibitors. 435-525		

1696	GSK3beta and beta-catenin modulate radiation cytotoxicity in pancreatic cancer. 2010 , 12, 357-65	38
1695	Plasma pharmacokinetics after combined therapy of gemcitabine and oral S-1 for unresectable pancreatic cancer. 2010 , 29, 15	6
1694	Supportive Cancer Care with Chinese Medicine. 2010 ,	9
1693	Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. <i>Journal of Clinical Oncology</i> , 2010 , 28, 3965-72	2.2 291
1692	Rexin-G, a targeted genetic medicine for cancer. 2010 , 10, 819-32	40
1691	Down-regulation of Rad51 expression overcomes drug resistance to gemcitabine in human non-small-cell lung cancer cells. 2010 , 335, 830-40	55
1690	Any progress in pancreatic cancer? Well, but progress for Acta Oncologica. 2010 , 49, 404-6	0
1689	Noninvasive monitoring of therapy-induced microvascular changes in a pancreatic cancer model using dynamic contrast-enhanced magnetic resonance imaging with P846, a new low-diffusible gadolinium-based contrast agent. 2011 , 175, 10-20	14
1688	New approaches to the treatment of pancreatic cancer: from tumor-directed therapy to immunotherapy. 2011 , 25, 207-16	7
1687	Phase I study of Oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients with advanced solid tumors. 2011 , 17, 6071-82	41
1686	Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy. 2011 , 10, 1993-9	110
1685	Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers. 2011 , 17, 6531-41	42
1684	OGX-427 inhibits tumor progression and enhances gemcitabine chemotherapy in pancreatic cancer. 2011 , 2, e221	66
1683	Reviewing the safety of erlotinib in non-small cell lung cancer. 2011 , 10, 147-57	18
1682	The past, present, and future of biomarkers: a need for molecular beacons for the clinical management of pancreatic cancer. 2011 , 45, 301-21	17
1681	Complications cardio-vasculaires des th�rapies cibl�es. 2011 , 2011, 12-17	
1680	L'impact des th�rapies cibl�es chez le patient atteint de cancer au stade palliatif. 2011 , 10, 51-63	
1679	Acycloguanosyl 5'-thymidyltriphosphate, a thymidine analogue prodrug activated by telomerase, reduces pancreatic tumor growth in mice. 2011 , 140, 709-720.e9	9

1678	Yet another nucleoside analog for pancreatic cancer. 2011 , 140, 400-4	2
1677	Medical treatment of pancreatic cancer: new hopes after 10 years of gemcitabine. 2011 , 35, 364-74	12
1676	Treatment trends in metastatic pancreatic cancer patients: Is it time to change?. 2011 , 43, 225-30	6
1675	Novel cytochrome p450 bioactivation of a terminal phenyl acetylene group: formation of a one-carbon loss benzaldehyde and other oxidative products in the presence of N-acetyl cysteine or glutathione. 2011 , 24, 677-86	5
1674	Cucurmosin induces apoptosis of BxPC-3 human pancreatic cancer cells via inactivation of the EGFR signaling pathway. 2012 , 27, 891-7	19
1673	Role of epidermal growth factor receptor expression on patient survival in pancreatic cancer: a meta-analysis. 2011 , 11, 595-600	22
1672	High EGFR mRNA expression is a prognostic factor for reduced survival in pancreatic cancer after gemcitabine-based adjuvant chemotherapy. 2011 , 38, 629-41	19
1671	ERK phosphorylation predicts synergism between gemcitabine and the epidermal growth factor receptor inhibitor AG1478. 2011 , 73, 274-82	8
1670	[New antitarget antineoplastic drugs. Clinical indications in the treatment of cancer]. 2011 , 137, 370-6	1
1669	Molecular pathogenesis of pancreatic cancer and clinical perspectives. 2011 , 81, 259-72	50
1668	A benefit-risk assessment of erlotinib in non-small-cell lung cancer and pancreatic cancer. 2011 , 34, 175-86	6
1667	Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines. 2011 , 50, 371-403	80
1666	Targeted therapies for gastric cancer: current status. 2011 , 71, 1367-84	31
1665	Targeted therapies for hepatocellular carcinoma. 2011 , 140, 1410-26	360
1664	Armed and targeted measles virus for chemovirotherapy of pancreatic cancer. 2011 , 18, 598-608	45
1663	Disclosure of erlotinib as a multikinase inhibitor in pancreatic ductal adenocarcinoma. 2011 , 13, 1026-34	37
1662	GI cancers in 2010: New standards and a predictive biomarker for adjuvant therapy. 2011 , 8, 70-2	15
1661	Efficacy and safety of standardized allergen-removed Rhus verniciflua Stokes extract in patients with advanced or metastatic pancreatic cancer: a Korean single-center experience. 2011 , 81, 312-8	19

1660	Induction Chemotherapy. 2011,	1
1659	Cancer Stem Cells in Solid Tumors. 2011,	6
1658	Chemotherapy-induced iatrogenic injury of skin: new drugs and new concepts. 2011, 29, 587-601	14
1657	Molecularly targeted therapies in unresectable-metastatic gastric cancer: a systematic review. 2011, 37, 599-610	26
1656	An RNA aptamer that specifically binds pancreatic adenocarcinoma up-regulated factor inhibits migration and growth of pancreatic cancer cells. 2011, 313, 76-83	24
1655	[New perspectives for radiosensitization in pancreatic carcinoma: a review of mechanisms involved in pancreatic tumorigenesis]. 2011, 15, 365-75	1
1654	A phase I, dose-escalation study of pomalidomide (CC-4047) in combination with gemcitabine in metastatic pancreas cancer. 2011, 47, 199-205	22
1653	Pancreatic Cancer Stem Cells as New Targets for Diagnostics and Therapy. 2011, 116-134	1
1652	The inverted pyramid of biomarker-driven trials. 2011, 8, 562-6	14
1651	Characterization of soluble and exosomal forms of the EGFR released from pancreatic cancer cells. 2011, 89, 304-12	87
1650	Role of chemotherapy in the very elderly patients with metastatic pancreatic cancer [A Veterans Affairs Cancer Registry analysis]. 2011, 2, 209-214	16
1649	Erlotinib-induced Hepatotoxicity-Clinical Presentation and Successful Management: A Case Report. 2011, 1, 38-40	8
1648	FOLFIRINOX: a new standard treatment for advanced pancreatic cancer?. 2011, 12, 8-9	38
1647	Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. 2011, 12, 256-62	311
1646	Delivering affordable cancer care in high-income countries. 2011, 12, 933-80	476
1645	FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. 2011, 364, 1817-25	4650
1644	Pancreatic cancer. 2011, 378, 607-20	1693
1643	Managing treatment-related adverse events associated with egfr tyrosine kinase inhibitors in advanced non-small-cell lung cancer. 2011, 18, 126-38	90

1642	[Second line chemotherapy for pancreatic cancer]. 2011 , 57, 207-12	
1641	Emerging therapeutic targets and agents for pancreatic cancer therapy--where are we and where we have to go?. 2011 , 11, 408-10	2
1640	Targeting EGFR in bilio-pancreatic and liver carcinoma. 2011 , 3, 16-22	5
1639	Signaling pathways in pancreatic cancer. 2011 , 21, 115-29	29
1638	Oral chemotherapeutic agents in current use. 2011 , 54, 1191	4
1637	Molecular diagnostics in pancreatic cancer. 2011 , 20-35	
1636	Gemcitabine in elderly patients with advanced pancreatic cancer. 2011 , 17, 3497-502	39
1635	EGFR genomic alterations in cancer: prognostic and predictive values. 2011 , 3, 879-87	23
1634	Possible role of epidermal growth factor receptors in the therapy of pancreatic cancer. 2011 , 28, 293-356	5
1633	Randomized trials in exocrine pancreatic cancer. 2011 , 2, 85-96	
1632	Safety and pharmacokinetics of motesanib in combination with panitumumab and gemcitabine-Cisplatin in patients with advanced cancer. 2011 , 2011, 853931	3
1631	Preemptive management of dermatologic toxicities associated with epidermal growth factor receptor inhibitors. 2011 , 15, 501-8	11
1630	Phase II study of radiation therapy combined with weekly low-dose gemcitabine for locally advanced, unresectable pancreatic cancer. 2011 , 34, 115-9	30
1629	DeltaNp63alpha-mediated induction of epidermal growth factor receptor promotes pancreatic cancer cell growth and chemoresistance. 2011 , 6, e26815	47
1628	Early Therapy Evaluation of Combined Cetuximab and Irinotecan in Orthotopic Pancreatic Tumor Xenografts by Dynamic Contrast-Enhanced Magnetic Resonance Imaging. 2011 , 10, 7290.2010.00040	15
1627	Modulation of GemOx chemotherapy according to CIRS in elderly patients with advanced pancreatic cancer. 2012 , 27, 423-32	2
1626	Interstitial lung disease under erlotinib plus gemcitabine for pancreatic carcinoma: a therapeutic dilemma. 2011 , 40, 170-1	2
1625	Phase 1 trial of Wilms tumor 1 (WT1) peptide vaccine and gemcitabine combination therapy in patients with advanced pancreatic or biliary tract cancer. 2011 , 34, 92-9	69

1624	Extracellular matrix metalloproteinase as a novel target for pancreatic cancer therapy. 2011 , 22, 864-74	16
1623	Advances in pancreatic cancer. 2011 , 27, 460-6	25
1622	Triphendiol (NV-196), development of a novel therapy for pancreatic cancer. 2011 , 22, 719-31	7
1621	Phase II and coagulation cascade biomarker study of bevacizumab with or without docetaxel in patients with previously treated metastatic pancreatic adenocarcinoma. 2011 , 34, 70-5	29
1620	Construction and validation of a prognostic index for patients with metastatic pancreatic adenocarcinoma. 2011 , 40, 415-21	33
1619	Fluorescence in situ hybridization and K-ras analyses improve diagnostic yield of endoscopic ultrasound-guided fine-needle aspiration of solid pancreatic masses. 2011 , 40, 1057-62	35
1618	Metastatic pancreatic cancer: old drugs, new paradigms. 2011 , 23, 390-5	27
1617	Criteria of evidence to move potential chemopreventive agents into late phase clinical trials. 2011 , 12, 1983-8	3
1616	Molecular targeted therapy of gastrointestinal cancer. 2011 , 11, 670-80	1
1615	Genetic and epigenetic alterations in pancreatic carcinogenesis. 2011 , 12, 15-24	82
1614	Myeloid-derived suppressor cells: general characteristics and relevance to clinical management of pancreatic cancer. 2011 , 11, 734-51	81
1613	Genetic effects and modifiers of radiotherapy and chemotherapy on survival in pancreatic cancer. 2011 , 40, 657-63	16
1612	Molecular targeted approaches for treatment of pancreatic cancer. 2011 , 17, 2221-38	19
1611	Co-expression of mesothelin and CA125 correlates with unfavorable patient outcome in pancreatic ductal adenocarcinoma. 2011 , 40, 1276-82	65
1610	Malignant Biliary Diseases. 2011 , 294-311	2
1609	Pancreatic cancer: a whistle-stop tour. 2011 , 9, 41-45	
1608	Therapeutic potential of the TWEAK/Fn14 pathway in intractable gastrointestinal cancer. 2011 , 2, 103-108	18
1607	PPAR δ potentiates anticancer effects of gemcitabine on human pancreatic cancer cells. 2012 , 40, 679-85	17

1606	Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in BXPC-3 and PANC-1 human pancreatic cancer cells. 2011 , 2, 969-975	7
1605	A randomized phase II trial of first-line treatment with gemcitabine, erlotinib, or gemcitabine and erlotinib in elderly patients (age \geq 70 years) with stage IIIB/IV non-small cell lung cancer. 2011 , 6, 1569-77	29
1604	Simultane Radiochemotherapie oder sequenzielle Radio- und Chemotherapie?. 2011 , 14, 22-24	
1603	Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer. 2011 , 102, 425-31	45
1602	Transforming growth factor-beta 2 gene silencing with trabedersen (AP 12009) in pancreatic cancer. 2011 , 102, 1193-200	77
1601	Antitumour activity of sunitinib in combination with gemcitabine in experimental pancreatic cancer. 2011 , 13, 597-604	14
1600	Management of cutaneous side effects of EGFR inhibitors: recommendations from a German expert panel for the primary treating physician. 2011 , 9, 195-203	18
1599	Management kutaner Nebenwirkungen von EGFR-Inhibitoren: Empfehlungen eines deutschen Expertengremiums für den primär behandelnden Arzt. 2011 , 9, 195-203	11
1598	Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. 2011 , 17, 500-3	988
1597	Cancer drugs should add months, not weeks, say experts. 2011 , 17, 7	5
1596	Harnessing synthetic lethal interactions in anticancer drug discovery. 2011 , 10, 351-64	204
1595	Small tyrosine kinase inhibitors interrupt EGFR signaling by interacting with erbB3 and erbB4 in glioblastoma cell lines. 2011 , 317, 1476-89	42
1594	Regional chemotherapy in locally advanced pancreatic cancer: RECLAP trial. 2011 , 12, 129	15
1593	The tyrphostin AG1478 inhibits proliferation and induces death of liver tumor cells through EGF receptor-dependent and independent mechanisms. 2011 , 82, 1583-92	13
1592	Targeting ErbB3-mediated stromal-epithelial interactions in pancreatic ductal adenocarcinoma. 2011 , 105, 523-33	26
1591	An oncolytic adenovirus defective in pRb-binding (dl922-947) can efficiently eliminate pancreatic cancer cells and tumors in vivo in combination with 5-FU or gemcitabine. 2011 , 18, 734-43	35
1590	Overcoming drug resistance in pancreatic cancer. 2011 , 15, 817-28	157
1589	Epidermal growth factor receptor-targeted treatment strategies in advanced pancreatic cancer: Is K-RAS mutational testing ready for prime time?. 2011 , 4, 257-259	

1588	Phase II study of gemcitabine and erlotinib as adjuvant therapy for patients with resected pancreatic cancer. 2011 , 18, 1122-9	24
1587	MicroRNA expression as a predictive marker for gemcitabine response after surgical resection of pancreatic cancer. 2011 , 18, 2381-7	63
1586	Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial. 2011 , 18, 1319-26	226
1585	Preclinical and clinical studies of NK012, an SN-38-incorporating polymeric micelles, which is designed based on EPR effect. 2011 , 63, 184-92	188
1584	Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC). 2011 , 29, 499-505	15
1583	A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer. 2011 , 29, 694-9	42
1582	Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer. 2011 , 29, 1057-65	8
1581	KRAS, BRAF, EGFR and HER2 gene status in a Spanish population of colorectal cancer. 2011 , 38, 1315-20	27
1580	Pancreatic cancer stem cells: new insights and perspectives. 2011 , 46, 966-73	33
1579	Somatic variation and cancer: therapies lost in the mix. 2011 , 130, 79-91	34
1578	Das ABC der medizinischen Statistik [Klinische Studien lesen und verstehen. 2011 , 25, 306-318	
1577	Tyrosinkinaseinhibitoren. 2011 , 17, 641-650	
1576	A 4-week versus a 3-week schedule of gemcitabine monotherapy for advanced pancreatic cancer: a randomized phase II study to evaluate toxicity and dose intensity. 2011 , 16, 637-45	6
1575	Modified vaccinia Ankara expressing survivin combined with gemcitabine generates specific antitumor effects in a murine pancreatic carcinoma model. 2011 , 60, 99-109	33
1574	Gemcitabine enhances Wilms' tumor gene WT1 expression and sensitizes human pancreatic cancer cells with WT1-specific T-cell-mediated antitumor immune response. 2011 , 60, 1289-97	41
1573	The promise of a personalized genomic approach to pancreatic cancer and why targeted therapies have missed the mark. 2011 , 35, 1766-9	6
1572	Imexon enhances gemcitabine cytotoxicity by inhibition of ribonucleotide reductase. 2011 , 67, 183-92	7
1571	A phase I study evaluating the role of the anti-epidermal growth factor receptor (EGFR) antibody cetuximab as a radiosensitizer with chemoradiation for locally advanced pancreatic cancer. 2011 , 67, 891-7	28

1570	Phase II study of a fixed dose-rate infusion of gemcitabine associated with erlotinib in advanced pancreatic cancer. 2011 , 67, 215-21	25
1569	Enhancing cytotoxic agent activity in experimental pancreatic cancer through EMAP II combination therapy. 2011 , 68, 571-82	12
1568	Prospective multicenter study to investigate the introduction rate of second-line S-1 in gemcitabine-refractory unresectable pancreatic cancer. 2011 , 68, 677-83	5
1567	Efficacy of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (IFAM) in the treatment of patients with gemcitabine-pretreated pancreatic cancer and analysis of prognostic factors in a salvage setting. 2011 , 68, 1017-26	4
1566	Bevacizumab plus gemcitabine and oxaliplatin as first-line therapy for metastatic or locally advanced pancreatic cancer: a phase II trial. 2011 , 68, 1431-8	20
1565	First-line treatment of pancreatic cancer patients with the combination of 5-fluorouracil/folinic acid plus gemcitabine: a multicenter phase II trial by the CONKO-study group. 2011 , 68, 1173-8	6
1564	Open-label trial on efficacy and security of treatment with gemcitabine and oral modulation with tegafur and levofolinic acid (GEMTG) in patients with advanced pancreatic cancer. 2011 , 13, 61-6	1
1563	SEOM clinical guidelines for the treatment of pancreatic cancer. 2011 , 13, 528-35	3
1562	Pulmonary toxicities from targeted therapies: a review. 2011 , 6, 235-43	77
1561	Improvement in treatment and outcome of pancreatic ductal adenocarcinoma in north China. 2011 , 15, 1026-34	8
1560	Neue Webseite: Mum hat Brustkrebs 2011 , 6, 10-10	
1559	Combination of Recombinant Adenovirus-p53 with Radiochemotherapy in Unresectable Pancreatic Carcinoma. 2011 , 23, 194-200	4
1558	Defining new paradigms for the treatment of pancreatic cancer. 2011 , 12, 111-25	33
1557	Current treatment options for pancreatic carcinoma. 2011 , 13, 195-205	29
1556	Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study. 2011 , 11, 313	9
1555	Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy. 2011 , 10, 37	166
1554	A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma. 2011 , 4, 11	52
1553	Concise review: Emerging concepts in clinical targeting of cancer stem cells. 2011 , 29, 883-7	73

1552	Phase 1 clinical trials in 83 patients with pancreatic cancer: The M. D. Anderson Cancer Center experience. 2011 , 117, 77-85	6
1551	Targeting IL-13R α in human pancreatic ductal adenocarcinoma with combination therapy of IL-13-PE and gemcitabine. 2011 , 128, 1221-31	21
1550	Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer. 2011 , 81, 181-8	188
1549	Targeted anti-cancer therapy in the elderly. 2011 , 78, 227-42	27
1548	MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts. 2011 , 17, 2799-806	188
1547	Role of the RAS in pancreatic cancer. 2011 , 11, 412-20	25
1546	Chemotherapy: Metastatic pancreatic cancer--is FOLFIRINOX the new standard?. 2011 , 8, 452-3	18
1545	Endoscopic management of malignant biliary obstruction by means of covered metallic stents: primary stent placement vs. re-intervention. 2011 , 43, 1039-44	21
1544	Therapy of locally advanced pancreatic adenocarcinoma: unresectable and borderline patients. 2011 , 11, 1555-65	12
1543	[Pancreatic diseases: update 2011]. 2011 , 136, 2037-9	1
1542	Potential applications of fish oils rich in n-3 fatty acids in the palliative treatment of advanced pancreatic cancer. 2011 , 106, 795-800	19
1541	Novel approaches to target pancreatic cancer. 2011 , 11, 698-713	9
1540	FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. 2011 , 365, 768-9; author reply 769	113
1539	Changing pathology with changing drugs: tumors of the gastrointestinal tract. 2011 , 78, 76-89	13
1538	The impact of thromboprophylaxis on cancer survival: focus on pancreatic cancer. 2011 , 11, 579-88	7
1537	Analgesic effect of high intensity focused ultrasound therapy for unresectable pancreatic cancer. 2011 , 27, 101-7	60
1536	Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment. 2011 , 10, 2135-45	152
1535	Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. <i>Journal of Clinical Oncology</i> , 2011 , 29, 4105-12	2.2 588

1534	Some essential considerations in the design and conduct of non-inferiority trials. 2011 , 8, 432-9		53
1533	Population analysis of erlotinib in adults and children reveals pharmacokinetic characteristics as the main factor explaining tolerance particularities in children. 2011 , 17, 4862-71		30
1532	FOLFIRINOX: a small step or a great leap forward?. <i>Journal of Clinical Oncology</i> , 2011 , 29, 3727-9	2.2	23
1531	Reporting of serious adverse drug reactions of targeted anticancer agents in pivotal phase III clinical trials. <i>Journal of Clinical Oncology</i> , 2011 , 29, 174-85	2.2	87
1530	Multicenter phase II study of gemcitabine and S-1 combination therapy (GS Therapy) in patients with metastatic pancreatic cancer. 2011 , 41, 953-8		38
1529	Anti-epidermal growth factor receptor treatment strategies in advanced pancreatic cancer: success or failure?. <i>Journal of Clinical Oncology</i> , 2011 , 29, e70-1; author reply e72-3	2.2	4
1528	The phosphatase inhibitor menadione (vitamin K3) protects cells from EGFR inhibition by erlotinib and cetuximab. 2011 , 17, 6766-77		28
1527	Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy. 2011 , 12, 1641-52		36
1526	[An experience of cyberknife treatment in patients with advanced pancreaticobiliary malignancy]. 2011 , 58, 264-9		3
1525	Hedgehog signaling and therapeutics in pancreatic cancer. 2011 , 32, 445-51		94
1524	Combining EGFR and mTOR blockade for the treatment of epithelioid sarcoma. 2011 , 17, 5901-12		32
1523	Metabolic disorder, inflammation, and deregulated molecular pathways converging in pancreatic cancer development: implications for new therapeutic strategies. 2011 , 3, 446-60		9
1522	The Hemostasis Apparatus in Pancreatic Cancer and Its Importance beyond Thrombosis. 2011 , 3, 267-84		3
1521	Assessment of chk1 phosphorylation as a pharmacodynamic biomarker of chk1 inhibition. 2011 , 17, 3706-15		71
1520	Targeted therapy in hepatocellular carcinoma. 2011 , 2011, 348297		19
1519	Oncolytic virotherapy for pancreatic cancer. 2011 , 13, e18		23
1518	When are "positive" clinical trials in oncology truly positive?. 2011 , 103, 16-20		83
1517	Randomized phase II trials: a long-term investment with promising returns. 2011 , 103, 1093-100		63

1516	Minimal modeling approaches to value of information analysis for health research. 2011 , 31, E1-E22	47
1515	Pancreatic cancer treatment and research: an international expert panel discussion. 2011 , 22, 1500-1506	39
1514	Systemic therapy for elderly patients with gastrointestinal cancer. 2011 , 5, 89-99	2
1513	Current immunotherapeutic approaches in pancreatic cancer. 2011 , 2011, 267539	62
1512	Neoadjuvant chemoradiotherapy has a potential role in pancreatic carcinoma. 2011 , 3, 27-33	17
1511	Correlation of basal EGFR expression with pancreatic cancer grading but not with clinical outcome after gemcitabine-based treatment. 2011 , 22, 482-4	8
1510	[Gastrointestinal tumors--interdisciplinary discussion over new data]. 2011 , 34 Suppl 3, 1-31	4
1509	Gemcitabine and oxaliplatin combination chemotherapy for patients with refractory pancreatic cancer. 2011 , 80, 97-101	13
1508	Inferior survival of advanced pancreatic cancer patients who received gemcitabine-based chemotherapy but did not participate in clinical trials. 2011 , 81, 143-50	13
1507	Long-Term Relapse-Free Survival by Interdisciplinary Collaboration in a Patient with Metastatic Pancreatic Cancer (UICC IV). 2011 , 4, 413-9	2
1506	Predicting the chemosensitivity of pancreatic cancer cells by quantifying the expression levels of genes associated with the metabolism of gemcitabine and 5-fluorouracil. 2011 , 39, 473-82	18
1505	KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOX CET) in first-line therapy. 2011 , 81, 3-8	35
1504	KRAS Mouse Models: Modeling Cancer Harboring KRAS Mutations. 2011 , 2, 335-43	21
1503	A prognostic model to predict clinical outcomes with first-line gemcitabine-based chemotherapy in advanced pancreatic cancer. 2011 , 80, 175-80	24
1502	Phase I dose-finding study of vandetanib in combination with gemcitabine in locally advanced unresectable or metastatic pancreatic adenocarcinoma. 2011 , 81, 50-4	37
1501	Consensus guidelines in pancreatic cancer treatment. 2011 , 62-83	
1500	Anti-cancer agent-induced dyspnea. 2011 , 19, 235-242	1
1499	A novel 3-dimensional culture system uncovers growth stimulatory actions by TGF β in pancreatic cancer cells. 2011 , 12, 198-207	43

1498	[Chemotherapy of metastatic pancreatic adenocarcinoma: challenges and encouraging results]. 2011 , 98, 1439-46		9
1497	Treatment of advanced pancreatic carcinoma with 90Y-Clivatuzumab Tetraxetan: a phase I single-dose escalation trial. 2011 , 17, 4091-100		50
1496	Imaging guided trials of the angiogenesis inhibitor sunitinib in mouse models predict efficacy in pancreatic neuroendocrine but not ductal carcinoma. 2011 , 108, E1275-84		55
1495	Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs. <i>Journal of Clinical Oncology</i> , 2011 , 29, 2543-9	2.2	52
1494	Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells. 2011 , 17, 2744-56		60
1493	Erlotinib 'dosing-to-rash': a phase II inpatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer. 2011 , 105, 938-44		33
1492	The molecular biology and novel treatments of vestibular schwannomas. 2011 , 115, 906-14		48
1491	Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells. 2011 , 105, 1554-62		54
1490	Safety profiles of erlotinib therapy in patients with advanced non-small-cell lung cancer. 2011 , 11, 991-7		4
1489	Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. <i>Journal of Clinical Oncology</i> , 2011 , 29, 4548-54	2.2	795
1488	Substrate-dependent modulation of the catalytic activity of CYP3A by erlotinib. 2011 , 32, 399-407		34
1487	Should the concomitant use of erlotinib and acid-reducing agents be avoided? The drug interaction between erlotinib and acid-reducing agents. 2011 , 17, 448-52		19
1486	Metastatic pancreatic cancer: what can nurses do?. 2011 , 15, 424-8		1
1485	Current surgical aspects of palliative treatment for unresectable pancreatic cancer. 2011 , 3, 636-51		13
1484	Management strategies in pancreatic cancer. 2011 , 68, 573-84		20
1483	Rationale for possible targeting of histone deacetylase signaling in cancer diseases with a special reference to pancreatic cancer. 2011 , 2011, 315939		13
1482	Treatment of pancreatic cancer: what can we really predict today?. 2011 , 3, 675-99		5
1481	Looking to the future: biomarkers in the management of pancreatic adenocarcinoma. 2011 , 12, 5895-907		10

1480	EGFR-Targeting as a Biological Therapy: Understanding Nimotuzumab's Clinical Effects. 2011 , 3, 2014-31	23
1479	Preclinical testing of erlotinib in a transgenic alveolar rhabdomyosarcoma mouse model. 2011 , 2011, 130484	8
1478	Novel strategy with gemcitabine for advanced pancreatic cancer. 2011 , 2011, 936893	7
1477	Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors. 2011 , 13, 109-18	112
1476	Early recurrence of pancreatic cancer after resection and during adjuvant chemotherapy. 2012 , 18, 118-21	55
1475	The case for a comparative, value-based alternative to the patient-centered outcomes research model for comparative effectiveness research. 2012 , 33, E8	1
1474	Phase II trial of erlotinib and bevacizumab in patients with advanced upper gastrointestinal cancers. 2012 , 51, 234-42	9
1473	Signaling Pathways in Inflammatory Breast Cancer. 2012 , 151-160	
1472	Anti-austerity agents from Rhizoma et Radix Notopterygii (Qianghuo). 2012 , 78, 796-9	11
1471	Metastatic pancreatic cancer: are we making progress in treatment?. 2012 , 2012, 898931	7
1470	Molecular imaging in tracking tumor stem-like cells. 2012 , 2012, 420364	17
1469	Hurdles in anticancer drug development from a regulatory perspective. 2012 , 9, 236-43	26
1468	BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer. 2012 , 23, 2799-2805	156
1467	Treatment of advanced pancreatic cancer. 2012 , 23 Suppl 10, x139-40	5
1466	Enhanced antitumor effect of combination therapy with gemcitabine and guggulsterone in pancreatic cancer. 2012 , 41, 1048-57	22
1465	Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2012 , 23 Suppl 7, vii33-40	245
1464	Postresection chemotherapy for pancreatic cancer. 2012 , 18, 614-23	4
1463	A Phase II trial of erlotinib as maintenance treatment after gemcitabine plus platinum-based chemotherapy in patients with recurrent and/or metastatic nasopharyngeal carcinoma. 2012 , 35, 255-60	36

1462	New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel. 2012 , 23, 570-576	54
1461	The pancreas cancer microenvironment. 2012 , 18, 4266-76	863
1460	Phase II open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: relationship between skin rash and survival (Pantar study). 2012 , 23, 1919-25	39
1459	Unresectable pancreatic cancer: arterial embolization to achieve a single blood supply for intraarterial infusion of 5-fluorouracil and full-dose IV gemcitabine. 2012 , 198, 1445-52	14
1458	The impact of the activated stroma on pancreatic ductal adenocarcinoma biology and therapy resistance. 2012 , 12, 288-303	61
1457	An epigenetic approach to pancreatic cancer treatment: the prospective role of histone deacetylase inhibitors. 2012 , 12, 439-52	24
1456	Harnessing gemcitabine metabolism: a step towards personalized medicine for pancreatic cancer. 2012 , 4, 341-6	21
1455	Methylation of death-associated protein kinase is associated with cetuximab and erlotinib resistance. 2012 , 11, 1656-63	47
1454	Aberrations and therapeutics involving the developmental pathway Hedgehog in pancreatic cancer. 2012 , 88, 355-78	4
1453	Radiotherapy in the adjuvant management of pancreatic adenocarcinoma: is it helpful?. 2012 , 6, 149-61	1
1452	The role of chemoradiation for patients with resectable or potentially resectable pancreatic cancer. 2012 , 12, 469-80	8
1451	Can pharmacogenomics guide effective anticancer therapy in pancreatic ductal adenocarcinoma?. 2012 , 13, 977-9	2
1450	Gemcitabine: a critical nucleoside for cancer therapy. 2012 , 19, 1076-87	61
1449	Targeted therapy at the end of life in advanced cancer patients. 2012 , 15, 991-7	18
1448	Mutated Ras-transfected, EBV-transformed lymphoblastoid cell lines as a model tumor vaccine for boosting T-cell responses against pancreatic cancer: a pilot trial. 2012 , 23, 1224-36	15
1447	Integrative survival-based molecular profiling of human pancreatic cancer. 2012 , 18, 1352-63	143
1446	Targeted therapies: Cetuximab dosing by rash--is the scaling of EVEREST meaningful?. 2012 , 9, 554-6	3
1445	A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas - a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network. 2012 , 107, 280-6	54

1444	A multicentre randomised phase II trial of gemcitabine alone vs gemcitabine and S-1 combination therapy in advanced pancreatic cancer: GEMSAP study. 2012 , 106, 1934-9		83
1443	Phase I first-in-human study of TAK-285, a novel investigational dual HER2/EGFR inhibitor, in cancer patients. 2012 , 106, 666-72		28
1442	Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer. 2012 , 106, 1033-8		128
1441	Prospective randomised evaluation of traditional Chinese medicine combined with chemotherapy: a randomised phase II study of wild toad extract plus gemcitabine in patients with advanced pancreatic adenocarcinomas. 2012 , 107, 411-6		62
1440	Genetically engineered mouse models: closing the gap between preclinical data and trial outcomes. 2012 , 72, 2695-700		103
1439	Progress against solid tumors in danger: the metastatic breast cancer example. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3444-7	2.2	17
1438	VEGF remains an interesting target in advanced pancreas cancer (APCA): results of a multi-institutional phase II study of bevacizumab, gemcitabine, and infusional 5-fluorouracil in patients with APCA. 2012 , 23, 2812-2820		25
1437	Phase I trial of gemcitabine combined with capecitabine and erlotinib in advanced pancreatic cancer: a clinical and pharmacological study. 2012 , 58, 371-80		2
1436	Dermatologic Toxicities from Monoclonal Antibodies and Tyrosine Kinase Inhibitors against EGFR: Pathophysiology and Management. 2012 , 2012, 351210		31
1435	Novel drugs targeting the epidermal growth factor receptor and its downstream pathways in the treatment of colorectal cancer: a systematic review. 2012 , 2012, 387172		11
1434	Treatment of epidermal growth factor receptor inhibitor-induced acneiform eruption with topical recombinant human epidermal growth factor. 2012 , 225, 135-40		17
1433	Aberrant glycogen synthase kinase 3 β in the development of pancreatic cancer. 2012 , 11, 15		10
1432	Cancer Stem Cells, EMT, and Developmental Pathway Activation in Pancreatic Tumors. 2012 , 4, 989-1035		25
1431	Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trial. 2012 , 23, 1214-1222		75
1430	A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer. 2012 , 23, 2834-2842		144
1429	Phase II study of gemcitabine, oxaliplatin, and cetuximab in advanced pancreatic cancer. 2012 , 35, 446-50		15
1428	New developments in management of oral mucositis in patients with head and neck cancer or receiving targeted anticancer therapies. 2012 , 69, 1031-7		16
1427	Folliculitis induced by EGFR inhibitors, preventive and curative efficacy of tetracyclines in the management and incidence rates according to the type of EGFR inhibitor administered: a systematic literature review. 2012 , 17, 555-68		34

1426	Neoadjuvant therapy of pancreatic cancer: the emerging paradigm?. 2012 , 17, 192-200	68
1425	Dual combination therapy targeting DR5 and EMMPRIN in pancreatic adenocarcinoma. 2012 , 11, 405-15	20
1424	Combined effects of EGFR and Hedgehog signaling pathway inhibition on the proliferation and apoptosis of pancreatic cancer cells. 2012 , 28, 519-26	13
1423	Acute Generalized Exanthematous Pustulosis Induced by Erlotinib (Tarceva) with Superimposed Staphylococcus aureus Skin Infection in a Pancreatic Cancer Patient: A Case Report. 2012 , 5, 253-9	4
1422	Prognosis in patients with non-small cell lung cancer who received erlotinib treatment and subsequent dose reduction due to skin rash. 2012 , 35, 747-52	7
1421	BMS-754807, a small-molecule inhibitor of insulin-like growth factor-1 receptor/insulin receptor, enhances gemcitabine response in pancreatic cancer. 2012 , 11, 2644-53	53
1420	Continuous inhibition of epidermal growth factor receptor phosphorylation by erlotinib enhances antitumor activity of chemotherapy in erlotinib-resistant tumor xenografts. 2012 , 27, 923-8	9
1419	Molecular and genetic bases of pancreatic cancer. 2012 , 13, 731-43	21
1418	Targeting the Epidermal Growth Factor Receptor in Glioblastoma Treatment. 2012 , 7, 3-13	
1417	Pancreatic cancer: between bench and bedside. 2012 , 13, 729-30	10
1416	Evidences and opinions for adjuvant therapy in pancreatic cancer. 2012 , 13, 789-94	2
1415	Systemic therapies for pancreatic cancer--the role of pharmacogenetics. 2012 , 13, 811-28	11
1414	Expanding surgical treatment of pancreatic cancer: the role of regional chemotherapy. 2012 , 41, 678-84	14
1413	Monoclonal antibodies and other targeted therapies for pancreatic cancer. 2012 , 18, 653-64	16
1412	A multi-centre randomized, open-label phase II trial of continuous erlotinib plus gemcitabine or gemcitabine as first-line therapy in ECOG PS2 patients with advanced non-small cell lung cancer. 2012 , 28, 763-7	3
1411	Dual ErbB1 and ErbB2 receptor tyrosine kinase inhibition exerts synergistic effect with conventional chemotherapy in pancreatic cancer. 2012 , 28, 2211-6	7
1410	Pancreatic cancer cells surviving gemcitabine treatment express markers of stem cell differentiation and epithelial-mesenchymal transition. 2012 , 41, 2093-102	52
1409	[EGFR/HER1: a target life]. 2012 , 99, 181-9	2

1408	Chemotherapy and other supportive modalities in the palliative setting for pancreatic cancer. 2012 , 18, 633-41	4
1407	Why is pancreatic cancer difficult to treat in the elderly?. 2012 , 8, 301-307	1
1406	Novel 3-Azaindoyl-4-arylmaleimides exhibiting potent antiangiogenic efficacy, protein kinase inhibition, and antiproliferative activity. 2012 , 55, 9531-40	29
1405	Association of creatine kinase and skin toxicity in phase I trials of anticancer agents. 2012 , 107, 1797-800	11
1404	Cost-effectiveness of treatment strategies for pancreatic head adenocarcinoma and potential opportunities for improvement. 2012 , 19, 3659-67	19
1403	Apricoxib, a novel inhibitor of COX-2, markedly improves standard therapy response in molecularly defined models of pancreatic cancer. 2012 , 18, 5031-42	48
1402	Treatment options for advanced pancreatic cancer: a review. 2012 , 12, 1327-36	32
1401	Percutaneous irreversible electroporation for downstaging and control of unresectable pancreatic adenocarcinoma. 2012 , 23, 1613-21	171
1400	What we have learned about pancreatic cancer from mouse models. 2012 , 142, 1079-92	129
1399	Can knowledge of germline markers of toxicity optimize dosing and efficacy of cancer therapy?. 2012 , 6, 349-62	6
1398	HLA polymorphisms influence the development of skin rash arising from treatment with EGF receptor inhibitors. 2012 , 13, 1469-76	9
1397	Array-based pharmacogenomics of molecular-targeted therapies in oncology. 2012 , 12, 185-96	11
1396	Phase I study of axitinib (AG-013736) in combination with gemcitabine in patients with advanced pancreatic cancer. 2012 , 30, 1531-9	16
1395	A phase II trial of Erlotinib in combination with gemcitabine and cisplatin in advanced pancreatic cancer. 2012 , 30, 2371-6	10
1394	Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer. 2012 , 30, 2391-9	85
1393	Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. 2012 , 13, 181-8	340
1392	A preclinical evaluation of Minnelide as a therapeutic agent against pancreatic cancer. 2012 , 4, 156ra139	180
1391	The antitumor activity of recombinant antitumor antiviral protein and the associated molecular mechanism in pancreatic tumor cells. 2012 , 27, 426-33	

1390	Impact of targeted neoadjuvant therapies in the treatment of solid organ tumours. 2013 , 100, 5-14	4
1389	Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth. 2012 , 61, 1373-85	187
1388	Comparison of the efficacy and the toxicity between gemcitabine with capecitabine (GC) and gemcitabine with erlotinib (GE) in unresectable pancreatic cancer. 2012 , 138, 1625-30	6
1387	EGF receptor is required for KRAS-induced pancreatic tumorigenesis. 2012 , 22, 304-17	355
1386	EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma. 2012 , 22, 318-30	272
1385	Ready, set, go: the EGF receptor at the pancreatic cancer starting line. 2012 , 22, 281-2	16
1384	Phase I study of conformal radiotherapy and concurrent full-dose gemcitabine with erlotinib for unresected pancreatic cancer. 2012 , 82, e187-92	6
1383	Treatment of locally advanced pancreatic cancer: the role of radiation therapy. 2012 , 82, 508-18	31
1382	Dose-volume analysis of predictors for gastrointestinal toxicity after concurrent full-dose gemcitabine and radiotherapy for locally advanced pancreatic adenocarcinoma. 2012 , 83, 1120-5	39
1381	Akt/mTOR signaling pathway is crucial for gemcitabine resistance induced by Annexin II in pancreatic cancer cells. 2012 , 178, 758-67	54
1380	Hedgehog signaling: from the cuirass to the heart of pancreatic cancer. 2012 , 12, 388-93	8
1379	Management of cancer in the older adult. 2012 , 28, 33-49	9
1378	Invasive markers identified by gene expression profiling in pancreatic cancer. 2012 , 12, 130-40	13
1377	Radiofrequency ablation of liver metastasis in patients with locally controlled pancreatic ductal adenocarcinoma. 2012 , 23, 635-41	33
1376	Sensitization of pancreatic cancer stem cells to gemcitabine by Chk1 inhibition. 2012 , 14, 519-25	62
1375	Pancreatic cancer: medical management (novel chemotherapeutics). 2012 , 41, 189-209	26
1374	Locally advanced pancreatic cancer. 2012 , 39, e9-22	5
1373	Celecoxib synergizes human pancreatic ductal adenocarcinoma cells to sorafenib-induced growth inhibition. 2012 , 12, 219-26	8

1372	HDAC gene expression in pancreatic tumor cell lines following treatment with the HDAC inhibitors panobinostat (LBH589) and trichostatine (TSA). 2012 , 12, 146-55		16
1371	Phase II trial of combined regional hyperthermia and gemcitabine for locally advanced or metastatic pancreatic cancer. 2012 , 28, 597-604		35
1370	Molecular profiling of direct xenograft tumors established from human pancreatic adenocarcinoma after neoadjuvant therapy. 2012 , 19 Suppl 3, S395-403		39
1369	Radiosensitization of human pancreatic cancer cells by MLN4924, an investigational NEDD8-activating enzyme inhibitor. 2012 , 72, 282-93		123
1368	Low expression of junctional adhesion molecule A is associated with metastasis and poor survival in pancreatic cancer. 2012 , 19, 4330-6		32
1367	Meta-analysis of phase III randomized trials of molecular targeted therapies for advanced pancreatic cancer. 2012 , 14, 260-8		17
1366	Phase I study of Rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer. 2012 , 18, 2048-55		43
1365	Ocular toxicity of targeted therapies. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3277-86	2.2	95
1364	A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker. 2012 , 106, 508-16		196
1363	Why RECIST works and why it should stay--counterpoint. 2012 , 72, 5151-7; discussion 5158		20
1362	Ack1 tyrosine kinase activation correlates with pancreatic cancer progression. 2012 , 180, 1386-93		42
1361	Combinational therapy: new hope for pancreatic cancer?. 2012 , 317, 127-35		70
1360	Comorbidity, age and overall survival in patients with advanced pancreatic cancer - results from NCIC CTG PA.3: a phase III trial of gemcitabine plus erlotinib or placebo. 2012 , 48, 1434-42		52
1359	The molecular and cellular heterogeneity of pancreatic ductal adenocarcinoma. 2011 , 9, 77-87		75
1358	Synergistic effects of photodynamic therapy with HPPH and gemcitabine in pancreatic cancer cell lines. 2012 , 44, 755-61		10
1357	Is there a role for the quantification of RRM1 and ERCC1 expression in pancreatic ductal adenocarcinoma?. 2012 , 12, 104		25
1356	Quality of life across chemotherapy lines in patients with cancers of the pancreas and biliary tract. 2012 , 12, 390		24
1355	RON is not a prognostic marker for resectable pancreatic cancer. 2012 , 12, 395		16

1354	New biomarkers and targets in pancreatic cancer and their application to treatment. 2012 , 9, 435-44	156
1353	Genomic biomarkers for patient selection and stratification: the cancer paradigm. 2012 , 4, 2499-511	7
1352	Anti-angiogenic drug discovery: lessons from the past and thoughts for the future. 2012 , 7, 723-43	25
1351	Systemic treatment of advanced pancreatic cancer. 2012 , 38, 843-53	98
1350	Emerging inorganic nanomaterials for pancreatic cancer diagnosis and treatment. 2012 , 38, 566-79	92
1349	Targeted destruction of the orchestration of the pancreatic stroma and tumor cells in pancreatic cancer cases: molecular basis for therapeutic implications. 2012 , 23, 343-56	28
1348	The interaction of EGFR and repair of DNA damage following chemotherapy and radiation. 2012 , 9, e69-e73	1
1347	EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer: a phase I/II study. 2012 , 75, 332-8	118
1346	Comparative analysis of traditional and coiled fiducials implanted during EUS for pancreatic cancer patients receiving stereotactic body radiation therapy. 2012 , 76, 962-71	78
1345	[Protein tyrosine kinase inhibitors in cancer therapy]. 2012 , 60, 229-33	5
1344	Genomics and pharmacogenomics of pancreatic adenocarcinoma. 2012 , 12, 1-9	10
1343	The role of stroma in pancreatic cancer: diagnostic and therapeutic implications. 2012 , 9, 454-67	418
1342	Drugs in preclinical and early-stage clinical development for pancreatic cancer. 2012 , 21, 143-52	26
1341	Emerging cell-cycle inhibitors for pancreatic cancer therapy. 2012 , 17, 571-82	7
1340	Systems Biology of Pancreatic Cancer: The Role of Tumor-Microenvironment Communication in Development, Progression and Therapy Resistance. 2012 , 135-164	
1339	Biological drugs: classic adverse effects and new clinical evidences. 2012 , 12, 285-97	6
1338	Pancreatic adenocarcinoma in young adults in a moroccan population. 2012 , 43, 607-11	7
1337	Sequential FOLFOX-6 and gemcitabine for locally advanced and/or metastatic pancreatic cancer. 2012 , 29, 2831-7	5

1336	Serum creatine kinase increase in patients treated with tyrosine kinase inhibitors for solid tumors. 2012 , 29, 3003-8	8
1335	Comparison of the prognostic values of various inflammation based factors in patients with pancreatic cancer. 2012 , 29, 3092-100	160
1334	In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption. 2012 , 14, 121-30	57
1333	Stromal cell-derived factor 1 mediates resistance to mTOR-directed therapy in pancreatic cancer. 2012 , 14, 690-701	40
1332	Locally advanced anaplastic pancreatic adenocarcinoma with initial response to FOLFIRINOX and rapid progression after five months. 2012 , 12, 35-8	3
1331	[New aspects of surgery for pancreatic cancer. Principles, results and evidence]. 2012 , 33 Suppl 2, 258-65	0
1330	Phase I trial of sunitinib and gemcitabine in patients with advanced solid tumors. 2012 , 70, 547-53	9
1329	Cystic Pancreatic Lesions. 2012 , 173-191	
1328	Pancreatic Ductal Adenocarcinoma. 2012 , 153-171	1
1327	Targeting the epidermal growth factor receptor in solid tumor malignancies. 2012 , 26, 83-99	27
1326	Aptamer-mediated delivery of chemotherapy to pancreatic cancer cells. 2012 , 22, 295-305	52
1325	Inflammatory Breast Cancer: An Update. 2012 ,	
1324	Molecular Characterization of Head and Neck Cancer. 2012 , 16, 209-222	20
1323	Early Gastrointestinal Cancers. 2012 ,	
1322	Knockdown of clusterin sensitizes pancreatic cancer cells to gemcitabine chemotherapy by ERK1/2 inactivation. 2012 , 31, 73	35
1321	Identification of anti-malarial compounds as novel antagonists to chemokine receptor CXCR4 in pancreatic cancer cells. 2012 , 7, e31004	47
1320	Targeting anticancer drug delivery to pancreatic cancer cells using a fucose-bound nanoparticle approach. 2012 , 7, e39545	41
1319	Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. 2012 , 7, e29794	163

1318	Management of venous thromboembolism in patients with advanced gastrointestinal cancers: what is the role of novel oral anticoagulants?. 2012 , 2012, 758385	9
1317	Role of Wnt/ β -catenin signaling in drug resistance of pancreatic cancer. 2012 , 18, 2464-71	114
1316	Current knowledge on pancreatic cancer. 2012 , 2, 6	55
1315	Radiotherapy and erlotinib combined: review of the preclinical and clinical evidence. 2012 , 2, 31	22
1314	Expression pattern and targeting of HER family members and IGF-IR in pancreatic cancer. 2012 , 17, 2698-724	15
1313	Novel therapeutic modalities and drug delivery in pancreatic cancer - an ongoing search for improved efficacy. 2012 , 2012, 212244	1
1312	Gemcitabine and Erlotinib (GE) Regimen for Pancreatic Cancer. 2012 , 47, 19-23	1
1311	Targeted Therapy in Oncology: A Key Player in the Move towards Personalized Medicine. 2012 , 01,	
1310	Hepatobiliary Pancreatic Cancer: Cutting-Edge Drug Therapy. 2012 , 23, xi67-xi68	
1309	Pancreatic Cancer. 2012 , 1289-1292	
1308	A New Direction for Pancreatic Cancer Treatment: FOLFIRINOX in Context. 2012 , 232-7	3
1307	Novel and Targeted Therapies. 2012 , 95-101	
1306	Report from the 13th annual Western canadian gastrointestinal cancer consensus conference; calgary, alberta; september 8-10, 2011. 2012 , 19, e468-77	1
1305	FDG PET/CT detected an insidious inguinal canal metastasis in a patient with pancreatic cancer. 2012 , 2,	
1304	Enhanced antitumor efficacy of gemcitabine by evodiamine on pancreatic cancer via regulating PI3K/Akt pathway. 2012 , 8, 1-14	49
1303	Membranous and cytoplasmic expression of epidermal growth factor receptor in metastatic pancreatic ductal adenocarcinoma. 2012 , 3, 931-936	15
1302	External validation of 2 prognostic indices for patients with advanced pancreatic cancer treated with first-line therapy. 2012 , 41, 738-44	1
1301	Recent advances of biliary stent management. 2012 , 13 Suppl 1, S62-6	10

1300 Targeted therapy for esophagogastric cancers: a review. **2012**, 5, 91-102

1299 A two-stage Bayesian design for co-development of new drugs and companion diagnostics. **2012**, 31, 901-14 32

1298 The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy. **2012**, 13, 1072-81 175

1297 The price we pay for progress: a meta-analysis of harms of newly approved anticancer drugs. *Journal of Clinical Oncology*, **2012**, 30, 3012-9 2.2 125

1296 Raising the bar: the curative potential of human cancer immunotherapy. **2012**, 4, 127ps8 189

1295 Combined modality treatment for patients with locally advanced pancreatic adenocarcinoma. **2012**, 99, 1083-8 54

1294 Long-term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancer. **2012**, 118, 3026-35 47

1293 Epidermal growth factor receptor and insulinlike growth factor 1 receptor expression predict poor survival in pancreatic ductal adenocarcinoma. **2012**, 118, 3484-93 87

1292 Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib. **2012**, 118, 5903-11 65

1291 Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial. **2012**, 118, 5497-506 68

1290 Pancreatic cancer. **2012**, 919-925.e1 1

1289 Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer. **2012**, 30, 1138-43 54

1288 A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research. **2012**, 30, 1164-74 19

1287 A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer. **2012**, 30, 1175-83 33

1286 Results of a phase II trial of S-1 as first-line treatment of metastatic pancreatic cancer (CESAR-study group). **2012**, 30, 1184-92 10

1285 A phase II study of the halichondrin B analog eribulin mesylate in gemcitabine refractory advanced pancreatic cancer. **2012**, 30, 1203-7 16

1284 Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma. **2012**, 108, 499-506 36

1283 (18)F-FDG PET/CT imaging detects therapy efficacy of anti-EMMPRIN antibody and gemcitabine in orthotopic pancreatic tumor xenografts. **2012**, 14, 237-44 17

1282	High vascular delivery of EGF, but low receptor binding rate is observed in AsPC-1 tumors as compared to normal pancreas. 2012 , 14, 472-9	25
1281	Maligne Erkrankungen des Gastrointestinaltrakts bei alten Patienten. 2012 , 7, 326-332	
1280	Multidisciplinary treatment with chemotherapy, targeted drug, and high-intensity focused ultrasound in advanced pancreatic carcinoma. 2012 , 29, 957-61	8
1279	A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors. 2012 , 69, 1013-20	6
1278	Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study). 2012 , 69, 1197-204	71
1277	FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study. 2012 , 69, 1641-5	68
1276	Escin augments the efficacy of gemcitabine through down-regulation of nuclear factor- κ B and nuclear factor- κ B-regulated gene products in pancreatic cancer both in vitro and in vivo. 2012 , 138, 785-97	64
1275	Glycogen synthase kinase 3 β inhibition sensitizes pancreatic cancer cells to gemcitabine. 2012 , 47, 321-33	44
1274	Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. 2012 , 21, 418-29	1309
1273	A prognostic model to identify patients with advanced pancreas adenocarcinoma who could benefit from second-line chemotherapy. 2012 , 24, 105-11	12
1272	Targeting heat shock response pathways to treat pancreatic cancer. 2012 , 17, 35-43	31
1271	Stroma and pancreatic ductal adenocarcinoma: an interaction loop. 2012 , 1826, 170-8	16
1270	Kinome-wide siRNA screening identifies molecular targets mediating the sensitivity of pancreatic cancer cells to Aurora kinase inhibitors. 2012 , 83, 452-61	21
1269	Pancreatic cancer tumour initiating cells: the molecular regulation and therapeutic values. 2012 , 16, 988-94	6
1268	Skin toxicities and survival in advanced hepatocellular carcinoma patients treated with sorafenib. 2012 , 42, 879-86	74
1267	Does health-related quality of life improve for advanced pancreatic cancer patients who respond to gemcitabine? Analysis of a randomized phase III trial of the cancer and leukemia group B (CALGB 80303). 2012 , 43, 205-17	48
1266	Stem cells as the root of pancreatic ductal adenocarcinoma. 2012 , 318, 691-704	40
1265	Molecularly targeted therapies in cervical cancer. A systematic review. 2012 , 126, 291-303	57

1264	Phase I trial of gemcitabine and candesartan combination therapy in normotensive patients with advanced pancreatic cancer: GECA1. 2012 , 103, 1489-92	29
1263	Bone marrow-derived proangiogenic cells in pancreatic cancer. 2012 , 27 Suppl 2, 23-6	6
1262	Predictive factors of solid food intake in patients with malignant gastric outlet obstruction receiving self-expandable metallic stents for palliation. 2012 , 24, 226-30	37
1261	Adjuvant PEEG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) or gemcitabine followed by chemoradiation in pancreatic cancer: a randomized phase II trial. 2012 , 19, 2256-63	22
1260	Identification of potential prognostic biomarkers in patients with untreated, advanced pancreatic cancer from a phase 3 trial (Cancer and Leukemia Group B 80303). 2012 , 118, 571-8	17
1259	Aberrant signaling pathways in pancreatic cancer: a two compartment view. 2012 , 51, 25-39	43
1258	Fatal interstitial lung disease associated with gemcitabine and erlotinib therapy for lung cancer. 2012 , 29, 212-4	6
1257	Cell membrane and cytoplasmic epidermal growth factor receptor expression in pancreatic ductal adenocarcinoma. 2012 , 29, 134-9	15
1256	A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen). 2012 , 69, 115-23	42
1255	A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma. 2012 , 69, 415-24	33
1254	The use of GTX as second-line and later chemotherapy for metastatic pancreatic cancer: a retrospective analysis. 2012 , 69, 425-30	9
1253	An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic function. 2012 , 69, 605-12	16
1252	Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium. 2012 , 30, 382-6	77
1251	A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer. 2012 , 30, 779-86	40
1250	Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Study Group. 2013 , 132, 236-45	59
1249	Outcomes of endoscopic pyloric stenting in malignant gastric outlet obstruction: a retrospective study. 2013 , 6, 280	9
1248	The management of skin toxicity during erlotinib in advanced non-small cell lung cancer: how much does it cost?. 2013 , 32, 248-51	5
1247	Epidermal growth factor receptor targeting in cancer: a review of trends and strategies. 2013 , 34, 8690-707	323

1246	Validity of the FACT Hepatobiliary (FACT-Hep) questionnaire for assessing disease-related symptoms and health-related quality of life in patients with metastatic pancreatic cancer. 2013 , 22, 1105-12	35
1245	Molecular Genetics of Pancreatic Cancer. 2013 ,	1
1244	Nuclear Medicine Therapy. 2013 ,	3
1243	Phase I/II study of albumin-bound nab-paclitaxel plus gemcitabine administered to Chinese patients with advanced pancreatic cancer. 2013 , 71, 1065-72	29
1242	Neoadjuvant therapy in resectable pancreatic cancer: a critical review. 2013 , 39, 518-24	31
1241	Triple approach strategy for patients with locally advanced pancreatic carcinoma. 2013 , 15, 623-7	37
1240	Fool's gold, lost treasures, and the randomized clinical trial. 2013 , 13, 193	36
1239	Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells. 2013 , 13, 41	40
1238	Understanding pancreatic cancer genomes. 2013 , 20, 549-56	26
1237	Hyaluronan, fluid pressure, and stromal resistance in pancreas cancer. 2013 , 108, 1-8	216
1236	Skin rash during erlotinib for advanced non-small cell lung cancer: is age a clinical predictor?. 2013 , 305, 653-8	3
1235	Benefit and harms of new anti-cancer drugs. 2013 , 15, 270-5	23
1234	Phase I study of oxaliplatin in combination with gemcitabine, irinotecan, and 5-fluorouracil/leucovorin (G-FLIE) in patients with metastatic solid tumors including adenocarcinoma of the pancreas. 2013 , 44, 182-9	2
1233	TL-118-anti-angiogenic treatment in pancreatic cancer: a case report. 2013 , 30, 585	8
1232	Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy. 2013 , 139, 681-9	106
1231	Risk of oral and gastrointestinal mucosal injury among patients receiving selected targeted agents: a meta-analysis. 2013 , 21, 3243-54	37
1230	Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year review. 2013 , 21, 1167-74	53
1229	Met, IGF1R, and other new targets in upper GI malignancies. 2013 , 14, 321-36	2

1228	The role of maintenance strategies in upper gastrointestinal (GI) and pancreatic carcinoma. 2013 , 6, 26-28	
1227	Synergistic interactions between sorafenib and everolimus in pancreatic cancer xenografts in mice. 2013 , 71, 1231-40	23
1226	Uridine diphosphate glucuronosyl transferase 1 family polypeptide A1 gene (UGT1A1) polymorphisms are associated with toxicity and efficacy in irinotecan monotherapy for refractory pancreatic cancer. 2013 , 71, 85-92	19
1225	Therapeutic advances in pancreatic cancer. 2013 , 144, 1316-26	220
1224	Reduction in circulating pro-angiogenic and pro-inflammatory factors is related to improved outcomes in patients with advanced pancreatic cancer treated with gemcitabine and intravenous omega-3 fish oil. 2013 , 15, 428-32	29
1223	Cáncer de páncreas exocrino. 2013 , 11, 1526-1531	
1222	United States Food and Drug Administration approved oral kinase inhibitors for the treatment of malignancies. 2013 , 37, 110-44	40
1221	Inhibition of the growth of patient-derived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented by combined treatment with the epidermal growth factor receptor/HER2 inhibitor lapatinib. 2013 , 15, 143-55	67
1220	Genetically engineered mouse models of pancreatic adenocarcinoma. 2013 , 7, 232-47	111
1219	Increased Survival After Resection of Pancreatic Cancer Liver Metastases. 2013 , 91, 390-392	1
1218	Cucurmosin induces the apoptosis of human pancreatic cancer CFPAC-1 cells by inactivating the PDGFR-β signalling pathway. 2013 , 65, 682-8	3
1217	The quest to overcome resistance to EGFR-targeted therapies in cancer. 2013 , 19, 1389-400	684
1216	Nicotinamide prohibits proliferation and enhances chemosensitivity of pancreatic cancer cells through deregulating SIRT1 and Ras/Akt pathways. 2013 , 13, 140-6	29
1215	Multidisciplinary management of pancreatic cancer. 2013 , 22, 265-87	23
1214	Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer. 2013 , 49, 2633-42	135
1213	Biliary tract carcinomas: from chemotherapy to targeted therapy. 2013 , 85, 136-48	33
1212	The management of metastatic pancreatic cancer: expert discussion and recommendations from the 14th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2012. 2013 , 24, iv5-iv10	6
1211	A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma. 2013 , 31, 707-13	67

1210	Margin status, recurrence pattern, and prognosis after resection of pancreatic cancer. 2013 , 154, 1078-86	73
1209	Andrographolide causes apoptosis via inactivation of STAT3 and Akt and potentiates antitumor activity of gemcitabine in pancreatic cancer. 2013 , 222, 23-35	28
1208	Molecular Pathology of Neoplastic Gastrointestinal Diseases. 2013 ,	2
1207	Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. 2013 , 369, 1691-703	3788
1206	A retrospective study of S-1 and oxaliplatin combination chemotherapy in patients with refractory pancreatic cancer. 2013 , 72, 985-90	11
1205	Identification of exon 19 and 21 mutations of EGFR gene in Chinese patients with esophageal squamous cell carcinoma. 2013 , 11, 266	8
1204	Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer. 2013 , 12, 104	33
1203	A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study. 2013 , 31, 943-8	9
1202	Targeting the Ras-ERK pathway in pancreatic adenocarcinoma. 2013 , 32, 147-62	76
1201	EGFR and HER2 inhibition in pancreatic cancer. 2013 , 31, 558-66	21
1200	Recent treatment advances and novel therapies in pancreas cancer: a review. 2014 , 45, 190-201	22
1199	Paracrine Activation of Chemokine Receptor CCR9 Enhances The Invasiveness of Pancreatic Cancer Cells. 2013 , 6, 241-5	22
1198	Role of radiotherapy in combination with chemotherapy, targeted therapy, and immunotherapy in the management of pancreatic cancer. 2013 , 2, 369-379	3
1197	[Will molecular diagnostics become established in pancreatic pathology?]. 2013 , 34 Suppl 2, 214-20	
1196	Regionale Therapie maligner Tumoren. 2013 ,	
1195	Exploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunities. 2013 , 65, 1731-47	189
1194	Cardiovascular toxicities of cancer chemotherapy. 2013 , 40, 156-67	28
1193	Epidermal growth factor receptor: pathway, therapies, and pipeline. 2013 , 35, 1282-303	66

1192	Regorafenib for gastrointestinal malignancies : from preclinical data to clinical results of a novel multi-target inhibitor. 2013 , 27, 213-24	35
1191	Pharmacogenetic predictors for EGFR-inhibitor-associated skin toxicity. 2013 , 13, 181-8	26
1190	Protein kinase inhibitors in metastatic colorectal cancer. Let's pick patients, tumors, and kinase inhibitors to piece the puzzle together!. 2013 , 14, 2203-20	4
1189	Pancreatic cancer genomics: insights and opportunities for clinical translation. 2013 , 5, 26	18
1188	EGFR mutational status in penile cancer. 2013 , 17, 501-5	12
1187	Targeted drugs in combination with radiotherapy for the treatment of solid tumors: current state and future developments. 2013 , 6, 663-76	9
1186	A phase I/II, non-randomized, feasibility/safety and efficacy study of the combination of everolimus, cetuximab and capecitabine in patients with advanced pancreatic cancer. 2013 , 31, 85-91	26
1185	Radioimmunotherapy of Pancreatic Adenocarcinoma. 2013 , 239-255	
1184	Persistent activation of pancreatic stellate cells creates a microenvironment favorable for the malignant behavior of pancreatic ductal adenocarcinoma. 2013 , 132, 993-1003	66
1183	Diagnostic Yield of Pancreatic Percutaneous Puncture Depending on the Size of the Lesion. 2013 , 91, 361-365	
1182	"Chronic" metastatic pancreatic acinar cell carcinoma. 2013 , 13, 549-52	12
1181	Molecular mechanisms underlying the antitumor activity of 3-aminopropanamide irreversible inhibitors of the epidermal growth factor receptor in non-small cell lung cancer. 2013 , 15, 61-72	12
1180	A small-molecule induces apoptosis and suppresses metastasis in pancreatic cancer cells. 2013 , 48, 658-67	8
1179	Molecular biology of adenocarcinoma of the pancreatic duct, current state and future therapeutic avenues. 2013 , 22, 69-76	5
1178	Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer. 2013 , 86, 678-85	30
1177	Nested case control study of proteomic biomarkers for interstitial lung disease in Japanese patients with non-small-cell lung cancer treated with erlotinib: a multicenter phase IV study (JO21661). 2013 , 14, 407-17	8
1176	An evaluation of the possible interaction of gastric acid suppressing medication and the EGFR tyrosine kinase inhibitor erlotinib. 2013 , 82, 136-42	43
1175	Synthetic lethality screen identifies RPS6KA2 as modifier of epidermal growth factor receptor activity in pancreatic cancer. 2013 , 15, 1354-62	24

1174	Radiosensitizers in pancreatic cancer--preclinical and clinical exploits with molecularly targeted agents. 2013 , 37, 301-12		1
1173	Current concepts and novel targets in advanced pancreatic cancer. 2013 , 62, 317-26		123
1172	[Diagnostic yield of pancreatic percutaneous puncture depending on the size of the lesion]. 2013 , 91, 361-5		2
1171	[Increased survival after resection of pancreatic cancer liver metastases]. 2013 , 91, 390-2		
1170	A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours. 2013 , 49, 2077-85		65
1169	Monogalactosyl diacylglycerol, a replicative DNA polymerase inhibitor, from spinach enhances the anti-cell proliferation effect of gemcitabine in human pancreatic cancer cells. 2013 , 1830, 2517-25		19
1168	Efficacy and safety profile of combining agents against epidermal growth factor receptor or vascular endothelium growth factor receptor with gemcitabine-based chemotherapy in patients with advanced pancreatic cancer: a meta-analysis. 2013 , 13, 415-22		18
1167	Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomised trials. 2013 , 49, 593-603		89
1166	FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity. 2013 , 30, 361		109
1165	Successful adjuvant bi-weekly gemcitabine chemotherapy for pancreatic cancer without impairing patients' quality of life. 2013 , 11, 3		6
1164	SnapShot: pancreatic cancer. 2013 , 23, 424-424.e1		29
1163	Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1405-14	2.2	162
1162	Multidisciplinary management of locally advanced-borderline resectable adenocarcinoma of the head of the pancreas. 2013 , 15, 173-81		9
1161	The role of the FOLFIRINOX regimen for advanced pancreatic cancer. 2013 , 15, 182-9		70
1160	The war on cancer: are we winning?. 2013 , 34, 1275-84		36
1159	Nontoxic radioactive Listeria(at) is a highly effective therapy against metastatic pancreatic cancer. 2013 , 110, 8668-73		90
1158	Investigational therapies targeting the ErbB (EGFR, HER2, HER3, HER4) family in GI cancers. 2013 , 22, 341-56		24
1157	Interactions of everolimus and sorafenib in pancreatic cancer cells. 2013 , 15, 78-84		12

1156	Whole blood interferon- γ levels predict the therapeutic effects of adoptive T-cell therapy in patients with advanced pancreatic cancer. 2013 , 133, 1119-25	16
1155	Targeting apoptosis pathways in pancreatic cancer. 2013 , 332, 346-58	94
1154	Cetuximab: still an option in the treatment of pancreatic cancer?. 2013 , 13, 791-801	14
1153	Stromal expression of SPARC in pancreatic adenocarcinoma. 2013 , 32, 585-602	90
1152	EGFR-tyrosine kinase inhibitor treatment beyond progression in long-term Caucasian responders to erlotinib in advanced non-small cell lung cancer: a case-control study of overall survival. 2013 , 80, 306-12	38
1151	Advanced-stage pancreatic cancer: therapy options. 2013 , 10, 323-33	141
1150	Toward the goal of personalized therapy in pancreatic cancer by targeting the molecular phenotype. 2013 , 779, 91-143	7
1149	Lokale Therapieverfahren beim Pankreaskarzinom. 2013 , 8, 36-43	
1148	The cost-effectiveness of neoadjuvant chemoradiation is superior to a surgery-first approach in the treatment of pancreatic head adenocarcinoma. 2013 , 20 Suppl 3, S500-8	57
1147	Efficacy of a metallic stent covered with a paclitaxel-incorporated membrane versus a covered metal stent for malignant biliary obstruction: a prospective comparative study. 2013 , 58, 865-71	37
1146	The winning formulation: the development of paclitaxel in pancreatic cancer. 2013 , 19, 5572-9	46
1145	Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104). 2013 , 62, 751-9	87
1144	Phase II trial of gemcitabine and S-1 for patients with advanced pancreatic cancer. 2013 , 72, 845-52	11
1143	Aspirin prolongs survival and reduces the number of Foxp3+ regulatory T cells in a genetically engineered mouse model of pancreatic cancer. 2013 , 398, 989-96	12
1142	The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer. 2013 , 31, 1375-83	6
1141	A multicenter phase II trial of gemcitabine and candesartan combination therapy in patients with advanced pancreatic cancer: GECA2. 2013 , 31, 1294-9	38
1140	Adjuvant therapy for pancreas adenocarcinoma. 2013 , 107, 78-85	12
1139	Indications et prise en charge des effets secondaires des biothérapies anti-EGFR. 2013 , 143-158	

1138	Healthcare costs, treatment patterns, and resource utilization among pancreatic cancer patients in a managed care population. 2013 , 16, 1379-86	14
1137	Personalizing pancreatic cancer medicine: what are the challenges?. 2013 , 10, 45-59	2
1136	Putative predictive biomarkers of survival in patients with metastatic pancreatic adenocarcinoma treated with gemcitabine and ganitumab, an IGF1R inhibitor. 2013 , 19, 4282-9	50
1135	Dermatologic adverse events associated with afatinib: an oral ErbB family blocker. 2013 , 13, 721-8	63
1134	Equipoise abandoned? Randomization and clinical trials. 2013 , 24, 2471-2474	19
1133	Médecine personnalisée en cancérologie digestive. 2013 ,	
1132	Pancreatic Cancer: Current Options for Diagnosis, Staging and Therapeutic Management. 2013 , 1, 41-52	13
1131	Adjuvante und palliative Therapie des Pankreaskarzinoms - Update. 2013 , 09, 171-193	
1130	[S3-guideline exocrine pancreatic cancer]. 2013 , 51, 1395-440	127
1129	Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials. 2013 , 24, 1972-9	101
1128	Systemic treatment of advanced pancreatic cancer--step by step progress. 2013 , 62, 660-1	3
1127	What is recent in pancreatic cancer immunotherapy?. 2013 , 2013, 492372	18
1126	Cost-effectiveness of systemic therapies for metastatic pancreatic cancer. 2013 , 20, e90-e106	47
1125	Non-inferiority cancer clinical trials: scope and purposes underlying their design. 2013 , 24, 1942-1947	22
1124	Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer. 2013 , 24, 1792-1801	24
1123	Risk factors and therapeutic targets in pancreatic cancer. 2013 , 3, 282	28
1122	Pancreatic cancer: why is it so hard to treat?. 2013 , 6, 321-37	193
1121	Safety and effectiveness of gemcitabine in 855 patients with pancreatic cancer under Japanese clinical practice based on post-marketing surveillance in Japan. 2013 , 43, 139-45	4

1120	The Hepatobiliary and Pancreatic Oncology (HBPO) Group of the Japan Clinical Oncology Group (JCOG): history and future direction. 2013 , 43, 2-7	3
1119	Pooled survival and response data from phase III randomized controlled trials for gemcitabine-based regimes in the treatment of advanced pancreatic cancer. 2013 , 36, 411-4	20
1118	Clinical outcomes of chemotherapy for diabetic and nondiabetic patients with pancreatic cancer: better prognosis with statin use in diabetic patients. 2013 , 42, 202-8	47
1117	Clinical pharmacokinetics of tyrosine kinase inhibitors: implications for therapeutic drug monitoring. 2013 , 35, 562-87	63
1116	Erlotinib prolongs survival in pancreatic cancer by blocking gemcitabine-induced MAPK signals. 2013 , 73, 2221-34	39
1115	Vitamin E Eocotrienol prolongs survival in the LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre (KPC) transgenic mouse model of pancreatic cancer. 2013 , 6, 1074-83	27
1114	Phase II study of gemcitabine in combination with regional arterial infusion of nafamostat mesilate for advanced pancreatic cancer. 2013 , 36, 44-8	26
1113	Molecularly targeted therapies in metastatic pancreatic cancer: a systematic review. 2013 , 42, 760-73	23
1112	Gemcitabine-associated "pseudocellulitis" and "pseudosepsis": a case report and review of the literature. 2013 , 20, 118-20	9
1111	Modest improvement in overall survival for patients with metastatic pancreatic cancer: a trend analysis using the surveillance, epidemiology, and end results registry from 1988 to 2008. 2013 , 42, 1157-63	51
1110	A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancer. 2013 , 36, 151-6	86
1109	FOLFIRI in patients with locally advanced or metastatic pancreatic or biliary tract carcinoma: a monoinstitutional experience. 2013 , 24, 980-5	15
1108	Combination treatment with comprehensive cryoablation and immunotherapy in metastatic pancreatic cancer. 2013 , 42, 1143-9	61
1107	Disrupting cytokine signaling in pancreatic cancer: a phase I/II study of etanercept in combination with gemcitabine in patients with advanced disease. 2013 , 42, 813-8	46
1106	Cancer drugs in the United States: Justum Pretium--the just price. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3600-4	2.2 228
1105	ERK1/2 activity contributes to gemcitabine resistance in pancreatic cancer cells. 2013 , 41, 300-6	46
1104	PARP-1 regulates resistance of pancreatic cancer to TRAIL therapy. 2013 , 19, 4750-9	50
1103	Phase III trials of targeted anticancer therapies: redesigning the concept. 2013 , 19, 4931-40	17

1102	Subtype-specific MEK-PI3 kinase feedback as a therapeutic target in pancreatic adenocarcinoma. 2013 , 12, 2213-25		30
1101	Pancreatic cancer clinical trials and accrual in the United States. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3432-8	2.2	41
1100	Evolving panorama of treatment for metastatic pancreas adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1621-3	2.2	4
1099	Depletion of RAD17 sensitizes pancreatic cancer cells to gemcitabine. 2013 , 126, 3380-9		23
1098	Multicenter phase II trial to investigate safety and efficacy of gemcitabine combined with cetuximab as adjuvant therapy in pancreatic cancer (ATIP). 2013 , 24, 2576-2581		27
1097	Inhibition of pancreatic carcinoma by homo- and heterocombinations of antibodies against EGF-receptor and its kin HER2/ErbB-2. 2013 , 110, 15389-94		34
1096	Value of carbohydrate antigen 19-9 in predicting response and therapy control in patients with metastatic pancreatic cancer undergoing first-line therapy. 2013 , 3, 155		21
1095	Diagnosis and management of pancreatic cancer. 2013 , 185, 1219-26		28
1094	Pharmacokinetics, clinical indications, and resistance mechanisms in molecular targeted therapies in cancer. 2013 , 65, 1351-95		26
1093	Recent progress in pancreatic cancer. 2013 , 63, 318-48		606
1092	Adenovirus-mediated interferon- γ gene therapy induced human pancreatic carcinoma Capan-2 cell apoptosis in vitro and in vivo. 2013 , 296, 604-10		8
1091	Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive patients with unresectable or metastatic pancreatic cancer. 2013 , 2, 925-32		65
1090	Fibroblast growth factor receptor 1 gene amplification in pancreatic ductal adenocarcinoma. 2013 , 63, 157-66		30
1089	Lenalidomide in combination with gemcitabine as first-line treatment for patients with metastatic carcinoma of the pancreas: a Sarah Cannon Research Institute phase II trial. 2013 , 14, 340-6		11
1088	Chemical kinetic mechanistic models to investigate cancer biology and impact cancer medicine. 2013 , 10, 026004		2
1087	Mechanisms of resistance to EGFR targeted therapies. 2013 , 14, 304-14		41
1086	EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104. 2013 , 108, 469-76		76
1085	Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study. 2013 , 108, 1393-401		18

1084	Gemcitabine-mediated tumour regression and p53-dependent gene expression: implications for colon and pancreatic cancer therapy. 2013 , 4, e791		44
1083	Knockdown of RON receptor kinase delays but does not prevent tumor progression while enhancing HGF/MET signaling in pancreatic cancer cell lines. 2013 , 2, e76		28
1082	Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1640-8	2.2	448
1081	Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1415-21	2.2	156
1080	Not all antibodies are equal. 2013 , 14, 1075-6		
1079	From bench to bedside: lessons learned in translating preclinical studies in cancer drug development. 2013 , 105, 1441-56		41
1078	The just price of cancer drugs and the growing cost of cancer care: oncologists need to be part of the solution. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3487-9	2.2	30
1077	A phase II study of a personalized peptide vaccination for chemotherapy-resistant advanced pancreatic cancer patients. 2013 , 30, 1094-100		45
1076	Pancreatic cancer: is combination treatment better?. 2013 , 10, 695-700		1
1075	Role of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of esophageal carcinoma and the suggested mechanisms of action. 2013 , 5, 19-24		5
1074	Disposition of Erlotinib and Its Metabolite OSI420 in a Patient with High Bilirubin Levels. 2013 , 6, 602-8		3
1073	Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Advanced Pancreatic Ductal Adenocarcinoma: Impact of Baseline Fluctuation and Changes during Chemotherapy. 2013 , 99, 516-522		12
1072	Pharmacologic and radiotherapeutic interventions for advanced pancreatic cancer. 2013 ,		
1071	The clinical significance of SWI/SNF complex in pancreatic cancer. 2013 , 42, 403-10		42
1070	Screening for pancreatic cancer: why, how, and who?. 2013 , 257, 17-26		147
1069	Reply: To PMID 22623561. 2013 , 200, 468		5
1068	Targeting HER receptors in cancer. 2013 , 19, 808-17		32
1067	Differences in transcript levels of ABC transporters between pancreatic adenocarcinoma and nonneoplastic tissues. 2013 , 42, 707-16		71

1066	Preoperative gemcitabine-based chemoradiation therapy for resectable and borderline resectable pancreatic cancer. 2013 , 258, 1040-50	110
1065	Erlotinib-induced thrombocytosis in patients with recurrence of pancreatic cancer after distal pancreatectomy. 2013 , 42, 1196-7	1
1064	A retrospective analysis of VeriStrat status on outcome of a randomized phase II trial of first-line therapy with gemcitabine, erlotinib, or the combination in elderly patients (age 70 years or older) with stage IIIB/IV non-small-cell lung cancer. 2013 , 8, 443-51	44
1063	Small molecule inhibitors of CXCR4. 2013 , 3, 47-75	195
1062	[Current topics and future to vaccine for pancreatic cancer]. 2013 , 116, 573-80	
1061	[Recent update of molecular targeted therapy in pancreatic cancer]. 2013 , 61, 147-54	2
1060	Emerging concepts in pancreatic cancer medicine: targeting the tumor stroma. 2013 , 7, 33-43	54
1059	Treatment outcome of advanced pancreatic cancer patients who are ineligible for a clinical trial. 2013 , 6, 491-6	10
1058	Rationing cancer care: a survey among the members of the german society of hematology and oncology. 2013 , 11, 658-65	4
1057	Medikamentöse Therapie der Peritonealkarzinose. 2013 , 29, 5-5	
1056	Mechanistic evaluation of a novel small molecule targeting mitochondria in pancreatic cancer cells. 2013 , 8, e54346	14
1055	Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis. 2013 , 8, e55128	101
1054	Inhibiting the growth of pancreatic adenocarcinoma in vitro and in vivo through targeted treatment with designer gold nanotherapeutics. 2013 , 8, e57522	23
1053	Gemcitabine plus erlotinib for advanced pancreatic cancer: a systematic review with meta-analysis. 2013 , 8, e57528	45
1052	Lithium inhibits tumorigenic potential of PDA cells through targeting hedgehog-GLI signaling pathway. 2013 , 8, e61457	32
1051	Clinical, molecular and genetic validation of a murine orthotopic xenograft model of pancreatic adenocarcinoma using fresh human specimens. 2013 , 8, e77065	52
1050	A view on EGFR-targeted therapies from the oncogene-addiction perspective. 2013 , 4, 53	29
1049	The role of the renin angiotensin system in the treatment of advanced pancreatic cancer. 2013 , 28, 49-55	

1048 Radioactive bacteria attack cancer. **2013,**

1047 Efficacy and safety of gemcitabine-fluorouracil combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomized controlled trials. **2014, 9, e104346** 31

1046 Antiproliferative effects and mechanisms of liver X receptor ligands in pancreatic ductal adenocarcinoma cells. **2014, 9, e106289** 31

1045 A Bayesian meta-analysis of multiple treatment comparisons of systemic regimens for advanced pancreatic cancer. **2014, 9, e108749** 27

1044 Sustained complete response after maintenance therapy with topotecan and erlotinib for recurrent cervical cancer with distant metastases. **2014, 7, 97-101** 3

1043 Nab-paclitaxel: potential for the treatment of advanced pancreatic cancer. **2014, 7, 187-92** 20

1042 Genetic determinants and potential therapeutic targets for pancreatic adenocarcinoma. **2014, 5, 87** 21

1041 Optimum chemotherapy in the management of metastatic pancreatic cancer. **2014, 20, 2352-7** 15

1040 Neoadjuvant therapy for pancreas cancer: past lessons and future therapies. **2014, 20, 15564-79** 37

1039 [Chemo-sensitivity study in pancreatic cancer]. **2014, 64, 317-9**

1038 [Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine chemotherapy: clinical characteristics of long-term survivors]. **2014, 64, 356-63** 0

1037 Assessing the role of the EGF receptor in the development and progression of pancreatic cancer. **2014, 23** 3

1036 Pancreatic Cancer Treatment. **2014, 05,** 2

1035 Therapeutic options for the management of pancreatic cancer. **2014, 20, 11142-59** 94

1034 A Near-Complete Response to Treatment with Gemcitabine plus nab (®)-Paclitaxel in a Patient with Metastatic Pancreatic Cancer and Poor Performance Status: A Case Report. **2014, 7, 711-7** 4

1033 HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models. **2014, 5, 7138-48** 29

1032 The inhibitory effect of heat treatment against epithelial-mesenchymal transition (EMT) in human pancreatic adenocarcinoma cell lines. **2014, 55, 56-61** 14

1031 Emerging treatments for advanced pancreatic cancer: clinical potential of albumin-bound paclitaxel. **2014, 89**

1030	Druggable Targets in Pancreatic Adenocarcinoma. 2014 , 5, 195-214	
1029	Beyond first-line chemotherapy for advanced pancreatic cancer: an expanding array of therapeutic options?. 2014 , 20, 2224-36	44
1028	EGFR and c-Met Inhibitors are Effective in Reducing Tumorigenicity in Cancer. 2014 , 05,	5
1027	N-methylhemaneanthidine chloride, a novel Amaryllidaceae alkaloid, inhibits pancreatic cancer cell proliferation via down-regulating AKT activation. 2014 , 280, 475-83	23
1026	Current and future intratumoral targeted treatment for pancreatic cancer. 2014 , 5, 913-26	6
1025	International comparison of the factors influencing reimbursement of targeted anti-cancer drugs. 2014 , 14, 595	9
1024	Klinische Krebsforschung im Wandel. 2014 , 29, 485-492	1
1023	Promising new therapies in advanced pancreatic adenocarcinomas. 2014 , 10, 2629-41	10
1022	Pilot clinical trial of hedgehog pathway inhibitor GDC-0449 (vismodegib) in combination with gemcitabine in patients with metastatic pancreatic adenocarcinoma. 2014 , 20, 5937-5945	202
1021	Nab-paclitaxel and gemcitabine for the treatment of patients with metastatic pancreatic cancer. 2014 , 8, 739-47	26
1020	Prognostic nomogram for nonresectable pancreatic cancer treated with gemcitabine-based chemotherapy. 2014 , 110, 1943-9	48
1019	Advanced stage pancreatic cancer: novel therapeutic options. 2014 , 7, 487-98	13
1018	Outcome of gemcitabine plus molecular targeted agent for treatment of pancreatic cancer: a meta-analysis of prospective phase III studies. 2014 , 35, 11551-8	4
1017	Dual targeting of ErbB-2/ErbB-3 results in enhanced antitumor activity in preclinical models of pancreatic cancer. 2014 , 3, e117	12
1016	Metabolism addiction in pancreatic cancer. 2014 , 5, e1065	96
1015	Orally active microtubule-targeting agent, MPT0B271, for the treatment of human non-small cell lung cancer, alone and in combination with erlotinib. 2014 , 5, e1162	15
1014	A synthetic lethal screen identifies the Vitamin D receptor as a novel gemcitabine sensitizer in pancreatic cancer cells. 2014 , 13, 3839-56	23
1013	Advanced pancreatic cancer: flourishing novel approaches in the era of biological therapy. 2014 , 19, 937-50	7

1012	Desmoplasia and chemoresistance in pancreatic cancer. 2014 , 6, 2137-54	85
1011	Altered Signaling Pathways and Potential Therapeutic Targets in Pancreatic Cancer. 2014 , 2265-2273	
1010	Stratified Medicine for Pancreatic Cancer. 2014 , 807-814	
1009	FOLFIRINOX - a new paradigm in the treatment of pancreatic cancer. 2014 , 14, 1115-25	14
1008	Integrating traditional medicine into modern inflammatory diseases care: multitargeting by Rhus verniciflua Stokes. 2014 , 2014, 154561	30
1007	Use of a preclinical model of pancreas cancer to identify potential candidates for rapalogue therapy. 2014 , 63, 1379-80	
1006	Allogeneic cell-based immunotherapy combined with chemotherapy and targeted therapy in advanced pancreatic cancer with metastases: A case report. 2014 , 7, 1594-1598	5
1005	Small-molecule inhibitors of the receptor tyrosine kinases: promising tools for targeted cancer therapies. 2014 , 15, 13768-801	135
1004	Icotinib combined with rapamycin in a renal transplant recipient with epidermal growth factor receptor-mutated non-small cell lung cancer: A case report. 2014 , 7, 171-176	2
1003	Immunotherapeutic and oncolytic viral therapeutic strategies in pancreatic cancer. 2014 , 10, 1255-75	5
1002	Molecular mechanisms underlying the role of microRNAs in the chemoresistance of pancreatic cancer. 2014 , 2014, 678401	35
1001	Targeted therapy in gastrointestinal malignancies. 2014 , 13, 4	5
1000	Progress in the knowledge and treatment of advanced pancreatic cancer: from benchside to bedside. 2014 , 40, 1039-47	76
999	Can we move towards personalised pancreatic cancer therapy?. 2014 , 8, 335-8	3
998	Phase II study of FOLFIRINOX for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer. 2014 , 105, 1321-6	107
997	[Incidence and treatment of chemotherapy-induced nausea and emesis in gastrointestinal cancer]. 2014 , 52, 821-30	2
996	nab-Paclitaxel: novel clinical and experimental evidence in pancreatic cancer. 2014 , 52, 360-6	23
995	Parp-1 genetic ablation in Ela-myc mice unveils novel roles for Parp-1 in pancreatic cancer. 2014 , 234, 214-27	12

994	Analysis of second-line chemotherapies for ductal pancreatic adenocarcinoma in a German single-center cohort. 2014 , 49, 1480-5	2
993	Loss of membranous expression of the intracellular domain of EpCAM is a frequent event and predicts poor survival in patients with pancreatic cancer. 2014 , 64, 683-92	30
992	Phase II, randomized, biomarker identification trial (MARK) for erlotinib in patients with advanced pancreatic carcinoma. 2014 , 25, 1384-1390	25
991	Phase II trial of sorafenib and erlotinib in advanced pancreatic cancer. 2014 , 3, 572-9	22
990	The role of pancreatic and duodenal homeobox 1 as a therapeutic target in pancreatic cancer. 2014 , 18, 1277-83	3
989	DNA synthesis inhibitors for the treatment of gastrointestinal cancer. 2014 , 15, 2361-72	3
988	Selected gastrointestinal cancer presentations from the American Society of Clinical Oncology annual meeting 2013 in review: it is not about the destination, it is about the journey. 2014 , 15, 143-50	6
987	Radioembolization with Yttrium-90 microspheres (SIRT) in pancreatic cancer patients with liver metastases: efficacy, safety and prognostic factors. 2014 , 86, 24-32	38
986	Smarter drugs emerging in pancreatic cancer therapy. 2014 , 25, 1260-1270	62
985	Comparison of the efficacy of covered versus uncovered metallic stents in treating inoperable malignant common bile duct obstruction: a randomized trial. 2014 , 25, 1912-20	25
984	Multi-institutional phase I study of low-dose ultra-fractionated radiotherapy as a chemosensitizer for gemcitabine and erlotinib in patients with locally advanced or limited metastatic pancreatic cancer. 2014 , 113, 35-40	12
983	Improved survival with combined gemcitabine and S-1 for locally advanced pancreatic cancer: pooled analysis of three randomized studies. 2014 , 21, 761-6	21
982	Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study. 2014 , 111, 2067-75	35
981	A 60-year-old male with synchronous acute myeloid leukemia and metastatic adenocarcinoma of the pancreas. 2014 , 41, e51-9	2
980	Neutrophil-to-lymphocyte ratio for predicting palliative chemotherapy outcomes in advanced pancreatic cancer patients. 2014 , 3, 406-15	89
979	Pancreatic cancer: current standards, working towards a new therapeutic approach. 2014 , 14, 495-7	8
978	Response to GEMOX plus erlotinib in pancreatic cancer is associated with ERCC1 overexpression. 2014 , 44, 958-64	8
977	Enhancement of nab-paclitaxel antitumor activity through addition of multitargeting antiangiogenic agents in experimental pancreatic cancer. 2014 , 13, 1032-43	18

976	Molecular tumor board: the University of California-San Diego Moores Cancer Center experience. 2014 , 19, 631-6	125
975	Zweitlinientherapie bei fortgeschrittenem Pankreaskarzinom. 2014 , 9, 562-564	
974	Boolean ErbB network reconstructions and perturbation simulations reveal individual drug response in different breast cancer cell lines. 2014 , 8, 75	26
973	Chemotherapeutic strategies in advanced or metastatic pancreatic adenocarcinoma. 2014 , 37, 194-200	8
972	Antiprotease strategy in pancreatic cancer treatment: emergence from a preclinical study. 2014 , 43, 53-63	3
971	Emerging combination therapies to overcome resistance in EGFR-driven tumors. 2014 , 25, 127-39	14
970	Effect of erlotinib on CYP3A activity, evaluated in vitro and by dual probes in patients with cancer. 2014 , 25, 832-40	9
969	Maximum standardized uptake value on 18F-fluoro-2-deoxy-glucose positron emission tomography/computed tomography and glucose transporter-1 expression correlates with survival in invasive ductal carcinoma of the pancreas. 2014 , 43, 1060-5	31
968	Targeting the epidermal growth factor receptor in solid tumors: focus on safety. 2014 , 13, 535-49	22
967	Clinical characteristics of long-term survivors of inoperable pancreatic cancer: an 8-year cohort analysis in Korea. 2014 , 43, 1022-31	8
966	A phase I clinical trial of vaccination with KIF20A-derived peptide in combination with gemcitabine for patients with advanced pancreatic cancer. 2014 , 37, 36-42	50
965	Taxanes: impact on pancreatic cancer. 2014 , 25, 584-92	15
964	Wilms tumor gene (WT1) peptide-based cancer vaccine combined with gemcitabine for patients with advanced pancreatic cancer. 2014 , 37, 105-14	69
963	The RON receptor tyrosine kinase in pancreatic cancer pathogenesis and its potential implications for future targeted therapies. 2014 , 43, 183-9	19
962	Expression of Akt kinase-interacting protein 1, a scaffold protein of the PI3K/PDK1/Akt pathway, in pancreatic cancer. 2014 , 43, 1093-100	9
961	Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma. 2014 , 20, 4047-58	31
960	Treatment of experimental pancreatic cancer with 213-Bismuth-labeled chimeric antibody to single-strand DNA. 2014 , 14, 1243-9	12
959	Erlotinib. 2014 , 201, 109-23	10

958	Autophagy and cell death to target cancer cells: exploiting synthetic lethality as cancer therapies. 2014 , 772, 167-88	35
957	Oncolytic viral therapy for pancreatic cancer: current research and future directions. 2014 , 3, 35-46	8
956	Pancreatic adenocarcinoma: treating a systemic disease with systemic therapy. 2014 , 106, dju011	99
955	Comparative outcomes between initially unresectable and recurrent cases of advanced pancreatic cancer following palliative chemotherapy. 2014 , 43, 411-6	14
954	KRAS mutations in codon 12 or 13 are associated with worse prognosis in pancreatic ductal adenocarcinoma. 2014 , 43, 578-83	31
953	Clinical characteristics of adenosquamous carcinoma of the pancreas: a matched case-control study. 2014 , 43, 287-90	37
952	The roles of interferon regulatory factors 1 and 2 in the progression of human pancreatic cancer. 2014 , 43, 909-16	27
951	Antitumor effect of angiotensin II type 1 receptor blocker losartan for orthotopic rat pancreatic adenocarcinoma. 2014 , 43, 886-90	19
950	Epidermal growth factor inhibition, a novel pathway to prevent chronic allograft injury. 2014 , 98, 821-7	11
949	Pancreatic cancer, treatment options, and GI-4000. 2014 , 10, 3347-53	11
948	Epigenetic targeting in pancreatic cancer. 2014 , 40, 656-64	31
947	The enone motif of (+)-grandifloracin is not essential for 'anti-austerity' antiproliferative activity. 2014 , 24, 2815-9	11
946	The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study. 2014 , 50, 1422-9	25
945	Polychemotherapy or gemcitabine in advanced pancreatic cancer: a meta-analysis. 2014 , 46, 452-9	15
944	Safety and efficacy of addition of VEGFR and EGFR-family oral small-molecule tyrosine kinase inhibitors to cytotoxic chemotherapy in solid cancers: a systematic review and meta-analysis of randomized controlled trials. 2014 , 40, 636-47	31
943	Rechallenge with imatinib in GIST: is more always RIGHT?. 2014 , 15, e2-3	5
942	Neoadjuvant therapy in pancreatic cancer [Finding its feet?]. 2014 , 4, 49-50	
941	Neoadjuvant therapy in pancreatic cancer. 2014 , 4, 56-61	2

940	Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II study. 2014 , 46, 182-6	34
939	A spectroscopic study on the interaction between the anticancer drug erlotinib and human serum albumin. 2014 , 78, 405-413	12
938	Interplay between autophagy and apoptosis in pancreatic tumors in response to gemcitabine. 2014 , 9, 123-34	30
937	Phase I trials in patients with relapsed, advanced upper gastrointestinal carcinomas: experience in a specialist unit. 2014 , 17, 621-629	6
936	Two immune faces of pancreatic adenocarcinoma: possible implication for immunotherapy. 2014 , 63, 59-65	47
935	Randomized double-blinded, placebo-controlled phase II trial of simvastatin and gemcitabine in advanced pancreatic cancer patients. 2014 , 73, 125-30	82
934	Biological insights into effective and antagonistic combinations of targeted agents with chemotherapy in solid tumors. 2014 , 33, 295-307	3
933	The effect of rifampicin, a prototypical CYP3A4 inducer, on erlotinib pharmacokinetics in healthy subjects. 2014 , 73, 613-21	30
932	Phase I dosage finding and pharmacokinetic study of intravenous topotecan and oral erlotinib in adults with refractory solid tumors. 2014 , 73, 561-8	9
931	Combination treatment of human pancreatic cancer xenograft models with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib and oncolytic herpes simplex virus HF10. 2014 , 21, 691-8	17
930	Perifosine inhibits S6K1-Gli1 signaling and enhances gemcitabine-induced anti-pancreatic cancer efficiency. 2014 , 73, 711-9	24
929	[Multimodal treatment of pancreatic cancer]. 2014 , 55, 31-6	1
928	Cyclooxygenase 2 promoted the tumorigenicity of pancreatic cancer cells. 2014 , 35, 2271-8	14
927	Efficacy of nimotuzumab plus gemcitabine usage as first-line treatment in patients with advanced pancreatic cancer. 2014 , 35, 2313-8	24
926	Therapeutic potential of histone deacetylase inhibitors in pancreatic cancer. 2014 , 347, 183-90	38
925	Claudin 18.2 is a target for IMAB362 antibody in pancreatic neoplasms. 2014 , 134, 731-9	31
924	Targeting cancer stem cells by curcumin and clinical applications. 2014 , 346, 197-205	136
923	ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. 2014 , 25, 282-303	631

922	Critical analysis of 3-D organoid in vitro cell culture models for high-throughput drug candidate toxicity assessments. 2014 , 69-70, 1-18	139
921	Standing the test of time: targeting thymidylate biosynthesis in cancer therapy. 2014 , 11, 282-98	236
920	Notch pathway activation is associated with pancreatic cancer treatment failure. 2014 , 14, 48-53	27
919	ABC transporters in multi-drug resistance and ADME-Tox of small molecule tyrosine kinase inhibitors. 2014 , 31, 2237-55	36
918	Phase I/II study of verteporfin photodynamic therapy in locally advanced pancreatic cancer. 2014 , 110, 1698-704	230
917	Antitumor Activities of Rauwolfia vomitoria Extract and Potentiation of Gemcitabine Effects Against Pancreatic Cancer. 2014 , 13, 217-25	19
916	Adjuvant therapy for resectable pancreatic adenocarcinoma: review of the current treatment approaches and future directions. 2014 , 40, 78-85	25
915	The ErbB/HER family of protein-tyrosine kinases and cancer. 2014 , 79, 34-74	750
914	Sequential gemcitabine and platinum versus first-line combination of gemcitabine and platinum for advanced pancreatic cancer treatment: a retrospective study. 2014 , 19, 634-42	2
913	Randomized controlled study of gemcitabine plus S-1 combination chemotherapy versus gemcitabine for unresectable pancreatic cancer. 2014 , 73, 389-96	37
912	Tumor microenvironment and cellular stress: signaling, metabolism, imaging, and therapeutic targets. Preface. 2014 , 772, v-viii	22
911	Multimodal Therapies for Pancreatic Cancer. 2014 , 39-73	
910	Pancreaticoduodenectomy combined with hepatic artery resection following preoperative hepatic arterial embolization. 2014 , 21, 850-5	21
909	A phase I/II trial of Erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failure. 2014 , 38, 1430-4	13
908	A PAUF-neutralizing antibody targets both carcinoma and endothelial cells to impede pancreatic tumor progression and metastasis. 2014 , 454, 144-50	8
907	FOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma: the Royal Marsden experience. 2014 , 13, 232-8	55
906	Association between baseline pulmonary status and interstitial lung disease in patients with non-small-cell lung cancer treated with erlotinib--a cohort study. 2014 , 15, 448-54	13
905	Challenges and future directions in therapeutics for pancreatic ductal adenocarcinoma. 2014 , 23, 1499-515	14

904	Metabolomics in cell culture--a strategy to study crucial metabolic pathways in cancer development and the response to treatment. 2014 , 564, 100-9		55
903	Specificity delivers: therapeutic role of tumor antigen-specific antibodies in pancreatic cancer. 2014 , 41, 559-75		3
902	Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727). 2014 , 120, 2980-5		71
901	Response to nab-paclitaxel plus gemcitabine in a patient with primary resistance to FOLFIRINOX. 2014 , 45 Suppl 1, 278-81		1
900	Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1620-9	2.2	45
899	1-Acetyl-3,5-diaryl-4,5-dihydro(1H)pyrazoles: exhibiting anticancer activity through intracellular ROS scavenging and the mitochondria-dependent death pathway. 2014 , 347, 717-27		18
898	Risk of incremental toxicities and associated costs of new anticancer drugs: a meta-analysis. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3634-42	2.2	52
897	βMangostin: a dietary antioxidant derived from the pericarp of <i>Garcinia mangostana</i> L. inhibits pancreatic tumor growth in xenograft mouse model. 2014 , 21, 682-99		53
896	Small-molecule EGFR tyrosine kinase inhibitors for the treatment of cancer. 2014 , 23, 1333-48		41
895	Synthesis and biological evaluation of isoprenylated coumarins as potential anti-pancreatic cancer agents. 2014 , 24, 4654-4658		27
894	Structure and function of human DnaJ homologue subfamily a member 1 (DNAJA1) and its relationship to pancreatic cancer. 2014 , 53, 1360-72		35
893	Chronic pancreatitis and systemic inflammatory response syndrome prevent impact of chemotherapy with gemcitabine in a genetically engineered mouse model of pancreatic cancer. 2014 , 16, 463-70		13
892	Screening for pancreatic cancer. 2014 , 48, 115-36		17
891	Co-treatment with panitumumab and trastuzumab augments response to the MEK inhibitor trametinib in a patient-derived xenograft model of pancreatic cancer. 2014 , 16, 562-71		25
890	Lentiviral vector-based insertional mutagenesis identifies genes involved in the resistance to targeted anticancer therapies. 2014 , 22, 2056-2068		14
889	Immune-based therapies in pancreatic and colorectal cancers and biomarkers of responsiveness. 2014 , 14, 1219-28		1
888	Oncogenic KRAS signalling in pancreatic cancer. 2014 , 111, 817-22		351
887	FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study. 2014 , 14, 441		24

886	Chemotherapy regimens for advanced pancreatic cancer: a systematic review and network meta-analysis. 2014 , 14, 471	84
885	pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104. 2014 , 14, 624	24
884	Adoptive immunotherapy with MUC1-mRNA transfected dendritic cells and cytotoxic lymphocytes plus gemcitabine for unresectable pancreatic cancer. 2014 , 12, 175	42
883	Pancreatic adenocarcinoma. 2014 , 371, 1039-49	1394
882	ALK expression is absent in pancreatic ductal adenocarcinoma. 2014 , 140, 1625-8	2
881	Pilot study of a novel combination of two therapeutic vaccines in advanced non-small-cell lung cancer patients. 2014 , 63, 737-47	7
880	Phase II clinical trial of ex vivo-expanded cytokine-induced killer cells therapy in advanced pancreatic cancer. 2014 , 63, 939-46	57
879	A phase I and pharmacokinetic study of capecitabine in combination with radiotherapy in patients with localised inoperable pancreatic cancer. 2014 , 74, 131-9	
878	Phase I dose escalation study of capecitabine and erlotinib concurrent with radiation in locally advanced pancreatic cancer. 2014 , 74, 205-10	9
877	Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001). 2014 , 74, 379-87	45
876	Frontline treatment with gemcitabine, oxaliplatin and erlotinib for the treatment of advanced or metastatic pancreatic cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG). 2014 , 74, 333-40	11
875	Analysis of dysregulation of immune system in pancreatic cancer based on gene expression profile. 2014 , 41, 4361-7	5
874	Intratumoral Mistletoe (<i>Viscum album</i> L) Therapy in Patients With Unresectable Pancreas Carcinoma: A Retrospective Analysis. 2014 , 13, 332-40	19
873	Targeting inhibitors of the tumor suppressor PP2A for the treatment of pancreatic cancer. 2014 , 12, 924-39	75
872	Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2423-9	2.2 313
871	Comparison of gemcitabine combined with targeted agent therapy versus gemcitabine monotherapy in the management of advanced pancreatic cancer. 2014 , 36, 1054-63	9
870	Management options in locally advanced pancreatic cancer. 2014 , 16, 388	27
869	TTD consensus document on the diagnosis and management of exocrine pancreatic cancer. 2014 , 16, 865-78	5

868	Case report of nab-paclitaxel in metastatic pancreatic cancer. 2014 , 7, 39-42	1
867	Bufalin exerts antitumor effects by inducing cell cycle arrest and triggering apoptosis in pancreatic cancer cells. 2014 , 35, 2461-71	38
866	Intensified chemotherapy and simultaneous treatment with heparin in outpatients with pancreatic cancer - the CONKO 004 pilot trial. 2014 , 14, 204	12
865	Homozygous deletion of the activin A receptor, type IB gene is associated with an aggressive cancer phenotype in pancreatic cancer. 2014 , 13, 126	21
864	Peptide-functionalized nanoparticles for selective targeting of pancreatic tumor. 2014 , 192, 29-39	35
863	Pancreatic cancer genomics. 2014 , 24, 74-81	40
862	Ophthalmic complications of targeted cancer therapy and recently recognized ophthalmic complications of traditional chemotherapy. 2014 , 59, 493-502	20
861	Gemcitabine-treated pancreatic cancer cell medium induces the specific CTL antitumor activity by stimulating the maturation of dendritic cells. 2014 , 19, 10-6	12
860	Chronic stress accelerates pancreatic cancer growth and invasion: a critical role for beta-adrenergic signaling in the pancreatic microenvironment. 2014 , 40, 40-7	142
859	[Management of the cardiovascular complications of treatment in thoracic oncology]. 2014 , 31, 173-80	
858	Ring-enhancement pattern on contrast-enhanced CT predicts adenosquamous carcinoma of the pancreas: a matched case-control study. 2014 , 14, 221-6	17
857	Chemotherapy for advanced pancreatic adenocarcinoma in elderly patients (≥ 70 years of age): a retrospective cohort study at the National Center for Tumor Diseases Heidelberg. 2014 , 14, 211-5	23
856	Tumour-stroma interactions in pancreatic ductal adenocarcinoma: rationale and current evidence for new therapeutic strategies. 2014 , 40, 118-28	96
855	Is arterial infiltration still a criterion for unresectability in pancreatic adenocarcinoma?. 2014 , 92, 305-15	4
854	Selection of pancreatic cancer cell-binding landscape phages and their use in development of anticancer nanomedicines. 2014 , 27, 235-43	17
853	Prediction of the likelihood of drug interactions with kinase inhibitors based on in vitro and computational studies. 2014 , 28, 551-82	15
852	Intra-articular metastatic pancreatic carcinoma of the right knee mimicking septic arthritis. 2014 , 13, 131-3	2
851	Adrenocortical carcinoma: the management of metastatic disease. 2014 , 92, 123-32	36

850	A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. 2014 , 50, 2072-81	203
849	Is Arterial Infiltration Still a Criterion for Unresectability in Pancreatic Adenocarcinoma?. 2014 , 92, 305-315	
848	A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancer. 2014 , 50, 1909-15	23
847	Methylation-mediated silencing of the miR-124 genes facilitates pancreatic cancer progression and metastasis by targeting Rac1. 2014 , 33, 514-24	177
846	Molecular-targeted agents combination therapy for cancer: developments and potentials. 2014 , 134, 1257-69	93
845	Epidermal growth factor receptor inhibitors: coming of age. 2014 , 21, 74-9	51
844	Nab-paclitaxel for metastatic pancreatic cancer: clinical outcomes and potential mechanisms of action. 2014 , 37, 128-34	22
843	HS-104, a PI3K inhibitor, enhances the anticancer efficacy of gemcitabine in pancreatic cancer. 2014 , 45, 311-21	7
842	Female gender may predict response to FOLFIRINOX in patients with unresectable pancreatic cancer: a single institution retrospective review. 2014 , 44, 319-26	27
841	Cancer of the liver, biliary tract and pancreas. 2014 , 290-307	
840	Phase I trial of MES, a novel polyethylene glycosylated recombinant human endostatin, plus gemcitabine in advanced pancreatic cancer. 2014 , 2, 586-590	3
839	Personalization of chemotherapy for metastatic pancreatic cancer. 2014 , 7, 59-61	1
838	Carcinoma of unknown primary site treated with Carboplatin + Paclitaxel + bevacizumab + erlotinib and its maintenance chemotherapy. 2014 , 7, 583-90	3
837	Mass spectrometry-based metabolic profiling of gemcitabine-sensitive and gemcitabine-resistant pancreatic cancer cells. 2014 , 43, 311-8	17
836	The basic helix-loop-helix transcription factor E47 reprograms human pancreatic cancer cells to a quiescent acinar state with reduced tumorigenic potential. 2015 , 44, 718-27	29
835	[Current standards in the treatment of pancreatic cancer]. 2015 , 140, 1813-6	1
834	Pancreatic cancer and FOLFIRINOX: a new era and new questions. 2015 , 4, 853-63	30
833	Therapeutic potential of targeting protein for Xklp2 silencing for pancreatic cancer. 2015 , 4, 1091-100	8

832	Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study. 2015 , 106, 883-90	59
831	Adenocarcinoma of the Pancreas. 2015 , 1761-1781	
830	Establishment of human pancreatic cancer gemcitabine-resistant cell line with ribonucleotide reductase overexpression. 2015 , 33, 383-90	17
829	New Advances in the Treatment of Metastatic Pancreatic Cancer. 2015 , 92, 175-84	15
828	Treatment of Advanced Pancreatic Cancer. 2015 , 451-470	
827	Efficacy of Prophylactic G-CSF in Patients Receiving FOLFIRINOX: A Preliminary Retrospective Study. 2015 , 54, 2969-73	9
826	[Pancreatic cancer. Evidence based management guidelines of the Hungarian Pancreatic Study Group]. 2015 , 156, 326-39	8
825	Pancreatic Cancer: Progress in Systemic Therapy. 2014 , 1, 167-79	7
824	More than a Decade of Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: What We Have Learned and What the Future Holds. 2015 , 10, 33-40	7
823	Measuring body composition using the bioelectrical impedance method can predict the outcomes of gemcitabine-based chemotherapy in patients with pancreatobiliary tract cancer. 2015 , 10, 3535-3541	4
822	Chinesische Medizin in der Onkologie. 2015 , 30, 171-182	
821	Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies. 2015 , e52801	12
820	Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancer. 2015 , 76, 1309-14	34
819	Chemotherapy-induced neutropenia as a prognostic factor in patients with unresectable pancreatic cancer. 2015 , 76, 1217-24	12
818	[Metastasis of pancreatic tumors]. 2015 , 36 Suppl 2, 176-80	
817	Nur in seltenen Fällen besteht die Chance auf Heilung. 2015 , 18, 45-54	
816	Therapie des metastasierten Pankreaskarzinoms. 2015 , 21, 1044-1053	
815	Therapie des Pankreaskarzinoms. 2015 , 10, 50-59	

814	Evaluation of low-dose fractionated radiation therapy as a chemopotentiator of gemcitabine in advanced pancreatic cancer: results from an international multi-institutional phase II trial. 2015 , 4, 401-409	
813	The inflammatory milieu within the pancreatic cancer microenvironment correlates with clinicopathologic parameters, chemoresistance and survival. 2015 , 15, 783	33
812	Phase II trial of selective internal radiation therapy and systemic chemotherapy for liver-predominant metastases from pancreatic adenocarcinoma. 2015 , 15, 802	13
811	A clinical role of staging laparoscopy in patients with radiographically defined locally advanced pancreatic ductal adenocarcinoma. 2016 , 14, 14	27
810	EGFR is not a major driver for osteosarcoma cell growth in vitro but contributes to starvation and chemotherapy resistance. 2015 , 34, 134	40
809	HER family receptor expression and prognosis in pancreatic cancer. 2015 , 30, e327-32	8
808	Erlotinib-associated interstitial lung disease in advanced pancreatic carcinoma: a case report and literature review. 2015 , 101, e122-7	4
807	Impact of Smoking on Pancreatic Cancer Patients Receiving Current Chemotherapy. 2015 , 44, 1155-60	4
806	Prognostic value of altered N-glycosylation of circulating glycoproteins in patients with unresectable pancreatic cancer treated with gemcitabine. 2015 , 44, 551-6	6
805	Primary and liver metastasis-derived cell lines from KrasG12D; Trp53R172H; Pdx-1 Cre animals undergo apoptosis in response to triptolide. 2015 , 44, 583-9	13
804	Gemcitabine Compared With Gemcitabine and S-1 Combination Therapy in Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis. 2015 , 94, e1345	7
803	Genetic alterations in glioblastoma multiforme. 323-344	
802	Cancer care burden: aiming at the Achilles heel. 2015 , 22, e134-8	3
801	Emerging therapies for pancreatic ductal carcinoma. 2015 , 6,	1
800	The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenib. 2015 , 6, 35087-94	36
799	[Recent Advances in Palliative Chemotherapy for Unresectable Pancreatic Cancer]. 2015 , 66, 150-3	3
798	Higher overall survival in metastatic pancreatic cancer: the impact of where and how treatment is delivered. 2015 , 13, 347-51	8
797	Inactivation of Rab23 inhibits the invasion and motility of pancreatic duct adenocarcinoma. 2015 , 14, 2707-15	12

796	Eastern Canadian Gastrointestinal Cancer Consensus Conference 2014. 2015 , 22, e305-15	
795	Hepatotoxicity of molecular targeted therapy. 2015 , 19, 87-92	13
794	Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies. 2015 , 9, 3529-45	101
793	GEM-loaded magnetic albumin nanospheres modified with cetuximab for simultaneous targeting, magnetic resonance imaging, and double-targeted thermochemotherapy of pancreatic cancer cells. 2015 , 10, 2507-19	30
792	Albumin-bound paclitaxel in solid tumors: clinical development and future directions. 2015 , 9, 3767-77	132
791	Coexpression of EGFR and CXCR4 predicts poor prognosis in resected pancreatic ductal adenocarcinoma. 2015 , 10, e0116803	13
790	A phase I dose-escalation study of lenalidomide in combination with gemcitabine in patients with advanced pancreatic cancer. 2015 , 10, e0121197	8
789	A multistep high-content screening approach to identify novel functionally relevant target genes in pancreatic cancer. 2015 , 10, e0122946	11
788	Nursing Implications of Chemotherapy Agents and Their Associated Side Effects in Patients With Pancreatic Cancer. 2015 , 19, 751-7	1
787	The Emerging Genetic Basis and Its Clinical Implication in Pancreatic Cancer. 2015 , 2, 131-143	
786	Histone deacetylase inhibitors merged with protein tyrosine kinase inhibitors. 2015 , 9, 147-55	6
785	Prolonged Complete Response in a Patient with Metastatic Pancreatic Adenocarcinoma after FOLFIRINOX Chemotherapy and Maintenance with FOLFIRI. 2015 , 2015, 659624	3
784	Prognosis Relevance of Serum Cytokines in Pancreatic Cancer. 2015 , 2015, 518284	12
783	Making sense of current and emerging therapies in pancreatic cancer: balancing benefit and value. 2015 , e222-7	1
782	Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial. 2015 , 6, 18162-73	69
781	Current status and progress of pancreatic cancer in China. 2015 , 21, 7988-8003	172
780	Pancreatic cancer vaccine: a unique potential therapy. 2015 , 1	
779	Current Concepts in Pancreatic Cancer. 2015 ,	

778	Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer. 2015 , 16, 438-49	39
777	Stromal biology and therapy in pancreatic cancer: a changing paradigm. 2015 , 64, 1476-84	345
776	Pancreatic cancer stromal biology and therapy. 2015 , 2, 133-143	85
775	Novel approaches in the management of pancreatic ductal adenocarcinoma: potential promises for the future. 2015 , 8, 44	28
774	RasGRP1 opposes proliferative EGFR-SOS1-Ras signals and restricts intestinal epithelial cell growth. 2015 , 17, 804-15	39
773	The Quest for an Effective Treatment for an Intractable Cancer: Established and Novel Therapies for Pancreatic Adenocarcinoma. 2015 , 127, 283-306	3
772	Optimal indication of neoadjuvant chemoradiotherapy for pancreatic cancer. 2015 , 400, 477-85	21
771	Pharmacodynamic separation of gemcitabine and erlotinib in locally advanced or metastatic pancreatic cancer: therapeutic and biomarker results. 2015 , 20, 518-24	20
770	Systemic therapy for advanced pancreatic cancer: individualising cytotoxic therapy. 2015 , 16, 851-61	7
769	Patient-derived xenograft models for pancreatic adenocarcinoma demonstrate retention of tumor morphology through incorporation of murine stromal elements. 2015 , 185, 1297-303	75
768	Nanoparticle albumin-bound (nab)-paclitaxel for the treatment of pancreas ductal adenocarcinoma. 2015 , 11	4
767	Multidisciplinary neoadjuvant management for potentially curable pancreatic cancer. 2015 , 4, 1224-39	12
766	microRNA: Cancer. 2015 ,	1
765	Vaccinia virus, a promising new therapeutic agent for pancreatic cancer. 2015 , 7, 1249-58	34
764	Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors. 2015 , 76, 1025-32	43
763	Initial Metastatic Site as a Prognostic Factor in Patients With Stage IV Pancreatic Ductal Adenocarcinoma. 2015 , 94, e1012	17
762	Pancreatic Cancer. 2015 , 343-392	
761	Standards de chimiothérapie, perspectives et thérapies ciblées dans l'adénocarcinome du pancréas. 2015 , 17, 519-527	

760	Insights into the Role of microRNAs in Pancreatic Cancer Pathogenesis: Potential for Diagnosis, Prognosis, and Therapy. 2015 , 889, 71-87	36
759	Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract Cancer. 2015 , 8, 40-6	14
758	CT-guided high-dose-rate brachytherapy in the interdisciplinary treatment of patients with liver metastases of pancreatic cancer. 2015 , 14, 530-8	17
757	N,N'-di-(m-methylphenyl)-3,6-dimethyl-1,4-dihydro-1,2,4,5-tetrazine-1,4-dicarboamide (ZGDHu-1) suppresses the proliferation of PANC-1 pancreatic cancer cells via apoptosis and G2/M cell cycle arrest. 2015 , 33, 1915-21	3
756	Le point sur hENT1, autres biomarqueurs. 2015 , 17, 528-534	
755	Outcomes and endpoints in trials of cancer treatment: the past, present, and future. 2015 , 16, e32-42	111
754	Low expression of the E3 ubiquitin ligase CBL confers chemoresistance in human pancreatic cancer and is targeted by epidermal growth factor receptor inhibition. 2015 , 21, 157-65	20
753	Chemotherapy use and survival in older adults with metastatic pancreatic cancer in the combination therapy era. 2020 , 11, 640-646	3
752	Glycofullerenes as non-receptor tyrosine kinase inhibitors- towards better nanotherapeutics for pancreatic cancer treatment. 2020 , 10, 260	13
751	HB-EGF-EGFR Signaling in Bone Marrow Endothelial Cells Mediates Angiogenesis Associated with Multiple Myeloma. 2020 , 12,	13
750	Sitravatinib Sensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs. 2020 , 12,	12
749	The past, present, and future status of multimodality treatment for resectable/borderline resectable pancreatic ductal adenocarcinoma. 2020 , 50, 335-343	1
748	In silico analysis of the prognostic value of FAS mRNA in malignancies. 2020 , 11, 542-550	1
747	Theranostic nanoparticles enabling the release of phosphorylated gemcitabine for advanced pancreatic cancer therapy. 2020 , 8, 2410-2417	4
746	Crosstalk between Epidermal Growth Factor Receptors (EGFR) and integrins in resistance to EGFR tyrosine kinase inhibitors (TKIs) in solid tumors. 2020 , 99, 151083	12
745	Cardiovascular Complications of Systemic Therapy in Non-Small-Cell Lung Cancer. 2020 , 9,	12
744	Adjuvant chemotherapy in biliary tract cancer patients: A systematic review and meta-analysis of randomized controlled trials. 2020 , 149, 102940	3
743	Role of Dimerized C16orf74 in Aggressive Pancreatic Cancer: A Novel Therapeutic Target. 2020 , 19, 187-198	3

742	Unraveling ERBB network dynamics upon betacellulin signaling in pancreatic ductal adenocarcinoma in mice. 2020 , 14, 1653-1669	1
741	Impact of circulating tumor DNA in hepatocellular and pancreatic carcinomas. 2020 , 146, 1625-1645	5
740	NDRG1 suppresses basal and hypoxia-induced autophagy at both the initiation and degradation stages and sensitizes pancreatic cancer cells to lysosomal membrane permeabilization. 2020 , 1864, 129625	4
739	Oncolytic Virus-Mediated Targeting of the ERK Signaling Pathway Inhibits Invasive Propensity in Human Pancreatic Cancer. 2020 , 17, 107-117	11
738	Choice of first line systemic treatment in pancreatic cancer among national experts. 2020 , 20, 686-690	4
737	A 15-Gene Immune, Stromal, and Proliferation Gene Signature that Significantly Associates with Poor Survival in Patients with Pancreatic Ductal Adenocarcinoma. 2020 , 26, 3641-3648	23
736	Antireflux metal stent for biliary obstruction: Any benefits?. 2021 , 33, 310-320	8
735	Molecular Targets in Cholangiocarcinoma. 2021 , 73 Suppl 1, 62-74	14
734	Autophagy in the physiological endometrium and cancer. 2021 , 17, 1077-1095	36
733	Therapeutic resistance of pancreatic cancer: Roadmap to its reversal. 2021 , 1875, 188461	19
732	Epigenetic and Transcriptional Control of the Epidermal Growth Factor Receptor Regulates the Tumor Immune Microenvironment in Pancreatic Cancer. 2021 , 11, 736-753	17
731	Metformin inhibits pancreatic cancer metastasis caused by SMAD4 deficiency and consequent HNF4G upregulation. 2021 , 12, 128-144	19
730	Phase II study evaluating the association of gemcitabine, trastuzumab and erlotinib as first-line treatment in patients with metastatic pancreatic adenocarcinoma (GATE 1). 2021 , 148, 682-691	5
729	Causal survival analysis: A guide to estimating intention-to-treat and per-protocol effects from randomized clinical trials with non-adherence. 2021 , 2, 39-49	1
728	Risk factors for gemcitabine plus nab-paclitaxel-induced interstitial lung disease in pancreatic cancer patients. 2021 , 26, 543-551	4
727	Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study. 2021 , 147, 1529-1536	1
726	Implementing biological markers as a tool to guide clinical care of patients with pancreatic cancer. 2021 , 14, 100965	5
725	Net benefit in the presence of correlated prioritized outcomes using generalized pairwise comparisons: A simulation study. 2021 , 40, 553-565	3

724	Glycosyltransferase ST6Gal-I promotes the epithelial to mesenchymal transition in pancreatic cancer cells. 2021 , 296, 100034	14
723	Discordant reporting of VTE in pancreatic cancer: A systematic review and meta-analysis of thromboprophylaxis versus chemotherapeutic trials. 2021 , 19, 489-501	7
722	Design, synthesis, and biological evaluation of 2,6,7-substituted pyrrolo[2,3-d]pyrimidines as cyclin dependent kinase inhibitor in pancreatic cancer cells. 2021 , 33, 127725	1
721	DIAPH3 promotes pancreatic cancer progression by activating selenoprotein TrxR1-mediated antioxidant effects. 2021 , 25, 2163-2175	7
720	A retrospective comparative study of S-IROX and modified FOLFIRINOX for patients with advanced pancreatic cancer refractory to gemcitabine plus nab-paclitaxel. 2021 , 39, 605-613	2
719	Effect of adoptive T-cell immunotherapy on immunological parameters and prognosis in patients with advanced pancreatic cancer. 2021 , 23, 137-145	4
718	An evaluation of olaparib for the treatment of pancreatic cancer. 2021 , 22, 521-526	1
717	Essential updates 2018/2019: Current topics in the surgical treatment of pancreatic ductal adenocarcinoma. 2021 , 5, 7-23	11
716	Pancreatic cancer drug-sensitivity predicted by synergy of p53-Activator Wnt Inhibitor-2 (PAWI-2) and protein biomarker expression. 2021 , 39, 131-141	0
715	DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives. 2021 , 70, 606-617	49
714	Systemic therapy in metastatic pancreatic adenocarcinoma: current practice and perspectives. 2021 , 13, 17588359211018539	2
713	Dysfunctional EGFR and oxidative stress-induced PKD1 signaling drive formation of DCLK1+ pancreatic stem cells. 2021 , 24, 102019	2
712	Arterial infusion and arterial chemoembolization for pancreatic cancer. 2021 , 319-328	
711	Molecular-targeted therapy of pancreatic carcinoma and its progress. 2021 , 487-503	
710	Can Patients with Pancreatic Cancer and Liver Metastases Obtain Survival Benefit from Surgery? A Population-Based Study. 2021 , 12, 539-552	2
709	Anti-tumoral activity of the Pan-HER (Sym013) antibody mixture in gemcitabine-resistant pancreatic cancer models. 2021 , 13, 1914883	0
708	Suppressing LncRNA HOXA-AS3 by CRISPR-dCas9 inhibits pancreatic cancer development. 2021 , 12, 6439-6444	0
707	Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRAS-mutant pancreatic ductal adenocarcinoma. 2021 , 39, 821-828	8

706	Molecular aspects of pancreatic cancer: focus on reprogrammed metabolism in a nutrient-deficient environment and potential therapeutic targets. 2021 , 46, 258-263	0
705	Incidence of bone metastases in patients with organ-specific cancers: A nationwide population-based cohort study. 2021 , 75, e13997	1
704	Internal medicine treatment of pancreatic lesions. 2021 , 141-180	
703	Overcoming Therapeutic Challenges for Pancreatic Ductal Adenocarcinoma with xCT Inhibitors. 2021 , 1301, 7-24	
702	CC Chemokine Receptor 2-Targeting Copper Nanoparticles for Positron Emission Tomography-Guided Delivery of Gemcitabine for Pancreatic Ductal Adenocarcinoma. 2021 , 15, 1186-1198	12
701	Treatment Approach for Pancreatic Cancer with Peritoneal Dissemination. 2021 , 195-205	
700	Advances in Targeted Therapy and Immunotherapy for Pancreatic Cancer. 2021 , 5, e1900236	2
699	Two decades of research toward the treatment of locally advanced and metastatic pancreatic cancer: Remarkable effort and limited gain. 2021 , 48, 34-46	3
698	Adjuvant therapy for patients with resectable pancreatic ductal adenocarcinoma. 2021 , 36, 12-19	
697	Pancreatic ductal adenocarcinoma in the era of precision medicine. 2021 , 48, 19-33	4
696	KRAS mutation in pancreatic cancer. 2021 , 48, 10-18	10
695	LAMC2 promotes cancer progression and gemcitabine resistance through modulation of EMT and ATP-binding cassette transporters in pancreatic ductal adenocarcinoma. 2021 , 42, 546-556	8
694	Aptamer-SH2 superbinder-based targeted therapy for pancreatic ductal adenocarcinoma. 2021 , 11, e337	1
693	[Diagnostics and therapy of pancreatic carcinoma]. 2021 , 146, 246-252	
692	The Effect of the EGFR - Targeting Compound 3-[(4-Phenylpyrimidin-2-yl) Amino] Benzene-1-Sulfonamide (13f) against Cholangiocarcinoma Cell Lines. 2021 , 22, 381-390	1
691	Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications. 2021 , 42, 1725-1741	6
690	Future directions in drug development in pancreatic cancer. 2021 , 48, 47-56	3
689	Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of the Arbeitsgemeinschaft Internistische Onkologie 'with an integrated analysis of the 'burden of therapy' method. 2021 , 146, 95-106	5

688	Robust Design and Analysis of Clinical Trials With Nonproportional Hazards: A Straw Man Guidance From a Cross-Pharma Working Group. 1-15	10
687	Metastatic Acinar Cell Carcinoma of the Pancreas: A Retrospective Cohort Study on Systemic Chemotherapy and Review of the Literature. 2021 , 50, 300-305	1
686	Phase II Study of Adjuvant Chemotherapy With Gemcitabine and Nafamostat Mesilate for Pancreatic Cancer. 2021 , 50, 313-316	1
685	Invadopodia: A potential target for pancreatic cancer therapy. 2021 , 159, 103236	4
684	FDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: Synthesis and clinical application. 2021 , 214, 113218	22
683	Prognostic Value of Peritoneal Lavage Cytology in Patients with Pancreatic Ductal Adenocarcinoma Stratified by the Resectability Status. 2021 , 25, 2871-2880	2
682	Knockdown of the DJ-1 (7) gene sensitizes pancreatic cancer to erlotinib inhibition. 2021 , 20, 364-372	3
681	Overcoming the Tumor Microenvironmental Barriers of Pancreatic Ductal Adenocarcinomas for Achieving Better Treatment Outcomes. 2021 , 4, 2000262	2
680	Chemotherapy for Nonresectable Pancreatic Cancer. 2021 , 530-537	
679	Efficacy and tolerability of the combination of nano-liposomal irinotecan and 5-fluorouracil/leucovorin in advanced pancreatic adenocarcinoma: post-approval clinic experience. 2021 , 12, 464-473	4
678	MiR-338-5p Inhibits EGF-Induced EMT in Pancreatic Cancer Cells by Targeting EGFR/ERK Signaling. 2021 , 11, 616481	2
677	The Latest Advancement in Pancreatic Ductal Adenocarcinoma Therapy: A Review Article for the Latest Guidelines and Novel Therapies. 2021 , 9,	8
676	Skeletal metastases in advanced pancreatic ductal adenocarcinoma: a retrospective analysis. 2021 , 12, 455-463	1
675	A novel gene signature for prognosis prediction and chemotherapy response in patients with pancreatic cancer. 2021 , 13, 12493-12513	1
674	Therapeutic Application of Monoclonal Antibodies in Pancreatic Cancer: Advances, Challenges and Future Opportunities. 2021 , 13,	3
673	3d tissue models as tools for radiotherapy screening for pancreatic cancer. 2021 , 94, 20201397	3
672	Eukaryotic Translation Initiation Factor 3 Subunit B Is a Promoter in the Development and Progression of Pancreatic Cancer. 2021 , 11, 644156	1
671	Cancer Drug Resistance Targets and Therapies. 1-27	

670	Risk Adapted Ablative Radiotherapy After Intensive Chemotherapy for Locally Advanced Pancreatic Cancer. 2021 , 11, 662205	1
669	New Pharmacological Approaches for Pancreatic Cancer Therapy. 2021 , 564-572	
668	A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: Results from the CONKO-005 trial. 2021 , 66, 103327	7
667	Role of stromal activin A in human pancreatic cancer and metastasis in mice. 2021 , 11, 7986	4
666	A Critical Overview of Systematic Reviews of Chemotherapy for Advanced and Locally Advanced Pancreatic Cancer using both AMSTAR2 and ROBIS as Quality Assessment Tools. 2021 , 16, 180-192	3
665	Pancreatic adenocarcinoma: Beyond first line, where are we?. 2021 , 27, 1847-1863	4
664	Treatment landscape of metastatic pancreatic cancer. 2021 , 96, 102180	18
663	Association between miRNA signatures in serum samples from epidermal growth factor inhibitor treated patients and skin toxicity. 2021 , 12, 982-995	
662	KRAS, A Prime Mediator in Pancreatic Lipid Synthesis through Extra Mitochondrial Glutamine and Citrate Metabolism. 2021 , 22,	1
661	Case Report: Combined Intra-Lesional IL-2 and Topical Imiquimod Safely and Effectively Clears Multi-Focal, High Grade Cutaneous Squamous Cell Cancer in a Combined Liver and Kidney Transplant Patient. 2021 , 12, 678028	1
660	Clinical Effects of Stereotactic Body Radiation Therapy Targeting the Primary Tumor of Liver-Only Oligometastatic Pancreatic Cancer. 2021 , 11, 659987	1
659	Microbial cancer therapeutics: A promising approach. 2021 ,	3
658	Systemische Therapie des duktaalen Pankreaskarzinoms. 2021 , 24, 37-47	
657	The case for a stratified application of targeted agents against pancreatic cancer. 2021 , 67, 103344	1
656	Combining Gemcitabine-Loaded Macrophage-like Nanoparticles and Erlotinib for Pancreatic Cancer Therapy. 2021 , 18, 2495-2506	5
655	Pancreatic Ductal Adenocarcinoma: The Dawn of the Era of Nuclear Medicine?. 2021 , 22,	4
654	Role of targeted immunotherapy for pancreatic ductal adenocarcinoma (PDAC) treatment: An overview. 2021 , 95, 107508	5
653	Targeting Growth Factor Signaling Pathways in Pancreatic Cancer: Towards Inhibiting Chemoresistance. 2021 , 11, 683788	1

652	Targeting of elevated cell surface phosphatidylserine with saposin C-dioleoylphosphatidylserine nanodrug as individual or combination therapy for pancreatic cancer. 2021 , 13, 550-559	1
651	Cardiovascular Complications Associated with Contemporary Lung Cancer Treatments. 2021 , 22, 71	2
650	A phase I study of the safety and activity of K-001 in patients with advanced pancreatic ductal adenocarcinoma. 2021 , 21, 672	
649	Performance status as prognostic factor in phase III trials of first-line chemotherapy of unresectable or metastatic pancreatic cancer: A trial-level meta-analysis. 2021 ,	1
648	Pharmacoeconomic Evaluation of Erlotinib for the Treatment of Pancreatic Cancer. 2021 , 43, 1107-1115	1
647	Phase II Study of 5-Fluorouracil, Oxaliplatin plus Dasatinib (FOLFOX-D) in First-Line Metastatic Pancreatic Adenocarcinoma. 2021 , 26, 825-e1674	3
646	Applications of Constrained Helices. 2021 , 107-158	
645	Treatment outcomes of erlotinib plus gemcitabine as late-line chemotherapy in unresectable pancreatic cancer. 2021 , 51, 1416-1422	4
644	Current Status of Treatment for Pancreatic Cancer in Japan and Prospects for the Future. 2021 , 17, 98-107	
643	The third-generation EGFR inhibitor almonertinib (HS-10296) resensitizes ABCB1-overexpressing multidrug-resistant cancer cells to chemotherapeutic drugs. 2021 , 188, 114516	4
642	Novel Anticancer and Treatment Sensitizing Compounds against Pancreatic Cancer. 2021 , 13,	2
641	Differently PEGylated Polymer Nanoparticles for Pancreatic Cancer Delivery: Using a Novel Near-Infrared Emissive and Biodegradable Polymer as the Fluorescence Tracer. 2021 , 9, 699610	3
640	Impact of Endoscopic Ultrasound-Guided Tissue Acquisition on Decision-Making in Precision Medicine for Pancreatic Cancer: Beyond Diagnosis. 2021 , 11,	3
639	Targeted agents in older patients with gastrointestinal cancers - An overview. 2021 , 12, 1240-1252	
638	Hacking Pancreatic Cancer: Present and Future of Personalized Medicine. 2021 , 14,	3
637	Emerging Treatment Strategies in Pancreatic Cancer. 2021 , 50, 773-787	0
636	S100A16 induces epithelial-mesenchymal transition in human PDAC cells and is a new therapeutic target for pancreatic cancer treatment that synergizes with gemcitabine. 2021 , 189, 114396	6
635	The Current Treatment Paradigm for Pancreatic Ductal Adenocarcinoma and Barriers to Therapeutic Efficacy. 2021 , 11, 688377	8

634	Emerging strategies to target RAS signaling in human cancer therapy. 2021 , 14, 116	10
633	Application of natural killer cells in pancreatic cancer. 2021 , 22, 647	0
632	3D tumor spheroid microarray for high-throughput, high-content natural killer cell-mediated cytotoxicity. 2021 , 4, 893	6
631	Pancreatic Adenocarcinoma Therapeutics Targeting RTK and TGF Beta Receptor. 2021 , 22,	4
630	First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study. 2021 , 151, 14-24	4
629	Exploring the metabolic landscape of pancreatic ductal adenocarcinoma cells using genome-scale metabolic modeling.	
628	Branerbrutinib (BMS-986195), a Bruton's Tyrosine Kinase Inhibitor, Resensitizes P-Glycoprotein-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Agents. 2021 , 9, 699571	0
627	Roles of voltage-gated potassium channels in the maintenance of pancreatic cancer stem cells. 2021 , 59,	0
626	Biological Treatments of Neurofibromatosis Type 2 and Other Skull Base Disorders. 2021 , 54, 789-801	0
625	Improved prognosis of pancreatic cancer patients with peritoneal metastasis. 2021 , 21, 903-911	4
624	The Second-Generation PIM Kinase Inhibitor TP-3654 Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs. 2021 , 22,	0
623	Adjuvant Treatment in Pancreatic Cancer: Shaping the Future of the Curative Setting. 2021 , 11, 695627	2
622	Tissue factor and its procoagulant activity on cancer-associated thromboembolism in pancreatic cancer. 2021 , 112, 4679-4691	4
621	AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer. 2021 , 21, 936	1
620	An urgent call to raise the bar in oncology. 2021 , 125, 1477-1485	5
619	Anorexia, pain and peripheral neuropathy are associated with a decrease in quality of life in patients with advanced pancreatic cancer receiving outpatient chemotherapy - a retrospective observational study. 2021 , 7, 27	0
618	Unraveling Tumor Heterogeneity by Using DNA Barcoding Technologies to Develop Personalized Treatment Strategies in Advanced-Stage PDAC. 2021 , 13,	1
617	Uncovered versus covered metallic stents for the management of unresectable malignant distal biliary obstruction: a randomized multicenter trial. 2021 , 56, 1229-1235	0

616	Antibody therapy in pancreatic cancer: mAb-ye we're onto something?. 2021 , 1876, 188557	0
615	Para-aortic lymph nodes and ductal adenocarcinoma of the pancreas: Distant neighbors?. 2021 , 170, 1807-1814	1
614	Mechanisms of Cancer Cell Death: Therapeutic Implications for Pancreatic Ductal Adenocarcinoma. 2021 , 13,	2
613	Retrospective Cohort Study of Caveolin-1 Expression as Prognostic Factor in Unresectable Locally Advanced or Metastatic Pancreatic Cancer Patients. 2021 , 28, 3525-3536	
612	Efficacy and Safety of First-Line Chemotherapies for Patients With Advanced Biliary Tract Carcinoma: A Systematic Review and Network Meta-Analysis. 2021 , 11, 736113	1
611	Erlotinib-Induced Cardiomyopathy in a Patient with Metastatic Non-Small Cell Lung Cancer. 2021 , 62, 1171-1175	1
610	SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer. 2021 , 6,	4
609	Prediction and identification of synergistic compound combinations against pancreatic cancer cells. 2021 , 24, 103080	1
608	Real-world evidence on first- and second-line palliative chemotherapy in advanced pancreatic cancer. 2021 , 12, 787-799	5
607	Tumor-Specific Delivery of 5-Fluorouracil-Incorporated Epidermal Growth Factor Receptor-Targeted Aptamers as an Efficient Treatment in Pancreatic Ductal Adenocarcinoma Models. 2021 , 161, 996-1010.e1	3
606	Overexpression of Circular RNA circ_0013587 Reverses Erlotinib Resistance in Pancreatic Cancer Cells Through Regulating the miR-1227/E-Cadherin Pathway. 2021 , 11, 754146	2
605	Future challenges in gastroenterology and hepatology, between innovations and unmet needs: A SIGE Young Editorial Board's perspective. 2021 ,	1
604	LncRNA HIF1A-AS1 Promotes Gemcitabine Resistance of Pancreatic Cancer by Enhancing Glycolysis through Modulating the AKT/YB1/HIF1 β Pathway. 2021 , 81, 5678-5691	6
603	Small extracellular vesicle non-coding RNAs in pancreatic cancer: molecular mechanisms and clinical implications. 2021 , 14, 141	10
602	Evolution of Systemic Therapy in Metastatic Pancreatic Ductal Adenocarcinoma. 2021 , 30, 673-691	
601	Modified FOLFIRINOX versus S-1 as second-line chemotherapy in gemcitabine-failed metastatic pancreatic cancer patients: A randomised controlled trial (MPACA-3). 2021 , 157, 21-30	3
600	Phytochemical based sestrin2 pharmacological modulators in the treatment of adenocarcinomas. 2021 , 1, 100133	
599	Pankreas. 2021 , 621-674	

598	Gemcitabine and Erlotinib with or without Oxaliplatin in Previously Untreated Advanced Pancreatic Cancer: A Randomized Phase II Trial. 2021 , 62, 671-678	1
597	Biomarkers in Pancreatic Cancer. 2021 , 467-487	1
596	Chemotherapy for Advanced Pancreatic Cancer: Available Drugs, Mechanisms and Toxicity. 2021 , 681-696	
595	Exceptional response to Erlotinib monotherapy in EGFR Exon 19-deleted, KRAS wild-type, Chemo-refractory advanced pancreatic adenocarcinoma. 2021 , 27, 100342	0
594	Jaundice in Pancreatic Cancer. 2021 , 1215-1225	
593	Interventional therapy combined with molecular-targeted therapy for pancreatic cancer. 2021 , 541-552	
592	Pancreatic adenocarcinoma: molecular drivers and the role of targeted therapy. 2021 , 40, 355-371	3
591	Landmark Series: Immunotherapy and Targeted Therapy for Pancreatic Cancer. 2021 , 28, 1400-1406	2
590	FOLFIRINOX in advanced pancreatic cancer patients with the double-variant type of UGT1A1 *28 and *6 polymorphism: a multicenter, retrospective study. 2021 , 87, 397-404	0
589	Strategies and methods for selecting suitable combined interventional therapy for pancreatic carcinoma. 2021 , 553-568	
588	A phase II study of gemcitabine, erlotinib and S-1 in patients with advanced pancreatic cancer. 2021 , 12, 912-917	3
587	A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administered to patients with metastatic pancreatic cancer: results from the NAPOLEON study. 2021 , 26, 941-950	3
586	Optimum Cytotoxic Therapy for Advanced Pancreatic Cancer. 2008 , 511-533	1
585	Chemotherapy for Advanced Pancreatic Cancer. 2010 , 913-949	1
584	Adjuvant Chemotherapy in Pancreatic Cancer. 2010 , 1051-1077	1
583	Signal Transduction Pathways as Therapeutic Targets in Cancer Therapy. 2010 , 37-83	2
582	The Role of Non-cancerous Cells in Cancer: Pancreatic Ductal Adenocarcinoma as a Model to Understand the Impact of Tumor Microenvironment on Epithelial Carcinogenesis. 2013 , 309-333	1
581	Crosstalk Between COX-2 and EGFR: A Potential Therapeutic Opportunity. 2008 , 325-339	2

580	Pancreatic Cancer. 2020 , 97-109	2
579	The role of inflammation in pancreatic cancer. 2014 , 816, 129-51	59
578	Pancreatic cancer: step by step forward. 2008 , 177, 1-2	1
577	Erlotinib. 2010 , 184, 21-31	3
576	Targeted drug therapies and cancer. 2011 , 185, 159-71	11
575	Radiotherapy of the pancreas: state of the art in 2012. 2012 , 196, 89-103	1
574	Toxicology, Safety and HerbDrug Interactions in Cancer Therapy. 2010 , 293-340	1
573	Pancreatic Cancer. 2018 , 427-469	3
572	Recent advances in chemotherapy for pancreatic cancer: evidence from Japan and recommendations in guidelines. 2020 , 55, 369-382	13
571	Carcinoma of the Pancreas. 2008 , 1595-1611	3
570	Chemotherapy and radiotherapy for pancreatic and periampullary cancer: Adjuvant, neoadjuvant, and palliative. 2012 , 972-978.e2	1
569	Biologics and Their Interactions with Radiation. 2012 , 83-94	1
568	Signaling adaptor protein Crk is involved in malignant feature of pancreatic cancer associated with phosphorylation of c-Met. 2020 , 524, 378-384	2
567	The overexpression of CPR and P450 3A4 in pancreatic cancer cells changes the metabolic profile and increases the cytotoxicity and pro-apoptotic activity of acridine antitumor agent, C-1748. 2017 , 142, 21-38	5
566	Mechanisms of drug resistance of pancreatic ductal adenocarcinoma at different levels. 2020 , 40,	9
565	Emerging roles for the IL-6 family of cytokines in pancreatic cancer. 2020 , 134, 2091-2115	17
564	Hepatotoxicity of FDA-approved small molecule kinase inhibitors. 2021 , 20, 335-348	4
563	A phase 2 trial of glufosfamide in combination with gemcitabine in chemotherapy-naive pancreatic adenocarcinoma. 2010 , 33, 111-6	14

562	Tumor-targeted delivery of childhood vaccine recall antigens by attenuated <i>Listeria</i> reduces pancreatic cancer.	1
561	A mechanical memory of pancreatic cancer cells.	1
560	RasGRP1 is a potential biomarker to stratify anti-EGFR therapy response in colorectal cancer. 2019 , 5,	9
559	Microdissected pancreatic cancer proteomes reveal tumor heterogeneity and therapeutic targets. 2020 , 5,	17
558	Radioembolization with Yttrium-90 Microspheres for Pancreatic Cancer Liver Metastases: Results from a Pilot Study. 2010 , 96, 955-958	14
557	Sequencing Strategies to Guide Decision Making in Cancer Treatment. 2016 , 13, e1002189	3
556	Hedgehog promotes neovascularization in pancreatic cancers by regulating Ang-1 and IGF-1 expression in bone-marrow derived pro-angiogenic cells. 2010 , 5, e8824	65
555	Comprehensive analysis of cellular galectin-3 reveals no consistent oncogenic function in pancreatic cancer cells. 2011 , 6, e20859	14
554	Cord blood stem cells inhibit epidermal growth factor receptor translocation to mitochondria in glioblastoma. 2012 , 7, e31884	13
553	FKBP5 as a selection biomarker for gemcitabine and Akt inhibitors in treatment of pancreatic cancer. 2012 , 7, e36252	34
552	Evaluation of poly-mechanistic antiangiogenic combinations to enhance cytotoxic therapy response in pancreatic cancer. 2012 , 7, e38477	29
551	Regional intra-arterial vs. systemic chemotherapy for advanced pancreatic cancer: a systematic review and meta-analysis of randomized controlled trials. 2012 , 7, e40847	32
550	Utilization of quantitative in vivo pharmacology approaches to assess combination effects of everolimus and irinotecan in mouse xenograft models of colorectal cancer. 2013 , 8, e58089	22
549	Targeting cancer-related inflammation: Chinese herbal medicine inhibits epithelial-to-mesenchymal transition in pancreatic cancer. 2013 , 8, e70334	28
548	Synergistic effects of concurrent blockade of PI3K and MEK pathways in pancreatic cancer preclinical models. 2013 , 8, e77243	26
547	Prognostic value of human equilibrative nucleoside transporter1 in pancreatic cancer receiving gemcitabine-based chemotherapy: a meta-analysis. 2014 , 9, e87103	13
546	Gemcitabine induces poly (ADP-ribose) polymerase-1 (PARP-1) degradation through autophagy in pancreatic cancer. 2014 , 9, e109076	15
545	A Novel Biomarker Panel Examining Response to Gemcitabine with or without Erlotinib for Pancreatic Cancer Therapy in NCIC Clinical Trials Group PA.3. 2016 , 11, e0147995	10

544	Decreased TUSC3 Promotes Pancreatic Cancer Proliferation, Invasion and Metastasis. 2016 , 11, e0149028	18
543	Whole Genome Sequencing of Newly Established Pancreatic Cancer Lines Identifies Novel Somatic Mutation (c.2587G>A) in Axon Guidance Receptor Plexin A1 as Enhancer of Proliferation and Invasion. 2016 , 11, e0149833	17
542	Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1, 2 and 3 in Periampullary Adenocarcinoma. 2016 , 11, e0153533	17
541	Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic Cancer. 2016 , 11, e0156910	8
540	Targeting Epithelial-Mesenchymal Transition for Identification of Inhibitors for Pancreatic Cancer Cell Invasion and Tumor Spheres Formation. 2016 , 11, e0164811	13
539	Current controversies in the stage-specific multidisciplinary management of pancreatic cancer. 2014 , e157-64	5
538	1-Pamitoyl-2-Linoleoyl-3-Acetyl-rac-Glycerol May Reduce Incidence of Gemcitabine-Induced Neutropenia: A Pilot Case-Controlled Study. 2015 , 6, 410-415	3
537	Chemotherapy and Targeted Therapy with Management of Related Complications in Pancreatic Cancer. 2015 , 20, 5-13	1
536	High-intensity focused ultrasound therapy as part of combined treatment for inoperable pancreatic cancer. 2020 , 9, 50	2
535	[Comorbidity of cardiovascular diseases and cancers: Problems in the diagnosis of cardiotoxic effects of chemo- and radiation therapy]. 2015 , 87, 4-10	6
534	Why HALO 301 Failed and Implications for Treatment of Pancreatic Cancer. 2019 , 3, e1-e4	43
533	Possibilities of palliative chemotherapy in patients with locally advanced and metastatic pancreatic cancer. 2020 , 7, 118-134	1
532	FHL3 promotes pancreatic cancer invasion and metastasis through preventing the ubiquitination degradation of EMT associated transcription factors. 2020 , 12, 53-69	12
531	N of 1 case reports of exceptional responders accrued from pancreatic cancer patients enrolled in first-in-man studies from 2002 through 2012. 2015 , 2, 285-93	4
530	Overexpression of C16orf74 is involved in aggressive pancreatic cancers. 2017 , 8, 50460-50475	9
529	MicroRNA-891b is an independent prognostic factor of pancreatic cancer by targeting Cbl-b to suppress the growth of pancreatic cancer cells. 2016 , 7, 82338-82353	19
528	Gemcitabine enhances cell invasion via activating HAb18G/CD147-EGFR-pSTAT3 signaling. 2016 , 7, 62177-62193	7
527	Targeted delivery of chemotherapy using HSP90 inhibitor drug conjugates is highly active against pancreatic cancer models. 2017 , 8, 4399-4409	11

526	An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma. 2016 , 7, 82953-82960	19
525	Deciphering the link between PI3K and PAK: An opportunity to target key pathways in pancreatic cancer?. 2017 , 8, 14173-14191	21
524	Prognostic significance of positive peritoneal cytology in resectable pancreatic cancer: a systemic review and meta-analysis. 2017 , 8, 15004-15013	17
523	Novel recombinant immunotoxin of EGFR specific nanobody fused with cucurmosin, construction and antitumor efficiency in vitro. 2017 , 8, 38568-38580	21
522	Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel future. 2010 , 1, 515-529	12
521	CHIP is a novel tumor suppressor in pancreatic cancer through targeting EGFR. 2014 , 5, 1969-86	48
520	Profiling tumour heterogeneity through circulating tumour DNA in patients with pancreatic cancer. 2017 , 8, 87221-87233	29
519	B7-H3 combats apoptosis induced by chemotherapy by delivering signals to pancreatic cancer cells. 2017 , 8, 74856-74868	12
518	Nab-paclitaxel plus S-1 in advanced pancreatic adenocarcinoma (NPSPAC): a single arm, single center, phase II trial. 2017 , 8, 92401-92410	12
517	Molecular targeting of cell-permeable peptide inhibits pancreatic ductal adenocarcinoma cell proliferation. 2017 , 8, 113662-113672	4
516	Functions of pancreatic stellate cell-derived soluble factors in the microenvironment of pancreatic ductal carcinoma. 2017 , 8, 102721-102738	29
515	Aberrant expression of STYK1 and E-cadherin confer a poor prognosis for pancreatic cancer patients. 2017 , 8, 111333-111345	10
514	Crizotinib exhibits antitumor activity by targeting ALK signaling not c-MET in pancreatic cancer. 2014 , 5, 9150-68	16
513	Distribution of erlotinib in rash and normal skin in cancer patients receiving erlotinib visualized by matrix assisted laser desorption/ionization mass spectrometry imaging. 2018 , 9, 18540-18547	9
512	Development of novel monoclonal antibodies against CD109 overexpressed in human pancreatic cancer. 2018 , 9, 19994-20007	10
511	The combination of everolimus and zoledronic acid increase the efficacy of gemcitabine in a mouse model of pancreatic adenocarcinoma. 2018 , 9, 28069-28082	4
510	Real life triplet FIr/FOx chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma patients: recommended schedule for expected activity and safety and phase II study. 2018 , 9, 31861-31876	4
509	Tumor penetrating nanomedicine targeting both an oncomiR and an oncogene in pancreatic cancer. 2019 , 10, 5349-5358	11

508	A comprehensive analysis of clinical trials in pancreatic cancer: what is coming down the pike?. 2020 , 11, 3489-3501	13
507	Molecular landscape of pancreatic cancer: implications for current clinical trials. 2015 , 6, 4553-61	65
506	Prognostic factors of survival in patients treated with nab-paclitaxel plus gemcitabine regimen for advanced or metastatic pancreatic cancer: a single institutional experience. 2015 , 6, 8255-60	13
505	Targeting EGF-receptor(s) - STAT1 axis attenuates tumor growth and metastasis through downregulation of MUC4 mucin in human pancreatic cancer. 2015 , 6, 5164-81	37
504	Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the "THERAPY" phase 1-2 trial. 2015 , 6, 12796-808	43
503	Macrolide analog F806 suppresses esophageal squamous cell carcinoma (ESCC) by blocking α integrin activation. 2015 , 6, 15940-52	7
502	Gemcitabine triggers angiogenesis-promoting molecular signals in pancreatic cancer cells: Therapeutic implications. 2015 , 6, 39140-50	17
501	Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancer. 2015 , 6, 15788-801	39
500	Novel agents for advanced pancreatic cancer. 2015 , 6, 39521-37	23
499	Simultaneous targeting of 5-LOX-COX and EGFR blocks progression of pancreatic ductal adenocarcinoma. 2015 , 6, 33290-305	20
498	Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses. 2015 , 6, 39538-49	23
497	Integrated experimental and simulation study of the response to sequential treatment with erlotinib and gemcitabine in pancreatic cancer. 2016 , 7, 15492-506	7
496	KRAS above and beyond - EGFR in pancreatic cancer. 2012 , 3, 1262-3	17
495	The role of histone lysine demethylases in cancer cells' resistance to tyrosine kinase inhibitors.. 2019 , 2, 326-334	1
494	Drug metabolism and pancreatic cancer. 2017 , 30, 54-61	3
493	Pancreatic cancer from bench to bedside: molecular pathways and treatment options. 2016 , 4, 165	16
492	Chemoradiotherapy is associated with improved survival for resected pancreatic adenosquamous carcinoma: a retrospective cohort study from the SEER database. 2019 , 7, 522	4
491	EGFR first- and second-generation TKIs-there is still place for them in -mutant NSCLC patients.. 2019 , 8, S23-S47	19

490	Role of erlotinib in the management of pancreatic cancer. 2006 , 2, 435-45	13
489	Molecular characterization of head and neck cancer: how close to personalized targeted therapy?. 2012 , 16, 209-22	12
488	Neoadjuvant Therapy is Essential for Resectable Pancreatic Cancer. 2019 , 26, 7196-7211	6
487	A Retrospective Look at Anti-EGFR Agents in Pancreatic Cancer Therapy. 2019 , 20, 958-966	6
486	Blocking IL-6/GP130 Signaling Inhibits Cell Viability/Proliferation, Glycolysis, and Colony Forming Activity in Human Pancreatic Cancer Cells. 2019 , 19, 417-427	15
485	Mathematical Modeling to Address Challenges in Pancreatic Cancer. 2020 , 20, 367-376	7
484	Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors. 2020 , 20, 815-834	64
483	A phase I study of gemcitabine and S-1 concurrent radiotherapy in patients with locally advanced pancreatic cancer. 2010 , 25, 109-116	2
482	Ductal pancreatic adenocarcinoma. 2014 , 111, 396-402	15
481	Molecular Targeted Intervention for Pancreatic Cancer. 2015 , 7, 1499-542	23
480	Treatment of gastrointestinal neuroendocrine tumors with inhibitors of growth factor receptors and their signaling pathways: recent advances and future perspectives. 2008 , 14, 2461-73	23
479	c-Met targeted therapy of cholangiocarcinoma. 2008 , 14, 2990-4	31
478	Experimental treatment of pancreatic cancer with two novel histone deacetylase inhibitors. 2008 , 14, 3681-92	25
477	Anti-tumor activity of erlotinib in the BxPC-3 pancreatic cancer cell line. 2008 , 14, 5403-11	12
476	A patient with unresectable advanced pancreatic cancer achieving long-term survival with gemcitabine chemotherapy. 2008 , 14, 6876-80	5
475	Exploiting novel molecular targets in gastrointestinal cancers. 2007 , 13, 5845-56	16
474	Intraoperative radiofrequency ablation combined with 125 iodine seed implantation for unresectable pancreatic cancer. 2010 , 16, 5104-10	31
473	Second-line therapy for gemcitabine-pretreated advanced or metastatic pancreatic cancer. 2012 , 18, 1357-64	15

472	Pancreatic cancer: translational research aspects and clinical implications. 2012 , 18, 1417-24	19
471	Adjuvant and neoadjuvant treatment in pancreatic cancer. 2012 , 18, 1565-72	39
470	Role of taxanes in pancreatic cancer. 2012 , 18, 4457-65	7
469	FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts. 2012 , 18, 4533-41	38
468	Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer?. 2012 , 18, 4944-58	57
467	Insights into erlotinib action in pancreatic cancer cells using a combined experimental and mathematical approach. 2012 , 18, 6226-34	13
466	Developments in metastatic pancreatic cancer: is gemcitabine still the standard?. 2012 , 18, 736-45	54
465	First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer. 2013 , 19, 4511-9	12
464	Propofol induces apoptosis and increases gemcitabine sensitivity in pancreatic cancer cells in vitro by inhibition of nuclear factor- B activity. 2013 , 19, 5485-92	33
463	Current evidence for histone deacetylase inhibitors in pancreatic cancer. 2013 , 19, 813-28	31
462	Histone deacetylase inhibitors and pancreatic cancer: are there any promising clinical trials?. 2013 , 19, 1173-81	41
461	Chemotherapy for advanced hepatocellular carcinoma in the sorafenib age. 2014 , 20, 4151-9	26
460	Pancreatic biomarkers: could they be the answer?. 2014 , 20, 7819-29	7
459	Epigenetics and pancreatic cancer: pathophysiology and novel treatment aspects. 2014 , 20, 7830-48	71
458	Personalising pancreas cancer treatment: When tissue is the issue. 2014 , 20, 7849-63	18
457	Distinct antifibrogenic effects of erlotinib, sunitinib and sorafenib on rat pancreatic stellate cells. 2014 , 20, 7914-25	11
456	Pancreatic cancer: advances in treatment. 2014 , 20, 9354-60	109
455	Translational research in pancreatic ductal adenocarcinoma: current evidence and future concepts. 2014 , 20, 10769-77	17

454	MicroRNAs as emerging biomarkers and therapeutic targets for pancreatic cancer. 2014 , 20, 11199-209	37
453	Adjuvant therapy in pancreatic cancer. 2014 , 20, 14733-46	29
452	S-1 in the treatment of pancreatic cancer. 2014 , 20, 15110-8	38
451	Icotinib plus gemcitabine for metastatic pancreatic cancer: a case report. 2015 , 21, 3441-6	3
450	Metastatic pancreatic cancer: Is there a light at the end of the tunnel?. 2015 , 21, 4788-801	48
449	New targeted therapies in pancreatic cancer. 2015 , 21, 6127-45	38
448	Effects of Yttrium-90 selective internal radiation therapy on non-conventional liver tumors. 2015 , 21, 8271-83	28
447	Perspectives in the treatment of pancreatic adenocarcinoma. 2015 , 21, 9297-316	92
446	Advanced pancreatic cancer - how to choose an adequate treatment option. 2015 , 21, 10709-13	3
445	Treatment-related gastrointestinal toxicities and advanced colorectal or pancreatic cancer: A critical update. 2015 , 21, 11793-803	20
444	Viro-immune therapy: A new strategy for treatment of pancreatic cancer. 2016 , 22, 748-63	11
443	Management of pancreatic cancer in the elderly. 2016 , 22, 764-75	80
442	Molecular targets for the treatment of pancreatic cancer: Clinical and experimental studies. 2016 , 22, 776-89	37
441	Bisphosphonates as potential adjuvants for patients with cancers of the digestive system. 2016 , 22, 906-16	9
440	FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer. 2016 , 22, 6987-7005	52
439	Nanovectors for anti-cancer drug delivery in the treatment of advanced pancreatic adenocarcinoma. 2016 , 22, 7080-90	9
438	Updated therapeutic outcome for patients with periampullary and pancreatic cancer related to recent translational research. 2016 , 22, 10502-10511	3
437	Extraordinary response of metastatic pancreatic cancer to apatinib after failed chemotherapy: A case report and literature review. 2017 , 23, 7478-7488	19

436	ATP-binding cassette transporters in progression and clinical outcome of pancreatic cancer: What is the way forward?. 2018 , 24, 3222-3238	45
435	Targeting retinoblastoma protein phosphorylation in combination with EGFR inhibition in pancreatic cancer cells. 2019 , 54, 527-536	5
434	High mobility group AT-hook 2 and c-MYC as potential prognostic factors in pancreatic ductal adenocarcinoma. 2020 , 19, 1584-1592	2
433	Synergistic activity of agents targeting growth factor receptors, CDKs and downstream signaling molecules in a panel of pancreatic cancer cell lines and the identification of antagonistic combinations: Implications for future clinical trials in pancreatic cancer. 2020 , 44, 2581-2594	5
432	Inflammatory markers as prognostic indicators in pancreatic cancer patients who underwent gemcitabine-based palliative chemotherapy. 2020 , 35, 171-184	7
431	Immunotherapy for pancreatic ductal adenocarcinoma: an overview of clinical trials. 2015 , 27, 376-91	11
430	Evaluation of phosphatidylinositol-3-kinase catalytic subunit (PIK3CA) and epidermal growth factor receptor (EGFR) gene mutations in pancreaticobiliary adenocarcinoma. 2013 , 4, 20-9	18
429	Treatment of locally advanced unresectable pancreatic cancer: a 10-year experience. 2012 , 3, 326-34	40
428	Nab-paclitaxel monotherapy in refractory pancreatic adenocarcinoma. 2013 , 4, 370-3	10
427	Current and future systemic treatment options in metastatic pancreatic cancer. 2014 , 5, 280-95	29
426	Adjuvant radiation therapy for pancreatic cancer: a review of the old and the new. 2015 , 6, 436-44	14
425	Targeted agents: how can we improve the outcome in biliary tract cancer?. 2013 , 2, 31-3	3
424	Histamine regulation of pancreatitis and pancreatic cancer: a review of recent findings. 2013 , 2, 216-26	6
423	Molecular characteristics of pancreatic ductal adenocarcinoma. 2011 , 2011, 620601	33
422	▣Mangostins Induce Autophagy and Show Synergistic Effect with Gemcitabine in Pancreatic Cancer Cell Lines. 2017 , 25, 609-617	11
421	Common pitfalls in statistical analysis: Clinical versus statistical significance. 2015 , 6, 169-70	91
420	The personalized medicine for pancreatic ductal adenocarcinoma patients: The oncologist perspective. 2017 , 6, S66-S68	2
419	Future role of endoscopic ultrasound in personalized management of pancreatic cancer. 2017 , 6, 300-307	3

418	Treatment practices for metastatic pancreatic cancer: Can we deliver an appropriately efficacious and safe regimen in Indian patients?. 2018 , 55, 138-143	3
417	Experience with non-cremophor-based paclitaxel-gemcitabine regimen in advanced pancreatic cancer: Results from a single tertiary cancer centre. 2018 , 148, 284-290	2
416	Gemcitabine versus gemcitabine combined with cisplatin treatment locally advanced or metastatic pancreatic cancer: a retrospective analysis. 2008 , 40, 22-6	9
415	A Phase II Trial of Gemcitabine plus Capecitabine for Patients with Advanced Pancreatic Cancer. 2012 , 44, 127-32	9
414	Gemcitabine Combined with Capecitabine Compared to Gemcitabine with or without Erlotinib as First-Line Chemotherapy in Patients with Advanced Pancreatic Cancer. 2015 , 47, 266-73	6
413	p21-Activated Kinase 4 (PAK4) as a Predictive Marker of Gemcitabine Sensitivity in Pancreatic Cancer Cell Lines. 2015 , 47, 501-8	22
412	Prognostic Factors for Risk Stratification of Patients with Recurrent or Metastatic Pancreatic Adenocarcinoma Who Were Treated with Gemcitabine-Based Chemotherapy. 2016 , 48, 1264-1273	29
411	Pancreatic cancer: A model cancer for the study of the therapeutic effects of anticoagulants. 2009 , 1, 38-40	3
410	FOLFIRINOX gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: Single-center cohort study. 2020 , 12, 182-194	23
409	Targeted therapies for pancreatic adenocarcinoma: Where do we stand, how far can we go?. 2015 , 7, 172-7	6
408	Genomic alterations in pancreatic cancer and their relevance to therapy. 2015 , 7, 250-8	21
407	State of the art biological therapies in pancreatic cancer. 2016 , 8, 55-66	17
406	Is metastatic pancreatic cancer an untargetable malignancy?. 2016 , 8, 297-304	7
405	Molecular therapeutics in pancreas cancer. 2016 , 8, 366-79	16
404	Prognostic value of inflammation-based markers in patients with pancreatic cancer administered gemcitabine and erlotinib. 2016 , 8, 555-62	28
403	Detecting circulating tumor material and digital pathology imaging during pancreatic cancer progression. 2017 , 9, 235-250	14
402	Evolving treatment landscape for early and advanced pancreatic cancer. 2017 , 9, 281-292	19
401	The molecular targets for the diagnosis and treatment of pancreatic cancer. 2010 , 4, 433-49	17

400	Phase II Trial of Erlotinib Plus Gemcitabine Chemotherapy in Korean Patients with Advanced Pancreatic Cancer and Prognostic Factors for Chemotherapeutic Response. 2013 , 7, 611-5	12
399	Expression of heat shock protein 70 modulates the chemoresponsiveness of pancreatic cancer. 2013 , 7, 739-46	16
398	Factors of Endoscopic Ultrasound-Guided Tissue Acquisition for Successful Next-Generation Sequencing in Pancreatic Ductal Adenocarcinoma. 2020 , 14, 387-394	11
397	Targeting metastatic upper gastrointestinal adenocarcinomas. 2011 , 2, 135-49	2
396	Recent progress and limitations of chemotherapy for pancreatic and biliary tract cancers. 2011 , 2, 158-63	19
395	Neoadjuvant treatment for resectable pancreatic adenocarcinoma. 2016 , 7, 1-8	11
394	Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations. 2011 , 30, 5-12	86
393	Systemic treatment for inoperable pancreatic adenocarcinoma: review and update. 2014 , 33, 267-76	14
392	Current Systemic Treatment Options for Metastatic and Unresectable Pancreatic Cancer.	1
391	Pathological Complete Response after S-1 Therapy for an Unresectable Pancreatic Head Cancer with Liver Metastasis. 2017 , 50, 461-468	1
390	The pathology and genetics of metastatic pancreatic cancer. 2009 , 133, 413-22	153
389	Systemic therapy of non-colorectal gastrointestinal malignancies in the elderly. 2015 , 12, 284-91	2
388	Regression of Stage IV Pancreatic Cancer to Curative Surgery and Introduction of a Novel Ex-Vivo Chemosensitivity Assay. 2015 , 7, e423	3
387	Cancer of Exocrine Pancreas. 2021 , 645-674	
386	Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges. 2021 , 20, 128	10
385	Safety and efficacy of depatuxizumab mafodotin in Japanese patients with malignant glioma: A nonrandomized, phase 1/2 trial. 2021 , 112, 5020-5033	3
384	Consensus statement of Russian experts on the prevention, diagnosis and treatment of cardiotoxicity of anticancer therapy. 2021 , 26, 4703	16
383	Pre-clinical Models of Metastasis in Pancreatic Cancer. 2021 , 9, 748631	2

382	The clinical outcomes of second-line chemotherapy in patients with advanced pancreatic cancer: a retrospective analysis. 2021 ,	1
381	Systemic Therapy for Metastatic Pancreatic Cancer. 2021 , 22, 106	6
380	Recent Advances in Pancreatic Cancer: Novel Prognostic Biomarkers and Targeted Therapy-A Review of the Literature. 2021 , 11,	0
379	Neues zur Therapie des Pankreaskarzinoms: Hoffnung am Horizont?. 2021 , 2, 138	
378	Identification of Candidate Biomarker ASXL2 and Its Predictive Value in Pancreatic Carcinoma. 2021 , 11, 736694	1
377	Therapeutic resistance in pancreatic ductal adenocarcinoma: Current challenges and future opportunities. 2021 , 27, 6527-6550	3
376	The Diverse Applications of Pancreatic Ductal Adenocarcinoma Organoids. 2021 , 13,	1
375	Role of human nucleoside transporters in pancreatic cancer and chemoresistance. 2021 , 27, 6844-6860	4
374	Thfapies ciblès: inhibiteurs de Ëactivit'tyrosine kinase du rēcepteur ^EGF. 2008 , 45-53	
373	HER Family of Receptors as Treatment Targets in Pancreatic Cancer. 2008 , 609-634	
372	An Overview of Clinical Trials of Targeted Therapies in Pancreatic Cancer. 2008 , 565-575	
371	Novel Targets for the Treatment of Pancreatic Cancer I: Insulin-like Growth Factor Receptor. 2008 , 665-676	
370	EGF-R Protein Expression and Gene Amplification do not Correlate in Pancreas Cancer. 2008 , 1, 55-56	
369	Pitfalls in Clinical Trials and Future Directions. 2008 , 723-731	
368	[Antiangiogenic therapy for gastrointestinal tumors]. 2008 , 149, 2317-24	
367	Targeting Signaling Pathways in Cancer Therapy. 2009 , 309-326	
366	JPN (Japan Pancreas Society) guidelines for the management of pancreatic cancer. 2009 , 121, 195-198	
365	Chemotherapy and Radiotherapy in Pancreatic Cancer. 2009 , 481-500	

364 CELL CYCLE PHARMACOLOGY, ANTIPROLIFERATION, AND APOPTOSIS. **2009**, 83-90

363 The Medical Oncologist's Point of View. **2009**, 37-47

362 Cancer of the Pancreas. **2010**, 801-819

361 EGFR Signaling Pathways in Pancreatic Cancer Pathogenesis. **2010**, 387-402

360 Evidence-Based Medicine: What does it Mean and Where Are We Going?. **2010**, 221-241

359 Application of molecular medicine to pancreatic cancer. **2010**, 25, 35-45

358 Biologisch zielgerichtete medikamentöse Therapie. **2010**, 265-275

357 DRUGS USED IN CANCER CHEMOTHERAPY. **2010**, 1-229

356 Antiangiogenic cancer therapy using peptide vaccine for patients with advanced pancreatic cancer. **2010**, 25, 53-58

355 A New Preclinical Paradigm for Pancreas Cancer. **2010**, 73-93

1

354 Proteomic Analysis of Blood and Pancreatic Juice. **2010**, 223-241

353 Drug Evaluations in Pancreatic Cancer Culture Systems. **2010**, 1-27

352 The Development of Pharmacodynamic Endpoint Models for Evaluation of Therapeutics in Pancreatic Cancer. **2010**, 271-289

351 Molecular Targeted Therapy. **2010**, 1523-1531

350 Gastrointestinal Stromal Tumor: Cause of Gastrointestinal Bleeding. **2010**, 3, 93-95

1

349 MicroRNA Profiling and Its Application in Drug Discovery in Pancreatic Cancer. **2010**, 171-180

348 Emerging Therapeutic Targets for Pancreatic Cancer. **2010**, 1319-1335

347 Unresectable Pancreatic Cancer. **2011**, 205-224

346 Targeted Therapeutics in Cancer Treatment. **2011**, 403-461

345 Phase III Clinical Trials with Anticancer Agents. **2011**, 163-188

344 Gastrointestinal Malignancies. **2011**, 421-434

343 Cancer Stem Cells in Pancreatic Cancer. **2011**, 79-97

342 Systemic and Regional Chemotherapy for Advanced and Metastasized Pancreatic Cancer. **2011**, 347-355

341 Translational Research in Head and Neck Oncology. **2011**, 179-189

340 Priorisierung in der Onkologie. **2011**, 39-58

339 Adjuvant trials for pancreatic cancer: where are we going and what is needed?. **2011**, 1, 651-667

338 Nanoscale Delivery Systems for Combination Chemotherapy. 1013-1050

1

337 Drugs in clinical trials & future directions. **2011**, 84-95

336 Pancreatic Cancer. **2012**, 935-957

335 Controversies in medicine: a learning opportunity. **2012**, 12, e5308-e5308

334 Le cancer du pancr as. **2012**, 196, 1819-1828

333 Molecular Mechanisms of Tumor Metastasis. **2013**, 213-228

332 Evidenz der Chemotherapie beim fortgeschrittenen Pankreaskarzinom. **2013**, 376-383

331 Neue Therapieprinzipien beim Pankreaskarzinom: Zweitlinientherapie/Second Line, Targeted Therapies. **2013**, 394-400

330 Prerequisite Genetic Traits for Metastasis. **2013**, 403-444

329 EGFR, Immunology. **2013**, 1-10

328 K-Ras. **2013**, 1-10

327 Kombination von Zytostatika mit Strahlentherapie: Radiochemotherapie. **2013**, 249-269

326 Biomarqueurs prédictifs d'efficacité. **2013**, 289-304

325 Recent Developments and Current Issues in the Treatment of Pancreatic Cancer. **2013**, 04, 13-27

1

324 Systemische und regionale Chemotherapie beim fortgeschrittenen und metastasierten Pankreaskarzinom. **2013**, 217-224

323 TYPES OF DNA DAMAGE. **2013**, 115-118

322 The Efficacy and Cost of Biological Targeted Agents in Oncology.

321 The Biology of K-Ras Signaling Pathways in Pancreatic Cancer. **2013**, 83-115

320 Endoscopy in Pancreatic Cancer: An Oncologist's Perspective. 181-189

319 Advances in systemic therapy for advanced pancreatobiliary malignancies. **2013**, 2, 105

1

318 The Role of microRNAs in Tumor Progression and Therapy. 153-165

317 The Role of Phase III Trials in Modern Drug Development. **2014**, 763-783

316 Preliminary Findings on the Use of Targeted Therapy in Combination with Sodium Phenylbutyrate in Recurrent Advanced Pancreatic Cancer: A Potential Strategy for Improved Survival. **2014**, 05, 1072-1091

1

315 Was tun mit all den Daten? Studiauswertung leicht gemacht!. **2014**, 37-51

314 Medical Oncology. **2014**, 71-82

313 EBM-based Clinical Guidelines for Pancreatic Cancer (2013): perspectives on chemotherapy. **2014**, 29, 892-897

312 Progress and perspectives of post-operative adjuvant chemotherapy for adenocarcinoma of the pancreas. **2014**, 29, 878-884

311 The current status of FOLFIRINOX for unresectable pancreatic cancer. **2014**, 29, 885-891

310 RAS Genes and Cancer. **2014**, 157-171

309 Carcinoma of the Pancreas. **2014**, 1397-1415.e7

1

308 Liver Metastases from Pancreatic Adenocarcinoma. **2015**, 95-109

307 Gemcitabine Plus Erlotinib Combination Therapy in Four Patients with Unresectable Advanced Recurrent Pancreatic Cancer. **2015**, 74, 106-108

306 Targeted Therapies for Pancreatic Cancer. **2015**, 127-135

305 Synthetic Sickness with Molecularly Targeted Agents Against the EGFR Pathway. **2015**, 381-412

304 Pancreatic Cancer Resistance to TRAIL Therapy: Regulators of the Death Inducing Signaling Complex. **2015**, 235-265

303 Pankreastumoren. **2015**, 557-567

302 Erlotinib for advanced pancreatic cancer.

301 E28 Literaturhinweise und Internetadressen. **2015**, e1-e79

300 Clinical Observation of High Intensity Focused Ultrasound (HIFU) Ablation Combined with Qingyihuaji Formula for Salvage Treatment for Advanced Pancreatic Cancer Patients Failed to Systemic Chemotherapy. **2015**, 04, 1-7

299 A case of long term survival of pancreatic cancer with paraaortic nodal metastasis. **2015**, 30, 137-143

298 Efficacy and Safety of Fixed-Dose-Rate Infusions of Gemcitabine Plus Erlotinib for Advanced Pancreatic Cancer. **2015**, 4, 44-51

297 Advanced pancreatic cancer. **2015**, 99-108

296 Pancreas. 270-279

295 Endoscopic Ultrasonography. 2763-2789

294 Neoplasia of the Gastrointestinal Tract. 587-616

293 Genetic factors affecting patient responses to pancreatic cancer treatment. **2016**, 29, 466-476

3

292 Adjuvant Chemotherapy in Pancreatic Cancer. **2016**, 1-34

291 Erlotinib. **2016**, 97-98

1

290 Strategies to Target Pancreatic Cancer. **2016**, 1-20

289 Molecular Targeted Anticancer Drugs. **2016**, 175-238

288 Systemic and Regional Chemotherapy for Advanced and Metastasized Pancreatic Cancer. **2016**, 243-251

287 Cardiovascular Emergencies. **2016**, 179-190

286 Pharmacokinetics and Pharmacodynamics of Tyrosine Kinase Inhibitors. **2016**, 121-150

285 Translational Research in Head and Neck Oncology. **2016**, 215-227

284 Indications for Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors. **2016**, 179-188

283 Resistance to Tyrosine Kinase Inhibitors in Different Types of Solid Cancer. **2016**, 27-107

282 Identification and functional analysis of an EMT-accelerating factor induced in pancreatic cancer cells by an anticancer agent. **2016**, 31, 76-84

1

281 Pankreaskarzinom beim alten und geriatrischen Patienten. **2016**, 1-9

280 Biological Principles and Clinical Application of EGFR Inhibitors in Cancer. **2017**, 709-726

279 EGFR (ErbB) Signaling Pathways in Pancreatic Cancer Pathogenesis. **2017**, 1-26

0

278 Development of Hypoxia: Activated Cytotoxic Prodrug. **2017**, 243-252

277 Palliative Onkologie [Möglichkeiten und Herausforderungen]. **2017**, 257-280

276 Anti-Angiogenics in Pancreatic Cancer Therapy. **2017**, 1-20

275 Chemotherapy in the Management of Pancreatic Cancer. **2017**, 387-419

- 274 Chemotherapy for Advanced Pancreatic Cancer. **2017**, 1-48
- 273 Palliative Management of Pancreatic Cancer. **2017**, 1-28
- 272 Differential Therapy Based on Tumor Heterogeneity in Pancreatic Cancer. **2017**, 1-15
- 271 Pancreas. 270-279
- 270 DLI Induced by Molecular Target Antineoplastic Drug: What Are the Characteristics of DLI in Molecular Target Antineoplastic Drugs?. **2018**, 139-164
- 269 Molecularly Targeted Therapies in Pancreatic Cancer. **2018**, 219-233
- 268 Cytotoxic Therapy in Advanced Pancreatic Cancer: Where We Are and Where We Are Headed. **2018**, 205-217
- 267 Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience. **2017**, 8, 87163-87173
- 266 Enhanced Selective Cytotoxicity in Pancreatic Cancer Cells Using EGF-Conjugated Liposome-Encapsulated Curcumin. **2018**, 217-221 0
- 265 Precision Medicine Based on Next Generation Sequencing and Master Controllers. **2018**, 1-35
- 264 Cytotoxic Effect of Bitter Melon (*Momordica charantia* L.) Ethanol Extract and Its Fractions on Pancreatic Cancer Cells in vitro. **2017**, 2, 1-11 3
- 263 EGFR and Cytoplasmic Kinase Src Targeting in Pancreatic Cancer. **2018**, 97-105
- 262 Pancreatic ductal adenocarcinoma: Role of chemotherapy & future perspectives. **2018**, 148, 254-257 1
- 261 Tyrosine Kinase Inhibitors and Their Clinical Prospective in Pancreatic Cancer. **2018**, 63-70
- 260 Stellenwert der systemischen Chemotherapie bei fortgeschrittener peritonealer Metastasierung. **2018**, 245-260
- 259 Pankreaskarzinom beim alten und geriatrischen Patienten. **2018**, 333-341
- 258 Drug Resistance Against Tyrosine Kinase Inhibitor in Gastrointestinal Malignancies. **2018**, 191-224
- 257 Hepatotoxicity and Hepatic Dysfunction. **2018**, 445-465

- 256 Treatment strategy for unresectable pancreatic cancer. **2018**, 33, 37-47
- 255 TGF- β II knock-down promotes tumor growth and chemoresistance to gemcitabine of pancreatic cancer cells via phosphorylation of STAT3.
- 254 Dosage Adjustments for Chemotherapy and Targeted Therapies in Colorectal and Pancreatic Cancer Patients with Hepatic Impairment. **2018**, 10, e2798
- 253 In vitro model of inflammatory, hypoxia, and cancer stem cell signaling in pancreatic cancer using heterocellular 3-dimensional spheroids. 1
- 252 Combining Survival and Toxicity Effect Sizes from Clinical Trials: NCCTG 89-20-52 (Alliance). **2018**, 7, 137-146
- 251 Treatment of Advanced Pancreatic Carcinoma. **2019**, 255-268
- 250 A Case of Pancreatic Head Cancer with a Hepatic Metastasis that Showed Complete Response to Administration of Gemcitabine + Nab-Paclitaxel Therapy. **2019**, 44, 113-119
- 249 Pancreatic Cancer. **2019**, 421-470
- 248 Multidisciplinary Management of Liver, Pancreatic, and Gastric Malignancies in Older Adults. **2019**, 1-28
- 247 Research Progress on the Treatment of Pancreatic Cancer. **2019**, 09, 638-644
- 246 Novel Strategies on the Horizon for Metastatic Pancreatic Cancer Management. **2019**, 15, 27 1
- 245 Resectable and Borderline Resectable Pancreatic Cancer. **2019**, 235-254
- 244 Novel Targeted Treatment Approaches in Pancreatic Cancer. **2019**, 479-491
- 243 Anti-angiogenics in Pancreatic Cancer Therapy. **2019**, 415-434
- 242 ??????. **2019**, 122, 717-723
- 241 Hepatocyte Growth Factor and Macrophage-stimulating Protein "Hinge" Analogs to Treat Pancreatic Cancer. **2019**, 19, 782-795 0
- 240 Chemotherapy for patients with unresectable pancreatic cancer is recommended in the Clinical Practice Guidelines for Pancreatic Cancer 2019. **2020**, 35, 69-74
- 239 TSPAN1 promotes human pancreatic cancer cells proliferation by modulating CDK1 via Akt.

- 238 Nicotinamide combined with gemcitabine is an immunomodulatory therapy that restrains pancreatic cancer in mice.
- 237 Role of Erlotinib in Influencing the Quality of Life of Cancer Patients. **2020**, 07,
- 236 Current and Emerging Molecular Therapies for Head and Neck Squamous Cell Carcinoma. **2021**, 13, 4
- 235 Diagnostik und Therapie des Pankreaskarzinoms. **2021**, 42, 655-661
- 234 Duktales Adenokarzinom des Pankreas [Entstehung, Diagnostik, Therapie. **2021**, 16, 41-50 0
- 233 Nonsurgical Management of Pancreatic Adenocarcinoma. **2021**, 1-22
- 232 Gastrointestinal Toxicities of Targeted Therapy. **2020**, 119-132
- 231 [Medicinal treatment of pancreatic cancer : Still a domain of chemotherapy?]. **2020**, 61, 226-232
- 230 Tumours of the pancreas. **2020**, 3227-3238
- 229 Dermatological Toxicities of Targeted Therapy. **2020**, 147-164 0
- 228 How to read a published clinical trial: A practical guide for clinicians. **2020**, 10, 68-75
- 227 Multidisciplinary Management of Liver, Pancreatic, and Gastric Malignancies in Older Adults. **2020**, 731-757 0
- 226 Current perspective on the treatment of advanced pancreatic adenocarcinoma. **2020**, 14, 37-39
- 225 Emerging agents for metastatic pancreatic cancer: spotlight on early phase clinical trials. **2021**, 1-19 0
- 224 Role of the microbiome in systemic therapy for pancreatic ductal adenocarcinoma (Review). **2021**, 59, 0
- 223 Update on optimal management for pancreatic cancer: expert perspectives from members of the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. **2021**, 1-13
- 222 Context Matters-Why We Need to Change From a One Size Fits all Approach to Made-to-Measure Therapies for Individual Patients With Pancreatic Cancer. **2021**, 9, 760705 1
- 221 Updates of Chemotherapy and Radiotherapy for Pancreatic Cancer. **2020**, 25, 72-82 1

220	Unresectable Locally Advanced Pancreatic Cancer: Concurrent Chemotherapy. 2008 , 227-236	
219	Rehabilitation and palliation of patients with pancreatic cancer. 2007 , 245-278	
218	Emerging therapies in pancreas cancer. 2011 , 2, 93-103	9
217	Nanovector-based therapies in advanced pancreatic cancer. 2011 , 2, 185-94	14
216	Adjuvant chemoradiation for pancreatic cancer: what does the evidence tell us?. 2014 , 5, 166-77	15
215	Thromboembolism in gastrointestinal cancers. 2008 , 2, 267-72	5
214	Section III: Treatment of Advanced Gastrointestinal Cancers. 2007 , 1, S8-S12	1
213	Section IV: Significance of Recent Study Results and Future Research Directions in Gastrointestinal Oncology. 2007 , 1, S13-6	
212	Skeletal metastases in pancreatic cancer: a retrospective study and review of the literature. 2009 , 82, 1-6	33
211	First- and second-line treatment of metastatic pancreatic adenocarcinoma: the conundrum continues. 2009 , 3, 37-9	2
210	Targeted therapies for pancreatic cancer. 2008 , 2, S16-9	15
209	Accomplishments in 2007 in the treatment of metastatic pancreatic cancer. 2008 , 2, S37-41	8
208	Pancreatic adenocarcinoma: new strategies for success. 2009 , 3, S11-5	14
207	Review of erlotinib in the treatment of advanced non-small cell lung cancer. 2007 , 1, 335-46	22
206	Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy. 2009 , 3, 419-28	29
205	Current use and potential role of bevacizumab in the treatment of gastrointestinal cancers. 2009 , 3, 429-41	3
204	Accomplishments in 2008 in the treatment of metastatic pancreatic cancer. 2009 , 3, S43-7	2
203	Accomplishments in 2008 in the management of localized pancreatic cancer. 2009 , 3, S37-42	2

202	Erlotinib (tarceva) for the treatment of non-small-cell lung cancer and pancreatic cancer. 2009 , 34, 554-64	15
201	The increasing role of pharmacogenetics in the treatment of gastrointestinal cancers. 2009 , 3, 197-203	3
200	Challenges in the evaluation, consent, ethics and history of early clinical trials - Implications of the Tuskegee 'trial' for safer and more ethical clinical trials. 2009 , 11, 481-4	4
199	Capecitabine: an evidence-based review of its effectiveness in the treatment of carcinoma of the pancreas. 2007 , 2, 111-9	0
198	Pancreatic cancer presenting with paraneoplastic thrombophlebitis--case report. 2010 , 3, 96-9	2
197	Major Advances in the Treatment of Cancer: What does a Non-Oncologist need to know?. 2008 , 8, 137-48	5
196	Diagnosing and managing pancreatic cancer. 2011 , 255, 21-5, 2-3	5
195	Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel future. 2010 , 1, 515-29	7
194	A 71-year-old man with a large cystic pancreatic mass. 2012 , 5, 29-31	
193	Inoperable pancreatic cancer patients who have prolonged survival exhibit an increased risk of cholangitis. 2011 , 12, 377-83	3
192	Personalized therapy for pancreatic cancer: Myth or reality in 2010?. 2010 , 1, 24-33	4
191	Pancreatic cancer: current standards, research updates and future directions. 2011 , 2, 123-5	8
190	A Multi-institutional Phase 2 Study of Imatinib Mesylate and Gemcitabine for First-Line Treatment of Advanced Pancreatic Cancer. 2012 , 5, 77-83	12
189	A phase I study of cetuximab in combination with gemcitabine and radiation for locally advanced pancreatic cancer. 2012 , 5, 112-8	5
188	A phase 2 trial of ixabepilone plus cetuximab in first-line treatment of metastatic pancreatic cancer. 2012 , 5, 155-60	3
187	Transforming growth factor beta receptor I inhibitor sensitizes drug-resistant pancreatic cancer cells to gemcitabine. 2012 , 32, 799-806	13
186	Synergistic activity of histone deacetylase and proteasome inhibition against pancreatic and hepatocellular cancer cell lines. 2011 , 31, 1093-103	35
185	Molecular targeted therapy for biliary tract malignancy: defining the target. 2012 , 1, 53-4	4

184	Early therapy evaluation of combined cetuximab and irinotecan in orthotopic pancreatic tumor xenografts by dynamic contrast-enhanced magnetic resonance imaging. 2011 , 10, 153-67	16
183	Arterial resection for pancreatic cancer: a modern surgeon should change its behavior according to the new therapeutic options. 2014 , 35, 5-14	2
182	Cytotoxicity of gemcitabine-loaded thermosensitive liposomes in pancreatic cancer cell lines. 2015 , 2, 133-142	8
181	Novel adjuvant therapies for pancreatic adenocarcinoma. 2015 , 6, 430-5	2
180	Prognostic value of clinicopathological characteristics in patients with pancreatic cancer. 2015 , 27, 509-15	2
179	Molecular profiling of a case of advanced pancreatic cancer identifies an active and tolerable combination of targeted therapy with backbone chemotherapy. 2016 , 7, E6-E12	1
178	Second-line panitumumab as a triweekly dose for patients with wild-type KRAS exon 2 metastatic colorectal cancer: a single-institution experience. 2016 , 13, 136-41	1
177	Preprogramming therapeutic response of PI3K/mTOR dual inhibitor via the regulation of EHMT2 and p27 in pancreatic cancer. 2018 , 8, 1812-1822	12
176	Inhibition of invasive pancreatic cancer: restoring cell apoptosis by activating mitochondrial p53. 2019 , 9, 390-405	7
175	Myelodysplastic Syndrome in Patients with Gastro-Pancreatic Malignancies: A Case Series and Review of Literature. 2021 , 4, 52-59	
174	New Developments in the Treatment of Pancreatic Cancer: Highlights from the 44th ASCO Annual Virtual Meeting, May 29-31, 2020. 2020 , 21, 108-111	0
173	Nuclear translocation of the receptor tyrosine kinase c-MET reduces the treatment efficacies of olaparib and gemcitabine in pancreatic ductal adenocarcinoma cells. 2021 , 11, 236-250	2
172	A new 7-gene survival score assay for pancreatic cancer patient prognosis prediction. 2021 , 11, 495-512	2
171	Doxycycline potentiates the anti-proliferation effects of gemcitabine in pancreatic cancer cells. 2021 , 11, 3515-3536	1
170	Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients' experience within a population-based study. 2021 , 13, 17588359211058255	1
169	Pancreatic cancer evolution and heterogeneity: integrating omics and clinical data. 2021 ,	16
168	Clinical Studies on Ultrafractionated Chemoradiation: A Systematic Review. 2021 , 11, 748200	0
167	Therapeutic Targeting of Autophagy in Pancreatic Ductal Adenocarcinoma.. 2021 , 12, 751568	1

166	Diagnostik und Therapie des Pankreaskarzinoms. 2021 , 12, 265-271	
165	ROR1 and ROR2 expression in pancreatic cancer. 2021 , 21, 1199	0
164	Deregulation of Transcription Factor Networks Driving Cell Plasticity and Metastasis in Pancreatic Cancer. 2021 , 9, 753456	0
163	Efficacy and safety of gemcitabine-capecitabine combination therapy for pancreatic cancer: A systematic review and meta-analysis of randomized controlled trials.. 2021 , 100, e27870	0
162	Potential of PAR-4 as a Therapeutic Target for Pancreatic Cancer. 2021 , 161-170	
161	Use of supportive anthroposophic medicine in a German integrative paediatric oncology centre. 2021 , 74, 472-477	
160	Selenium Induces Pancreatic Cancer Cell Death Alone and in Combination with Gemcitabine.. 2022 , 10,	1
159	Targeting RAS in neuroblastoma: Is it possible?. 2021 , 236, 108054	3
158	Medikamentöse Tumorthherapie des Pankreaskarzinoms. 2015 , 1-9	
157	Immune Landscape of Pancreas Ductal Adenocarcinoma: Current Therapeutic Strategies and Future Perspective. 2021 ,	
156	Comparative Outcomes of First-Line Chemotherapy for Metastatic Pancreatic Cancer Among the Regimens Used in Japan: A Systematic Review and Network Meta-analysis.. 2022 , 5, e2145515	0
155	Predicting patient treatment response and resistance via single-cell transcriptomics of their tumors.	
154	A Review of Potential Role of Capsule Endoscopy in the Work-Up for Chemotherapy-Induced Diarrhea.. 2022 , 10,	0
153	N064A (Alliance): Phase II Study of Panitumumab, Chemotherapy, and External Beam Radiation in Patients with Locally Advanced Pancreatic Adenocarcinoma.. 2022 ,	1
152	The Impact of Biomarkers in Pancreatic Ductal Adenocarcinoma on Diagnosis, Surveillance and Therapy.. 2022 , 14,	0
151	Pancreatic Cancer: Current Multimodality Treatment Options and the Future Impact of Molecular Biological Profiling.. 2022 , 38, 20-29	1
150	Zenocutuzumab, a HER2xHER3 bispecific antibody, is effective therapy for tumors driven by NRG1 gene rearrangements.. 2022 ,	8
149	Drug screening and genome editing in human pancreatic cancer organoids identifies drug-gene interactions and candidates for off-label treatment.. 2022 , 2, 100095	4

- 148 Anticancer drug resistance: An update and perspective.. **2021**, 100796 17
- 147 A Case of Multiple Gastric Metastases after Distal Pancreatectomy for Pancreatic Cancer.. **2022**, 0
- 146 Neurological complications of GI cancers. **2022**, 365-386
- 145 Genome analyses of pancreatic ductal adenocarcinoma: Current status and future perspectives. **2022**, 37, 40-46
- 144 Membrane-camouflaged supramolecular nanoparticles for co-delivery of chemotherapeutic and molecular-targeted drugs with siRNA against patient-derived pancreatic carcinoma. **2022**, 0
- 143 Cardiovascular Risks with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors and Monoclonal Antibody Therapy.. **2022**, 24, 475 0
- 142 Current Limitations and Novel Perspectives in Pancreatic Cancer Treatment.. **2022**, 14, 4
- 141 ACAGT-007a, an ERK MAPK Signaling Modulator, in Combination with AKT Signaling Inhibition Induces Apoptosis in KRAS Mutant Pancreatic Cancer T3M4 and MIA-Pa-Ca-2 Cells.. **2022**, 11, 0
- 140 Major histocompatibility complex class I molecule expression by pancreatic cancer cells is regulated by activation and inhibition of the epidermal growth factor receptor.. **2022**,
- 139 delivers tetanus toxoid protein to pancreatic tumors and induces cancer cell death in mice.. **2022**, 14, eabc1600 5
- 138 Interaction Analysis of Adenovirus L5 Protein With Pancreatic Cancer Cell Surface Receptor to Analyze Its Affinity for Oncolytic Virus Therapy.. **2022**, 12, 832277
- 137 Multiply robust subgroup analysis based on a single-index threshold linear marginal model for longitudinal data with dropouts.. **2022**,
- 136 Anlotinib plus nab-paclitaxel/gemcitabine as first-line treatment prolongs survival in patients with unresectable or metastatic pancreatic adenocarcinoma: a retrospective cohort.. **2022**, 10, 294 0
- 135 Evaluation of Proposed Protocol Changing Statistical Significance From 0.05 to 0.005 in Foot and Ankle Randomized Controlled Trials.. **2022**, 0
- 134 The Predictive Individual Effect for Survival Data.. **2022**, 56, 492-500 0
- 133 Effect of previous conventional irinotecan treatment in patients with pancreatic cancer being treated with liposomal irinotecan plus 5-fluorouracil and leucovorin.. **2022**, 0
- 132 Application of Pyrrolobenzodiazepines in Antibody Drug Conjugates. **2022**, 293-339 0
- 131 Late metachronous cerebral metastasis of pancreatic adenocarcinoma of the tail of the pancreas: a case report.. **2022**, 16, 144

- 130 Proteome and secretome analysis of pancreatic cancer cells.. **2022**, e2100320 1
- 129 The multi-targeted tyrosine kinase inhibitor SKLB610 resensitizes ABCG2-overexpressing multidrug-resistant cancer cells to chemotherapeutic drugs. **2022**, 149, 112922
- 128 Cetuximab, gemcitabine and radiotherapy in locally advanced pancreatic cancer: Long-term results of the randomized controlled phase II PARC trial.. **2022**, 34, 15-22 2
- 127 Molecular Targeted Positron Emission Tomography Imaging and Radionuclide Therapy of Pancreatic Ductal Adenocarcinoma.. **2021**, 13, 1
- 126 EUS-FNA Biopsies to Guide Precision Medicine in Pancreatic Cancer: Results of a Pilot Study to Identify Wild-Type Tumours for Targeted Therapy.. **2021**, 11, 770022 0
- 125 [Long-term response in advanced pancreatic adenocarcinoma - a case report and literature review].. **2021**, 0
- 124 Orphan Medicinal Products for the Treatment of Pancreatic Cancer: Lessons Learned From Two Decades of Orphan Designation.. **2021**, 11, 809035
- 123 Study of Gemcitabine Plus Nab-Paclitaxel-Based Chemotherapy Regimen as First-Line Treatment in Metastatic Pancreatic Carcinoma.
- 122 Treatment optimization of locally advanced and metastatic pancreatic cancer (Review). **2021**, 59, 2
- 121 Examining the efficacy of localised gemcitabine therapy for the treatment of pancreatic cancer using a hybrid agent-based model. 0
- 120 Pancreatic cancer. 409-420
- 119 Image_1.TIF. **2020**,
- 118 Molecular Characterization of Pancreatic Ductal Adenocarcinoma Using a Next-Generation Sequencing Custom-Designed Multigene Panel. **2022**, 12, 1058 0
- 117 Calcium channel blockers potentiate gemcitabine chemotherapy in pancreatic cancer.. **2022**, 119, e2200143119
- 116 FBXW2 inhibits prostate cancer proliferation and metastasis via promoting EGFR ubiquitylation and degradation.. **2022**, 79, 268 0
- 115 Extracellular PKC β signals to EGF receptor for tumor proliferation in liver cancer cells.. **2022**, 1
- 114 Rational Design and Systemic Appraisal of an EGFR-Targeting Antibody-Drug Conjugate LR-DM1 for Pancreatic Cancer.. **2022**,
- 113 Predicting Novel Drug Candidates for Pancreatic Neuroendocrine Tumors via Gene Signature Comparison and Connectivity Mapping.. **2022**, 0

112	Palliative laparoscopic Roux-en-Y choledochojejunostomy as a feasible treatment option for malignant distal biliary obstruction.. 2022 , 1	0
111	Pancreatic Cancer. 2022 , 341-353	
110	EGFR inhibition reverses resistance to lenvatinib in hepatocellular carcinoma cells.. 2022 , 12, 8007	2
109	Increased expression of SPRR1A is associated with a poor prognosis in pancreatic ductal adenocarcinoma. 2022 , 17, e0266620	0
108	Overcoming immunotherapeutic resistance in PDAC: SIRP α CD47 blockade. 2022 , 181, 106264	0
107	Systemic Therapies for Pancreatic Cancer. 2022 , 193-200	
106	Chemotherapy in Pancreatic Ductal Adenocarcinoma. 2022 , 171-176	
105	<i>In Silico&/i> Studies, Biological Activities, and Anti-human Pancreatic Cancer Potential of 6-Hydroxy-4-methylcoumarin and 2,5-Dihydroxyacetophenone as Flavonoid Compounds. 2022 , 71, 853-861	
104	Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma: A Physiopathologic and Pharmacologic Review. 2022 , 14, 2486	3
103	Systemic Therapy of Metastatic Pancreatic Adenocarcinoma: Current Status, Challenges, and Opportunities. 2022 , 14, 2588	0
102	Exploring the metabolic landscape of pancreatic ductal adenocarcinoma cells using genome-scale metabolic modeling. 2022 , 104483	0
101	Development of Irinotecan Liposome Armed with Dual-Target Anti-Epidermal Growth Factor Receptor and Anti-Fibroblast Activation Protein-Specific Antibody for Pancreatic Cancer Treatment. 2022 , 14, 1202	0
100	A Phase I/ II Study of Ivaltinostat Combined with Gemcitabine and Erlotinib in Patients with Untreated Locally Advanced or Metastatic Pancreatic Adenocarcinoma.	1
99	Nanoparticle-based therapeutic strategies targeting major clinical challenges in pancreatic cancer treatment. 2022 , 187, 114357	0
98	Treatment of biliary tract carcinoma over the last 30 years. 2022 ,	1
97	Immunotherapy for patients with pancreatic adenocarcinoma. 2022 , 16, 127-129	
96	S3-Leitlinie zum exokrinen Pankreaskarzinom [Kurzversion 2.0 Dezember 2021, AWMF-Registernummer: 032/010OL. 2022 , 60, 991-1037	0
95	Inhibitors of the Cancer Target Ribonucleotide Reductase, Past and Present. 2022 , 12, 815	0

94	Prospects of targeting PI3K/AKT/mTOR pathway in pancreatic cancer. 2022 , 103749	1
93	E2F2 enhances the chemoresistance of pancreatic cancer to gemcitabine by regulating the cell cycle and upregulating the expression of RRM2. 2022 , 39,	1
92	Early-onset pancreatic cancer: a review of molecular mechanisms, management, and survival. 2022 , 13, 828-841	0
91	An in-Depth Analysis of Ovarian Cancer: Pathogenesis and Clinical Manifestation.	
90	Germline Aberrations in Pancreatic Cancer: Implications for Clinical Care. 2022 , 14, 3239	2
89	Management of elderly patients with unresectable pancreatic cancer.	
88	Antibody-Based Approaches to Target Pancreatic Tumours. 2022 , 11, 47	2
87	Multimodal Therapies Against Pancreatic Ductal Adenocarcinoma: A Review on Synergistic Approaches Towards Ultimate Nanomedicine Treatments. 2200079	2
86	Case Report: A Case of Locally Advanced Pancreatic Cancer Which Achieved Progression Free for Over 12 Months by Subsequent Therapy with Anlotinib Hydrochloride Plus Tegafur-Gimeracil-Oteracil Potassium (TS-1). 12,	0
85	Claudin 18.2 is a potential therapeutic target for zolbetuximab in pancreatic ductal adenocarcinoma. 2022 , 14, 1252-1264	0
84	NNMT promotes the progression of intrahepatic cholangiocarcinoma by regulating aerobic glycolysis via the EGFR-STAT3 axis. 2022 , 11,	2
83	Systematic exploration of the underlying mechanism of gemcitabine resistance in pancreatic adenocarcinoma.	
82	Cystic Pancreatic Lesions. 2023 , 177-196	
81	Average treatment effect of facility hepatopancreatobiliary cancer volume on survival of non-resected pancreatic adenocarcinoma. 2022 ,	0
80	Defining clinically important overall survival thresholds: lessons from quality of life.	0
79	Role of inflammation and oxidative stress in chemotherapy-induced neurotoxicity.	2
78	Therapie des metastasierten Pankreaskarzinoms. 2022 , 63, 851-862	
77	Resveratrol effects on molecular pathways and microRNAs in gastrointestinal cancers.. 2022 , 29,	

- 76 Dual Targeting of the EGFR/HER2 Pathway in Combination with Systemic Chemotherapy in Refractory Pancreatic Cancer—The CONKO-008 Phase I Investigation. **2022**, 11, 4905
- 75 Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of pancreatic cancer. **2022**, ○
- 74 Therapeutic Targeting of RAS Mutant Cancers. **2022**, ○
- 73 PRECISION: the Belgian molecular profiling program of metastatic cancer for clinical decision and treatment assignment. **2022**, 7, 100524
- 72 The WD repeat-containing protein 5 (WDR5) antagonist WDR5-0103 restores the efficacy of cytotoxic drugs in multidrug-resistant cancer cells overexpressing ABCB1 or ABCG2. **2022**, 154, 113663 1
- 71 Nonsurgical Management of Pancreatic Adenocarcinoma. **2022**, 535-556 ○
- 70 Therapeutic advances in metastatic pancreatic cancer: a focus on targeted therapies. **2022**, 14, 175883592211180
- 69 Development and validation of a competing risk model for second primary pancreatic ductal adenocarcinoma: A population-based study. 9, ○
- 68 Role of drug catabolism, modulation of oncogenic signaling and tumor microenvironment in microbe-mediated pancreatic cancer chemoresistance. **2022**, 64, 100864 ○
- 67 Chemical Constituents of *Callistemon subulatus* and Their Anti-Pancreatic Cancer Activity against Human PANC-1 Cell Line. **2022**, 11, 2466 ○
- 66 Comparative proteomic analysis identifies key metabolic regulators of gemcitabine resistance in pancreatic cancer. **2022**, 100409 ○
- 65 Management of Advanced Pancreatic Cancer through Stromal Depletion and Immune Modulation. **2022**, 58, 1298 ○
- 64 Blockage of retinoic acid signaling via RAR β suppressed the proliferation of pancreatic cancer cells by arresting the cell cycle progression of the G1-S phase. 1
- 63 Small molecule inhibitor against onco-mucins disrupts Src/FosL1 axis to enhance gemcitabine efficacy in pancreatic ductal adenocarcinoma. **2022**, 215922 ○
- 62 Cytotoxic Chemotherapy in Advanced Pancreatic Cancer. **2022**, ○
- 61 Pancreatic Adenocarcinoma Management. 4
- 60 Engaging innate immunity for targeting the epidermal growth factor receptor: Therapeutic options leveraging innate immunity versus adaptive immunity versus inhibition of signaling. 12, ○
- 59 The anti-tumor effect of a novel agent MCL/ACT001 in pancreatic ductal adenocarcinoma. ○

- 58 Management of Locally Advanced/Metastatic Disease: Medical Oncology. **2022**, 97-106 ○
- 57 Patient Reported Outcomes and Quality of Life. **2022**, 351-373 ○
- 56 STAT3 Inhibitors: A Novel Insight for Anticancer Therapy of Pancreatic Cancer. **2022**, 12, 1450 ○
- 55 A generalized single-index linear threshold model for identifying treatment-sensitive subsets based on multiple covariates and longitudinal measurements. ○
- 54 Small molecule inhibitors targeting the cancers. **2022**, 3, ○
- 53 Emerging kinase inhibitors for the treatment of pancreatic ductal adenocarcinoma. 1-24 ○
- 52 Research advances and treatment perspectives of pancreatic adenosquamous carcinoma. ○
- 51 FDA approved six-membered ring fused pyrimidine-based derivatives. **2023**, 221-248 ○
- 50 Wild-type KRAS inhibits the migration and invasion of pancreatic cancer through the Wnt/ β -catenin pathway. **2022**, 27, ○
- 49 S3-Leitlinie zum exokrinen Pankreaskarzinom [Langversion 2.0 | Dezember 2021 | AWMF-Registernummer: 032/010OL. **2022**, 60, e812-e909 ○
- 48 Back to basic: Trials and tribulations of alkalizing agents in cancer. 12, ○
- 47 Are targeted therapies or immunotherapies effective in metastatic pancreatic adenocarcinoma?. **2022**, 7, 100638 6
- 46 Hypoxia activated HGF expression in pancreatic stellate cells confers resistance of pancreatic cancer cells to EGFR inhibition. **2022**, 86, 104352 ○
- 45 Clinical significance and functional role of adhesion G-protein-coupled receptors in human pancreatic ductal adenocarcinoma. ○
- 44 Cell-Surface Receptors: EGFR- and VEGFR-Targeted Agents. **2022**, 153-172 ○
- 43 Screening for Pancreatic Cancer: Current Status and Future Directions. 59-67 ○
- 42 Sialyltransferases and Neuraminidases: Potential Targets for Cancer Treatment. **2022**, 10, 114 ○
- 41 Targeted Delivery Polymeric Nanosystem Reinforced by Synergism of Embilin and RPI-1 for Therapeutics of Pancreatic Cancer. **2022**, 5, 18622-18636 ○

40	Integrated genomic analysis to identify druggable targets for pancreatic cancer. 12,	o
39	Transcriptomic and functional analysis of ANGPTL4 overexpression in pancreatic cancer nominates targets that reverse chemoresistance.	o
38	The antitumor effect of the novel agent MCL/ACT001 in pancreatic ductal adenocarcinoma.	o
37	Current treatment landscape of pancreatic cancer patients in a network of office-based oncologists in Germany.	o
36	LY6D marks pre-existing resistant basosquamous tumor subpopulations. 2022 , 13,	o
35	Pancreatic Cancer: Beyond Brca Mutations. 2022 , 12, 2076	1
34	Metastatic phenotype and immunosuppressive tumour microenvironment in pancreatic ductal adenocarcinoma: Key role of the urokinase plasminogen activator (PLAU). 13,	o
33	Adaptation to an acid microenvironment promotes pancreatic cancer organoid growth and drug resistance in a p53-dependent manner.	o
32	Objective response rate (ORR) targets for recurrent glioblastoma clinical trials based on the historic association between ORR and median overall survival.	o
31	TYRO3 promotes chemoresistance via increased LC3 expression in pancreatic cancer. 2023 , 28, 101608	o
30	HROP68: A rare case of medullary pancreatic cancer—characterization and chemosensitivity of the first patient-derived cell line. 12,	o
29	Transcriptomic and functional analysis of ANGPTL4 overexpression in pancreatic cancer nominates targets that reverse chemoresistance.	o
28	A real-world study of anlotinib combined with GS regimen as first-line treatment for advanced pancreatic cancer. 14,	o
27	Personalized matched targeted therapy in advanced pancreatic cancer: a pilot cohort analysis. 2023 , 8,	1
26	Examining the efficacy of localised gemcitabine therapy for the treatment of pancreatic cancer using a hybrid agent-based model. 2023 , 19, e1010104	o
25	Cardiovascular Toxicities Associated with Tyrosine Kinase Inhibitors. 2023 , 25, 269-280	o
24	Single cell lineage tracing reveals subclonal dynamics of anti-EGFR therapy resistance in triple negative breast cancer.	o
23	A Novel 3DNA Nanocarrier effectively delivers payloads to pancreatic tumors. 2023 , 32, 101662	o

- 22 Feasibility of Co-Targeting HER3 and EpCAM Using Seribantumab and DARPin α Toxin Fusion in a Pancreatic Cancer Xenograft Model. **2023**, 24, 2838 ○
- 21 Pancreatic melatonin enhances anti-tumor immunity in pancreatic adenocarcinoma through regulating tumor-associated neutrophils infiltration and NETosis. **2023**, 13, 1554-1567 ○
- 20 Cardiovascular toxicity of tyrosine kinase inhibitors during cancer treatment: Potential involvement of TRPM7. 10, ○
- 19 Phase Ib and Expansion Study of Gemcitabine, Nab-Paclitaxel, and Ficlaturumab in Patients With Metastatic Pancreatic Cancer. ○
- 18 Fluoropyrimidine combination therapy versus fluoropyrimidine monotherapy for gemcitabine-refractory advanced pancreatic cancer: A systematic review and meta-analysis of randomized controlled trials. **2023**, 18, e0282360 ○
- 17 Expert Consensus on the Diagnosis and Treatment of Anticancer Drug-Induced Interstitial Lung Disease. **2023**, 43, 1-12 ○
- 16 Targeting KRAS in pancreatic cancer: Emerging therapeutic strategies. **2023**, ○
- 15 Interplay between MAP kinases and tumor microenvironment: Opportunity for immunotherapy in pancreatic cancer. **2023**, ○
- 14 Novel strategy for oncogenic alteration-induced lipid metabolism reprogramming in pancreatic cancer. **2023**, ○
- 13 Hepatotoxicity of Small Molecule Protein Kinase Inhibitors for Cancer. **2023**, 15, 1766 ○
- 12 A novel approach to PAAD patient care: A 9-cuproptosis-related differential expression lncRNAs model for prognosis prediction. ○
- 11 Power. **2023**, 153-155 ○
- 10 Structure-Activity Relationship Studies Based on Quinazoline Derivatives as EGFR Kinase Inhibitors (2017-Present). **2023**, 16, 534 ○
- 9 Advanced pancreatic cancer with KRAS wild-type and EGFR-sensitive mutation respond favorably to furmonertinib: A case report. 13, ○
- 8 Recent advances in targeted therapy for pancreatic adenocarcinoma. 15, 571-595 ○
- 7 IgG-based B7-H3xCD3 bispecific antibody for treatment of pancreatic, hepatic and gastric cancer. 14, ○
- 6 Overcoming the Fibrotic Fortress in Pancreatic Ductal Adenocarcinoma: Challenges and Opportunities. **2023**, 15, 2354 ○
- 5 Chemoresistance in pancreatic ductal adenocarcinoma: Overcoming resistance to therapy. **2023**, ○

- 4 Multi-omics data integration in upper gastrointestinal cancers research: A review of concepts, approaches, and application. ○
- 3 Case report: A case study on the treatment using icaritin soft capsules in combination with lenvatinib achieving impressive PR and stage reduction in unresectable locally progressive pancreatic cancer and a literature review. 14, ○
- 2 Targeted therapy. **2023**, 205-411 ○
- 1 Preoperative treatments in borderline resectable and locally advanced pancreatic cancer: Current evidence and new perspectives. **2023**, 186, 104013 ○